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Abstract 
 
Chapter 1 
Hofmann-type Rearrangement of Imides by in-situ generaed Imide-combined 
Hypervalent Iodines 
Aromatic amino acids (e.q., anthranilic acid) and aliphatic  -amino acids were 
prepared from cyclic imides using hypervalent iodine generated in situ from iodoarene, 
TsOH, and m-CPBA. The Hofmann-type rearrangement was induced by nucleophilic 
attack of alcohol first followed by the Hofmann rearrangement. Here, imide-combined 
hypervalent iodine that was a key intermediate of the reaction, and played important 
role under basic conditions in alcohol. 
 
 
 
Chapter 2 
Preparation of Novel Imide-combined Hypervalent Iodines: (Heteroaryl)(aryl)- 
iodonium Imides 
(Heteroaryl)(aryl)iodonium imides were prepared from various heteroaromatics with 
(diacetoxyiodo)benzene (DIB) and bis(sulfonyl)imides. These novel hypervalent 
iodines were stable as white solid, and the unique structure was observed from two 
types of iodane (III), imide-combined -iodane and asymmetric diaryliodonium salt 
containing heterocycles. 
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Chapter 3 
Regioselective Bromo-amination of Indoles via (Indolyl)(aryl)iodonium Imides 
N-(3’-Bromo-1’-pivaloyl-1’H-indol-2’-yl)-4-methyl-N-tosylbenzenesulfonamides were 
obtained by bromo-amination of (indolyl)(phenyl)iodonium imides using brominating 
reagents. This reaction is C-H dual-functionalization on one-step with complete 
regioselectivity. 
 
 
 
Chapter 4 
Regioselective Iodo-amination of 2-Methylindoles via (Indolyl)(aryl)iodonium 
Imides 
 
N-((3-iodo-1-pivaloyl-1H-indol-2-yl)methyl)-N-(methanesulfonyl)methanesulfonamide
s were prepared by iodo-amination of 2-methylindole derivatives via  
(2-methylindolyl)(phenyl)iodonium imides using iodinating reagents. This reaction 
transformed both sp
2 
C-H and non-activated sp
3 
C-H bonds to C-I and C-N bonds, 
respectively. 
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Chapter 5 
Ligand Coupling Reaction of (Indolyl)(aryl)iodonium Imides to Form C-N Bond at 
3-Position in Indole Group; Effect of Substitutents of Hypervalent Iodine for 
Reaction Selectivity 
N-(1’-pivaloyl-1’H-indol-3’-yl)-4-methyl-N-tosylbenzenesulfonamides were generated 
by ligand coupling reaction of (indolyl)(aryl)iodonium imides using catalytic amount of 
cupper iodide (I) or under heat conditions. Substitutent on hypervalent iodines 
controlled the reaction with high regioselectivity. 
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General Introduction: 
C-N Bond Formation with I-N Bond-contained Hypervalent Iodines 
The first hypervalent iodine compound, (dichloroiodo)benzene, was discovered by 
Willgerodt in 1886
1
. Since then, various hypervalent iodines were synthesized and a lot 
of unique reactions using iodanes were reported
2
. For example, iodosylbenzene and 
(diacetoxyiodo)benzene (DIB) were prepared in 1892
3
, and 2-iodoxybenzoic acid was 
provided in 1893
4
. These compounds were used as low toxic and powerful oxidant 
instead of heavy metal reagents. Moreover, Dess and Martin developed a very useful 
pentavalent iodane in 1983
5
, which is called Dess-Martin periodinane and widely used 
as an oxidatnt for synthesis of medicinal and biologically active compounds. 
Hydroxy(tosyloxy)iodobenzene reported by Neiland and Karele in 1970 was named 
Koser’s reagent and known to oxidative C-O bond formation reagents6.  
All compounds exemplified above are I-O bond-combined polyvalent iodane. On the 
other hands, I-N bond contained hypervalent iodines are not so common. These species 
lack for stability and sensitive to air or moisture. Then, many scientists had studied to 
develop new hypervalent iodines possessing I-N bond and C-N bond formation 
reactions to utilize for synthesis of natural compounds. Since benziodazole (1) was 
released by Wolf and Steinberg in 1965
7
, many types of I-N bond-combined hypervalent 
iodines were prepared and used for oxdative C-N bond formations. Thus in this section, 
the author studied I-N bond-contained hypervalent iodines and their application to the 
C-N bond formation reactions. 
 
 
 
1-1 Azidoiodanes 
Azidoiodanes (2) are useful reagents for azidation reactions, and prepared from 
iodoxybenzene or DIB with trimethylsilyl azide or sodium azide. However, 
azidoiodanes are not stable and usually generated in situ. In 1970, Zbiral group reported 
the first study about azidoiodanes generated with DIB and TMSN3, and succeeded 
azidation of alkene (3) [Eq. 2]
8
. In 1980s, Moriarty group
9
, and Ochiai and Fujita 
group
10 
obtained azide (6) from alkene (5) using iodosylbenzene, NaN3, and acid [Eq. 3], 
5 
 
respectively. 
 
 
 
 
 
Kita group reported benzilic sp
3
 C-H azidation of electron rich aromatics (7) with 
PhI(N3)2 generated in situ from [bis(trifluoroacetoxy)iodo]benzene (PIFA) and TMSN3
 
[Eq. 4]
 11
.  
 
 
 
Magnus group studied metal-free sp
3
 C-H azidation of N,N-dimethylaniline (9)
11a
 and 
silyl enol ether (11)
11b
 derivatives, respectively, using iodosylbenzene and TMSN3 in 
high yields [Eq. 5, 6].  
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Telvekar group investigated synthesis of vinyl azide (14) and -azide carbonyl 
compounds (16) with hypervalent iodine and sodium azide [Eq. 7, 8]
12
. 
 
 
 
In 2012, Suna group reported azidation of indole-2-carboxylate derivatives (17) with 
DIB, TsOH, NaN3, and copper catalyst [Eq. 9]
13
. 
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To the focus on synthesis of novel azidoiodanes, Zhdankin group developed thermally 
stable and easily handling azidoiodanes (20, 22) in 1994
14
. Compounds 20 and 22 are 
generated from iodoxole (19, 21) with TMSN3, and able to be isolated [Eq. 10]. 
 
 
 
Benziodoxole azides (22) are widely uesd for C-N bond formation. For example, 
Zhdankin group reported metal-free azidation of various sp
3
 C-H bonds [Eq. 11]
15
. 
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Saito group succeeded metal-free azidation of aldehydes (29) with benziodoxole azides 
22 [Eq. 12]
16
. 
 
 
 
Loh group studied vicinal difunctionalization of styrenes (31) with benziodoxole azides 
(22) and copper catalyst [Eq. 13]
17
.  
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Recently, Greaney group reported direct benzylic C-H azidation with benziodoxole 
azides (22) and photoredox catalyst under irradiation with a visible light [Eq. 14]
18
. 
 
 
 
1-2 Amide and Iminoiodanes 
Amideiodanes are unstable species and rapidly decompose and produce isocyanates by 
the Hofmann rearrangement
19
. However, in 1997, Zhdankin group succeeded in 
preparation of stable amideiodane (37) and demonstrated metal-free amination of sp
3
 
carbon of adamantane (38) and N,N-dimethylaniline derivatives (40), respectively, with 
aminoiodane (37) [Eq. 16, 17]
20
. 
10 
 
 
 
On the other hands, iminoiodanes (ArI=NR) which are polyvalent iodine possessing 
I=N double bond are excellent reagent for oxidative amination and nitrogen source with 
metal complex. The most popular iminoiodane is PhI=NTs, which is synthesized from 
DIB or PIFA, TsNH2, and bases. In 1975, Yamada group reported preparation of 
iminoiodane and transformation of phosphine and sulfide (42) to phosphorane and 
surfurane (43), respectively [Eq. 18]
21
. 
 
 
 
Since then, many reactions with iminoidanes were reported
22
. In particular, focusing on 
C-N bond formation, Jacobsen
23a
 and Evans
23b
 group developed asymmetric aziridation 
11 
 
of olefins (44) with PhINTs and copper catalysts [Eq. 19].  
 
 
 
Zhdankin group reported metal free C-N bond formation of silyl enol ethers (46) with 
iminoiodane [Eq. 20]
24
. In this paper, they developed 2-alkoxyiminoiodanes and applied 
to amination reaction. Most iminoiodanes are less soluble in non-polar organic solvents, 
however, the hypervalent iodines which bear moderate solubility and high reactivity 
were developed. 
 
 
 
In 2012, Zhang group succeeded in amination of 1,3-dicarbonyl compounds (48) with 
PhINTs generated in situ from iodosobenzene, TsNH2, and Lewis acid [Eq. 21]
25
.  
 
 
 
Saito group investigated the reaction of alkynes (50) with iminoiodane and Lewis acid 
in nitriles, and obtained imidazoles (51) under metal-free conditions [Eq. 22]
26
.  
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Recently, Lamar group reported metal-free C-N bond formation at sp
3
 carbon with 
PhINNs (Ns : 4-nitrobenzenesulfonyl) under irradiation with a visible light [Eq. 23]
27
. 
 
 
 
1-3 Imide-combined Iodanes 
Imides, such as phthalimide and succinimide, possess electron-deficient nitrogen atom, 
and can be used for ligand of hypervalent iodines. In 1983, Hadjiarapoglou group 
succeeded in synthesis of imide-combined hypervalent iodines possessing two 
phthalimide groups
28
. However, phenyliodane (III) bis(phthalimidate) is soluble in only 
high polar solvents, such as DMSO, and sensitive to moisture. In 2011, Chang
29a
 group 
and DeBoef
29b,c
 group reported metal-free intermolecular amination of methylarenes (54, 
57) with phthalimide-combined hypervalent iodine generated in situ from DIB and 
phthalimide under heating or MW irradiation conditions [Eq. 24, 25]. 
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Minakata group developed benziodoxole-type imide-combined iodane (59) (III), and 
applied to amination of tertiary alkylamine (60) [Eq. 26]
30
. 59 is soluble in various 
organic solvents. 
 
 
Zhdankin group succeeded in preparation of -aminoketones with silyl enol ether (63) 
and saccharine-combined hypervalent iodine (62) [Eq. 27]
31
. 
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On the other hands, Muñis group reported enantioselective metal-free 1,2-diamination 
of styrenes (65) with ArI(OAc)NMs2 which was generated in situ from 
(diacetoxyiodo)arene and bis(mesyl)imide [Eq. 28]
32
.  
 
 
 
Bis(sulfonyl)-type imide-combined hypervalent iodines (67) are easy to prepare from 
only (diacetoxyiodo)arene and bis(sulfonyl)imides at room tempareture, and are soluble 
in various organic solvents. Muñis group also investigated C-N bond formation 
reactions of allylic compounds (68)
33a
, alkynes (70)
33b
, allenes (72)
33c
, and so on, with 
67 [Eq. 29]
33d,e
.   
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In 2014, Minakata group reported decarboxylation-amination of unsaturated carboxylic 
acids (75) with imide-combined hypervalent iodines [Eq. 30]
34
 .  
 
 
 
Conclusion  
Various hypervalent iodines possessing I-N bond were prepared and applied to C-N 
bond formation. However, some of them are unstable and require careful treatment and 
operation. Moreover, their synthetic utilities to substrates are limited. Thus, the author 
studied about the following programs: development of new synthetic method for 
phthalimide-combined hypervalent iodines (chaper 1), preparation of novel 
imide-combined iodanes (chapter 2), and discovery of C-N bond formation reaction 
with novel trivalent iodanes (chapters 1, 3, 4, 5).  
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Chapter 1 
Hofmann-type Rearrangement of Imides by in-situ generated Imide-combined 
Hypervalent Iodines 
 
Abstract 
Aromatic amino acids (e.q., anthranilic acid) and aliphatic  -amino acids were 
prepared from cyclic imides using hypervalent iodine generated in situ from iodoarene, 
TsOH, and m-CPBA. The Hofmann-type rearrangement was induced by nucleophilic 
attack of alcohol first followed by the Hofmann rearrangement. Here, imide-combined 
hypervalent iodine that was a key intermediate of the reaction, and played important 
role under basic conditions in alcohol. 
     
Introduction 
Amino acids are one of the most important compounds in living bodies, and some 
amino acid-like chemicals possess biological activity. Especially, aromatic amino acids 
are found in a lot of medicinal compounds
1
. However, synthetic methods of substituted 
anthranilic acids required many steps, with heavy metals
2
. On the other hands, 
Hofmann-type rearrangement of phthalimide is attractive strategy for preparation of 
anthranilic acid derivatives. Nevertheless, useful synthetic studies of anthranilic acid by 
Hofmann-type rearrangement have not been reported
3
.  
The Hofmann rearrangement is useful reaction to obtain amines from carboxyamides. 
Many types of haloganation reagents were used for the Hofmann rearrangement, and 
hypervalent iodines are also useful and efficient oxidants for the reaction
4
. The groups 
of Zhdankin
5
 and Ochiai
6
 reported that iodine (III) could be finitely employed for the 
Hofmann rearrangement of aliphatic amides. 
The author developed the first Hofmann-type rearrangement of cyclic imides by use of 
hypervalent iodine compounds generated in situ from iodoarenes, TsOH, and m-CPBA
7
, 
and discovered imide-combined hypervalent iodine as the key intermediate of the 
reaction. This method transformed cyclic imides to aromatic and aliphatic  -amino 
acids in high yields, respectively.  
 
Results and Discussion 
First, the author screened a series of bases, sulfonic acids, and substituted groups of 
iodoarenes on Hofmann-type rearrangement of phthalimide (Table 1). Trivalent iodines, 
HTIB analogue, were generated in situ from iodoarene, m-CPBA, and surfonic acid in 
chloroform. Then, the iodane (III), HTIB analogue, was treated with phthalimide, bases, 
19 
 
and Na2SO4 in methanol. The Hofmann-type rearrangement product was not obtained 
without base (entry 1), however, the yield was increased to 93 % by using K2CO3 (entry 
2). Other bases were not effective for the reaction (entries 3-6). Although phthalimide 
was also transformed to the product with methansulfonic acid and 
p-chlorobenzenesulfonic acid instead of p-toluenesulfonic acid (entries 7, 8) under the 
same conditions, the yield of anthranilic acid derivative (2a) was decreased without 
sulfonilic acid (entry 9). In addition, p-chloroiodobenzene, which has an 
electron-withdrawing group on iodobenzene, reduced the yield of the product, as 
compared with iodobenzene and t-butyliodobenzene (entries 10, 11).  
 
 
 
Next, the author examined Hofmann-type rearrangement of various phthalimides based 
on the optimized conditions, and DBU was used as a base instead of K2CO3 (Table 2). 
4-Substituted phthalimides bearing Me (1b), t-Bu (1c), Br (1d), or NO2 (1e) were 
transformed to the corresponding substituted anthranilic acid derivatives (2b-2e) in high 
yields, respectively. Strong electron-donating 4-methoxy phthalimide (1f) was 
converted into the product (2f) in good yield, and 3-fluoro phthalimide (1g) gave the 
20 
 
desired product (2g) in high yield.  
4,5-Dimethylphenyl (1h), 4,5-dichlorophenyl (1i), naphthyl (1j), and biphenyl (1k) 
imides provided the corresponding di-substituted products (2h-2k) in high yields, 
respectively. Amino-isonicotinic acid derivative (2l) was obtained from 3,4-pyridine 
dicarboximide (1l) in excellent yield. In addition, treatment of 1a with other alcohols, 
such as ethanol and 2,2,2-trifluoroethanol, instead of methanol for Hofmann-type 
rearrangement produced the anthranilic acid derivatives bearing ester and carbamate 
(2m, 2n) in good yields, respectively. 4,4’-Oxybisphthalimide (1o) was transformed to 
an oxybisanthranilic acid derivative (2o) in 60% yield using double amount of each 
reagents. Almost all substrates provided the small amount of by-product (3, X=H), 
however, 3a was easily converted to desired product (2a) with methylchloroformate in 
quantitative yield. Unfortunately, a mixture of two regioisomers was obtained with 
phthalimide (1b-1g, 1l, 1o) derivatives in law selectivity, and the ratios of 
regioselectivity were shown in experimental section. 
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The author also studied the application of Hofmann-type rearrangement to aliphatic 
cyclic imides to obtain - and -amino acid derivatives (Table 3). Succinimide (4a) and 
mono-substituted succinimides (4b-d) produced -amino acid derivatives in high yields, 
respectively, using the same reaction conditions as those of aromatic cyclic imides. 2,3- 
or 2,2- dimethylsuccinimide (4e, f) also provided desired products in good yields, 
respectively.  Moreover, glutarimide (4g) gave -amino acid derivatives, and 
3-isobutylglutarimide (4i) directly produced Pregabalin precursor. This precursor was 
easily transformed by hydrolysis to Pregabalin, which is used for neuropathic pain
8
. The 
result showed that Hofmann-type rearrangement is useful synthetic strategy for amino 
acid-like medicinal compounds. 
 
 
The author examined several reactions to clarify the mechanism of Hofmann-type 
rearrangement with hypervalent iodine (Scheme 2). N-methylphthalimide (6) was not 
converted into desired product (7) in optimized conditions, and the tratment of 
phthalimide with  [hydroxy(tosyloxy)iodo]benzene (HTIB) and K2CO3 in methanol 
gave 349.9663 peak on high resolution ESI-MS analysis, which is assigned to 
[PhI(phthalimidate)]
+
 (8), calculated MS : 349.9672). These results suggested that first 
phthalimide-combined hypervalent iodine species was formed in the presence of base, 
and then methanol attacked carbonyl group. On the other hands, treatment of 
phenyliodine(III) bis[phthalimidate] (9)
9
 in the presence of K2CO3 in methanol provided 
both 43 % yield of anthranilic acid derivatives (2a) and 45 % yield of phthalimide (1a). 
22 
 
Moreover, addition of HTIB to the above methanol solution of 9 under the same 
reaction conditions increased the desired product (2a or 3a) to 83 % yield and 1a was 
decreased to 16 % yield. This result suggests that 9 was a key intermediate of the 
reaction, and re-oxidized phthalimide by HTIB was converted into the product. 
 
 
 
According to some blank experiments shown in Scheme 2, the author proposed the 
mechanism of Hofmann-type rearrangement, as shown in Scheme 3. HTIB is formed 
from PhI, m-CPBA, and TsOH•H2O
7a
. This compound reacts with cyclic imide in the 
presence of base, and generates imide-combined hypervalent iodine intermediate (9 or 
A). The intermediates 9 or A is attacked by methanol followed by the Hofmann 
rearrangement to give isocyanate (B). Finally, isocyanate B is transformed to carbamate 
product 2 by methanol.  
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In conclusion, the author developed the new synthetic method of anthranilic acid and - 
and -amino acid derivatives from cyclic imides with Hofmann-type rearrangement 
using hypervalent iodines. This reaction produces wide range of aromatic and aliphatic 
amino acid under mild conditions without any metal reagents. In addition, it is the first 
report to prepare imide-combined hypervalent iodine species in situ from iodoarene.  
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Experimental 
1. General Methods. 
1
H NMR spectra were measured on a JEOL ECS-400 (400 MHz) 
spectrometer at ambient temperature. Data were recorded as follows: chemical shift in 
ppm f      te   l tet   ethyls l  e    the δ sc le,  lt pl c ty (s = s  glet; d = d  blet; 
t = triplet; q = quartet; sep = septet; m = multiplet; br = broad), coupling constant (Hz), 
integration, and assignment. 
13
C NMR spectra were measured on a JEOL ECS-400 (100 
MHz) spectrometer. Chemical shifts were recorded in ppm from the solvent resonance 
employed as the internal standard (deuterochloroform at 77.0 ppm). High-resolution 
mass spectra were recorded by Thermo Fisher Scientific Exactive Orbitrap mass 
spectrometers. Infrared (IR) spectra were recorded on a JASCO FT/IR 4100 
spectrometer. Single crystal X-ray diffraction data were collected at 173 K on a Bruker 
SMART APEX    CCD d ff  ct  ete  w th M  Kα (λ = 0.71073) radiation and graphite 
monochromeater. For thin-layer chromatography (TLC) analysis throughout this work, 
Merck precoated TLC plates (silica gel 60GF254 0.25 mm) were used. The products 
were purified by column chromatography on neutral silica gel (Kanto Chemical Co., Inc. 
silica gel 60N, Prod. No. 37560-84; Merck silica gel 60, Prod. No. 1.09385.9929). 
Visualization was accomplished by UV light (254 nm), anisaldehyde, KMnO4, and 
phosphomolybdic acid. In experiments that required dry solvents such as chloroform 
and methanol were distilled in prior to use. 
 
2. General procedure for the Hofmann-type rearrangement of imides (1) using 
hypervalent iodine generated from iodoarene, m-CPBA, and p-toluenesulfonic acid 
in situ. 
T  p ep  e hype   le t   d  es (0.33    l) we e  sed   d be  e e (36.4 μL, 0.33 
mmol), m-CPBA (94.9 mg, 0.36 mmol), and p-TsOH·H2O (68.0 mg, 0.36 mmol) in 
CHCl3 (1 mL), and the solution was stirred at room temperature for 2 h under argon 
atmosphere. The solvents were removed in vacuo, and the desired product was obtained 
in situ as a white solid. Then Na2SO4 (0.50 mmol, 71.0 mg) and MeOH (2 mL) was 
added, and the solution was stirred at 0 °C for 10 min. To the solution were added 1a 
(36.8 mg, 0.25 mmol) and K2CO3 (138.2 mg, 1.0 mmol) at 0 °C, and the obtained 
mixture was stirred at room temperature for 2 h. Saturated NaHCO3 aqueous solution 
(10 mL) was added to the reaction mixture, and the product was extracted with AcOEt 
(15 mL × 3). The combined extracts were washed by brine (10 mL) and dried over 
Na2SO4. The organic phase was concentrated under reduced pressure and the crude 
product was purified by silica-gel column chromatography (eluent: hexane/AcOEt = 
5/1), to give the desired product 2a (40.5 mg, 79% yield) and 3a (5.0 mg, 14% yield). 
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Methyl 2-[(methoxycarbonyl)amino]benzoate (2a): 
1
H NMR (400 MHz, CDCl3) δ 
3.79 (s, 3H), 3.92 (s, 3H), 7.03 (td, J = 8.2, 1.2 Hz, 1H), 7.53 (td, J = 8.0, 1.2 Hz, 1H), 
8.01 (dd, J = 8.0, 1.6 Hz, 1H), 8.43 (dd, J = 8.2, 1.2 Hz, 1H), 10.51 (brs, 1H). 
13
C NMR 
(100 MHz, CDCl3) δ 52.2 (2C), 114.5, 118.8, 121.5, 130.8, 134.6, 141.7, 154.1, 168.5. 
IR (neat) 3299, 1740, 1690, 1600, 1535, 1459, 1272 cm
–1
. MS (APCI) calcd for 
C10H12NO4 [M+H]
+
 210.0761, found 210.0761. 
 
Methyl anthranilate (3a): 
1
H NMR (400 MHz, CDCl3) δ 3.86 (s, 3H), 5.71 (b s, 2H), 
6.63 (t, J = 8.2 Hz, 1H), 6.65 (d, J = 8.2 Hz, 1H), 7.25 (td, J = 8.2, 1.6 Hz, 1H), 7.85 (dd, 
J = 8.2, 1.6 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 51.4, 110.7, 116.2, 116.6, 131.2, 
134.0, 150.4, 168.5. IR (neat) 3480, 3372, 1691, 1616, 1436, 1247 cm
–1
. MS (APCI) 
calcd for C8H10NO2 [M+H]
+
 152.0706, found 152.0702. 
 
Methyl 2-[(methoxycarbonyl)amino]methylbenzoate (2b, 4- and 5-isomers): In 
Table 2, 4-:5- = 56:44. The 4-isomer and 5-isomer were separeted by recrystallization. 
4-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 2.39 (s, 3H), 3.78 (s, 3H), 3.89 (s, 3H), 6.84 
(dd, J = 8.2, 1.1 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 8.26 (s, 1H), 10.51 (brs, 1H). 
13
C 
NMR (100 MH , CDCl3) δ 22.1, 52.1, 52.2, 112.0, 119.1, 122.6, 130.8, 141.7, 145.7, 
154.1, 168.5. 5-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 2.32 (s, 3H), 3.78 (s, 3H), 3.91 (s, 
3H), 7.34 (dd, J = 8.7, 1.6 Hz, 1H), 7.80 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 
10.36 (b s, 1H). 13C NMR (100 MH , CDCl3) δ 20.1, 52.2 (2C), 114.4, 118.8, 130.9, 
131.0, 135.3, 139.3, 154.1, 168.5. IR (KBr) 3273, 1740, 1688, 1594, 1533, 1440, 1249 
cm
–1
. MS (APPI) calcd for C11H13NO4  [M]
+
 223.0839, found 223.0841. 
 
Methyl tert-butyl-2-[(methoxycarbonyl)amino]benzoate (2c, 4- and 5-isomers): In 
Table 2, 4-:5- = 54:46. 4-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 1.34 (s, 9H), 3.79 (s, 
3H), 3.89 (s, 3H), 7.05 (dd, J = 8.5, 1.8 Hz, 1H), 7.91 (t, J = 8.5 Hz, 1H), 8.54 (d, J = 
1.8 Hz, 1H), 10.52 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 30.8 (3C), 35.3, 52.1 (2C), 
111.8, 115.7, 118.8, 130.5, 141.6, 154.1, 158.5, 168.3. 5-Isomer: 
1
H NMR (400 MHz, 
CDCl3) δ 1.31 (s, 9H), 3.77 (s, 3H), 3.91 (s, 3H), 7.57 (dd, J = 9.1, 2.5 Hz, 1H), 8.00 (d, 
J = 2.5 Hz, 1H), 8.34 (d, J = 9.1 Hz, 1H), 10.39 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) 
δ 31.1 (3C), 34.1, 52.0 (2C), 114.1, 118.6, 127.1, 131.8, 139.2, 114.3, 154.1, 168.5. IR 
(neat) 3302, 1739, 1693, 1582, 1524, 1438, 1260 cm
–1
. MS (APCI) calcd for 
C14H20NO4 [M+H]
+
 266.1387, found 266.1377. 
 
Methyl bromo-2-[(methoxycarbonyl)amino]benzoate (2d, 4- and 5-isomers): In 
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Table 2, 4-:5- = 55:45. 4-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 3.79 (s, 3H), 3.91 (s, 
3H), 7.16 (dd, J = 8.7, 2.0 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 8.69 (d, J = 2.0 Hz, 1H), 
10.53 (brs, 1H). 
13
C NMR (100 MH , CDCl3) δ 52.4, 52.5, 113.1, 121.7, 124.8, 129.6, 
131.9, 142.6, 153.9, 168.0. 5-Isomer: 
1H NMR (400 MH , CDCl3) δ 3.79 (s, 3H), 3.92 
(s, 3H), 7.61 (dd, J = 9.1, 2.5 Hz, 1H), 8.12 (d, J = 2.5 Hz, 1H), 8.36 (d, J = 9.1 Hz, 1H), 
10.42 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 52.40, 52.45, 113.8, 116.0, 120.5, 133.3, 
137.3, 140.8, 153.8, 167.3. IR (KBr) 3259, 1739, 1689, 1593, 1519, 1433, 1249 cm
–1
. 
MS (APPI)  calcd for  C 1 0 H1 0 BrNO 4  [M]
+
 286.9788,  found 286.9789. 
 
Methyl 2-[(methoxycarbonyl)amino]nitrobenzoate (2e, 4- and 5-isomers): In Table 
2, 4-:5- = 42:58. The 4-isomer and 5-isomer were separeted by column chromatography. 
4-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 3.84 (s, 3H), 3.99 (s, 3H), 7.82 (dd, J = 8.9, 
2.1 Hz, 1H), 8.17 (d, J = 8.9 Hz, 1H), 9.35 (d, J = 2.1 Hz, 1H), 10.57 (brs, 1H). 
13
C 
NMR (100 MHz, CDCl3) δ 52.7, 53.0, 113.8, 115.6, 118.7, 132.1, 142.7, 151.3, 153.7, 
167.0. 5-Isomer: 1H NMR (400 MHz, CDCl3) δ 3.84 (s, 3H), 4.00 (s, 3H), 8.37 (dd, J = 
9.4, 2.8 Hz, 1H), 8.67 (d, J = 9.4 Hz, 1H), 8.91 (d, J = 2.8 Hz, 1H), 10.87 (brs, 1H). 
13
C 
NMR (100 MHz, CDCl3) δ 52.9, 53.0, 114.1, 118.8, 127.0, 129.3, 141.2, 146.9, 153.5, 
167.0. IR (KBr) 3263, 1751, 1692, 1516, 1439, 1352, 1251 cm
–1
. MS (APCI) calcd for 
C10H9N2O6 [M–H]
–
 253.0455, found 253.0463. 
 
Methyl methoxy-2-[(methoxycarbonyl)amino]benzoate (2f, 4- and 5-isomers): In 
Table 2, 4-:5- = 63:37. The 4-isomer and 5-isomer were separeted by column 
chromatography. 4-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 3.79 (s, 3H), 3.869 (s, 3H), 
3.873 (s, 3H), 6.55 (dd, J = 8.9, 2.7 Hz, 1H), 7.92 (d, J = 8.9 Hz, 1H), 8.06 (d, J = 2.7 
Hz, 1H), 10.72 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 51.9, 52.2, 55.4, 102.3, 107.1, 
109.0, 132.4, 143.9, 154.1, 164.5, 168.3. 5-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 3.77 
(s, 3H), 3.81 (s, 3H), 3.92 (s, 3H), 7.12 (dd, J = 9.2, 3.2 Hz, 1H), 7.49 (d, J = 3.2 Hz, 
1H), 8.33 (d, J = 9.2 Hz, 1H), 10.19 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 52.2, 
52.3, 55.6, 114.4, 115.4, 120.4, 121.3, 135.4, 153.8, 154.2, 168.1. IR (KBr) 3258, 1740, 
1687, 1598, 1533, 1431, 1278 cm
–1
. MS (APPI) calcd for C11H13NO5 [M]
+
 239.0788, 
found 239.0790. 
 
Methyl fluoro-2-[(methoxycarbonyl)amino]benzoate (2g, 3- and 6-isomers): In 
Table 2, 3-:6- = 61:39. The 3-isomer and 6-isomer were separeted by column 
chromatography. 3-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 3.79 (s, 3H), 3.92 (s, 3H), 
7.18 (td, J = 8.2, 5.0 Hz, 1H), 7.33 (t, J = 8.2 Hz, 1H), 7.73 (dd, J = 8.2, 1.2 Hz, 1H), 
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8.38 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 52.4, 52.7, 106.0 (d, JC–F = 14.4 Hz), 
110.1 (d, JC–F = 24.0 Hz), 114.8 (d, JC–F = 3.8 Hz), 134.4 (d, JC–F = 10.5 Hz), 141.8 
(d, JC–F = 2.9 Hz), 153.9, 162.2 (d, JC–F = 258.7 Hz), 167.1 (d, JC–F = 3.8 Hz). 19F 
NMR (471 MHz, CDCl3) δ -116.5. 6-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 3.79 (s, 
3H), 3.96 (s, 3H), 6.79 (ddd, J = 11.0, 8.2, 1.2 Hz, 1H), 7.45 (td, J = 8.7, 6.1 Hz, 1H), 
8.17 (d, J = 8.7 Hz, 1H), 9.96 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 52.5, 52.9, 
120.9 (d, JC–F = 21.1 Hz), 123.7 (d, JC–F = 1.9 Hz), 125.1 (d, JC–F = 8.6 Hz), 125.9 
(d, JC–F = 3.8 Hz), 127.5 (d, JC–F = 13.4 Hz), 154.0, 156.2 (d, JC–F = 252.9 Hz), 
166.8 (d, JC–F = 3.8 Hz). 19F NMR (471 MHz, CDCl3) δ -105.4. IR (KBr) 3345, 1739, 
1702, 1512, 1445, 1280, 1238 cm
–1
. MS (APPI) calcd for C10H10NO4F [M]
+
 227.0588, 
found 227.0579.  
 
Methyl 2-[(methoxycarbonyl)amino]-4,5-dimethylbenzoate (2h): 
1
H NMR (400 
MHz, CDCl3) δ 2.22 (s, 3H), 2.30 (s, 3H), 3.77 (s, 3H), 3.89 (s, 3H), 7.74 (s, 1H), 8.21 
(s, 1H), 10.36 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 19.0, 20.5, 52.0, 52.1, 112.2, 
119.7, 129.9, 131.3, 139.6, 144.4, 154.1, 168.5. IR (KBr) 3253, 1733, 1690, 1592, 1524, 
1432, 1226 cm
–1
. MS (APPI) calcd for C12H15NO4 [M]
+
 237.0996, found 237.0096. 
 
Methyl 4,5-dichloro-2-[(methoxycarbonyl)amino]benzoate (2i): 
1
H NMR (400 MHz, 
CDCl3) δ 3.80 (s, 3H), 3.93 (s, 3H), 8.07 (s, 1H), 8.66 (s, 1H), 10.43 (b s, 1H). 
13
C 
NMR (100 MHz, CDCl3) δ 52.6, 52.7, 114.0, 120.5, 125.1, 132.0, 139.0, 140.7, 153.7, 
166.9. IR (KBr) 3256, 1736, 1694, 1580, 1503, 1311, 1220 cm
–1
. MS (APPI) calcd for 
C10H9NO4 [M]
+
 276.9903, found 276.9903. 
 
Methyl 3-[(methoxycarbonyl)amino]2-naphthoate (2j): 
1
H NMR (400 MHz, CDCl3) 
δ 3.82 (s, 3H), 3.97 (s, 3H), 7.38 (t, J = 8.0 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.79 (d, J 
= 8.0 Hz, 2H), 8.59 (s, 1H), 8.79 (s, 1H), 10.42 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) 
δ 52.2, 52.5, 115.4, 115.5, 125.1, 127.4, 127.9, 128.9, 129.2, 133.2, 136.4, 136.6, 154.3, 
168.4. IR (KBr) 3295, 1733, 1696, 1547, 1448, 1292, 1213 cm
–1
. MS (APPI) calcd for 
C14H13NO4 [M]
+
 259.0839, found 259.0839. 
Crystal data for 2j: Formula C14H13NO4, colorless, crystal dimensions 0.30 × 0.30 × 
0.20 mm
3
, tetragonal, space group P4 (3), a = 8.0618(11) Å, b = 8.0618(11) Å, c = 
37.917(5) Å, α = 90.00 °, β = 90.00 °, γ = 90.00 °, V = 2464.4(6) Å3, Z = 8, ρcalc = 1.398 
g cm
–3, F(000) = 1088, μ(M Kα) = 0.103 mm–1, T = 173 K. 13721 reflections collected, 
5515 independent reflections with I > 2σ(I) (2θmax = 27.56°), and 347 parameters were 
used for the solution of the structure. The non-hydrogen atoms were refined 
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anisotropically. Flack x = 0.1643. R1 = 0.0481 and wR2 = 0.1060. GOF = 1.023. 
Crystallographic data (excluding structure factors) for the structure reported in this 
paper have been deposited with the Cambridge Crystallographic Data Centre as 
supplementary publication no. CCDC-855556. Copies of the data can be obtained free 
of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. 
code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
 
 
Figure S1. OPTEP drawing of 2j. 
 
Methyl 2’-amino-(1,1’-bipheyl)-2-carboxylate (3k): 1H NMR (400 MHz, CDCl3) δ 
4.19 (s, 3H), 7.10 (d, J = 8.5 Hz, 1H), 7.35 (dd, J = 8.2, 7.4 Hz, 1H), 7.49 (dd, J = 8.5, 
7.4 Hz, 1H), 7.61 (dd, J = 8.2, 7.3 Hz, 1H), 7.81 (dd, J = 8.2, 7.6 Hz, 1H), 8.24-8.28 (m, 
2H), 8.50 (d, J = 7.6 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 55.9, 114.9, 118.6, 122.0, 
123.4, 123.7, 124.8, 128.4, 128.7, 129.7, 133.6, 134.0, 134.2, 153.9. IR (KBr) 3439, 
1763, 1664, 1607, 1440, 1329, 1238 cm
–1
. MS (APCI) calcd for C14H12NO4 [M–H]
+
 
226.0863, found 226.0862. 
 
Methyl [(methoxycarbonyl)amino]nicotinate (2l, 3- and 4-isomers): In Table 2, 3-:4- 
= 83:17. The 3-isomer and 4-isomer were separeted by column chromatography. 
3-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 3.83 (s, 3H), 3.97 (s, 3H), 8.35 (d, J = 6.0 Hz, 
1H), 8.58 (d, J = 6.0 Hz, 1H), 9.12 (s, 1H), 10.59 (brs, 1H). 13C NMR (100 MHz, 
CDCl3) δ 52.5, 52.8, 110.3, 112.2, 148.1, 152.5, 153.4, 154.3, 167.8. 4-Isomer: 1H 
NMR (400 MHz, CDCl3) δ 3.82 (s, 3H), 3.97 (s, 3H), 7.76 (d, J = 5.2 Hz, 1H), 8.38 (d, 
J = 5.2 Hz, 1H), 9.78 (s, 1H), 10.05 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 52.7, 52.9, 
120.3, 122.5, 136.3, 142.5, 143.0, 153.6, 167.2. IR (KBr) 3255, 1743, 1695, 1597, 1519, 
1442, 1302, 1229 cm
–1
. MS (APPI) calcd for C9H11N2O4 [M+H]
+
 211.0713, found 
211.0712. 
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Ethyl 2-[(ethoxycarbonyl)amino]benzoate (2m): 
1
H NMR (400 MHz, CDCl3) δ 1.32 
(t, J = 7.1 Hz, 3H), 1.41 (t, J = 7.1 Hz, 3H), 4.23 (q, J = 7.1 Hz, 2H), 4.38 (q, J = 7.1 Hz, 
2H), 7.02 (td, J = 8.0, 1.2 Hz, 1H), 7.52 (td, J = 8.7, 1.6 Hz, 1H), 8.02 (dd, J = 8.0, 1.6 
Hz, 1H), 8.44 (dd, J = 8.7, 1.2 Hz, 1H), 10.51 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
14.2, 14.5, 61.1, 61.2, 114.7, 118.7, 121.3, 130.8, 134.4, 141.9, 153.7, 168.1. IR (neat) 
3256, 1727, 1693, 1595, 1533, 1452, 1244 cm
–1
. MS (APPI) calcd for C12H15NO4 [M]
+
 
237.0096, found 237.0096. 
 
2”,2”,2”-Trifluoroethyl 2-{[(2’,2’,2’-trifluoroethoxy)carbonyl]amino}benzoate 
(2n): 
1
H NMR (400 MHz, CDCl3) δ 4.58 (q, J = 8.5 Hz, 2H), 4.70 (q, J = 8.5 Hz, 2H), 
7.13 (td, J = 8.2, 1.2 Hz, 1H), 7.62 (td, J = 8.2, 1.6 Hz, 1H), 8.08 (dd, J = 8.2, 1.6 Hz, 
1H), 8.42 (dd, J = 8.2, 1.2 Hz, 1H), 10.41 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
60.9 (q, JC–F = 37.4 Hz), 61.0 (q, JC–F = 37.4 Hz), 113.4, 119.1, 122.6, 122.87 (q, 
JC–F = 278.8 Hz), 122.92 (q, JC–F = 278.8 Hz), 131.2, 135.8, 141.3, 151.4, 166.2. 19F 
NMR (471 MHz, CDCl3) δ -73.9, -73.4. IR (KBr) 3289, 1752, 1704, 1599, 1535, 1452, 
1285, 1178 cm
–1
. MS (APPI) calcd for C12H8F6NO4 [M–H]– 344.0352, found 
344.0365. 
 
Dimethyl oxybis{2-[(methoxycarbonyl)amino]benzoate} (2o, 4,5’-, 4,4’-, and 
5,5’-isomers): In Table 2, 4,5’-:4,4’-:5,5’- = 61:22:17. 4,5’-Isomer: 1H NMR (400 MHz, 
CDCl3) δ 3.75 (s, 3H), 3.80 (s, 3H), 3.89 (s, 6H), 6.53 (dd, J = 8.9, 3.0 Hz, 1H), 7.29 
(dd, J = 9.0, 2.5 Hz, 1H), 7.73 (d, J = 3.0 Hz, 1H), 7.95 (d, J = 8.9 Hz, 1H), 8.06 (d, J = 
2.5 Hz, 1H), 8.48 (d, J = 9.0 Hz, 1H), 10.42 (brs, 1H), 10.64 (brs, 1H). 
13
C NMR (100 
MHz, CDCl3) δ 52.26 (2C), 52.29, 52.4, 106.8, 108.8, 110.1, 112.1, 120.5, 122.4, 127.0, 
132.8, 138.6, 143.8, 148.7, 153.8 (2C), 162.9, 167.6, 168.0. 4,4’-Isomer: 1H NMR (400 
MHz, CDCl3) δ 3.76 (s, 6H), 3.90 (s, 6H), 6.69 (dd, J = 8.9, 2.3 Hz, 2H), 8.01 (d, J = 
8.9 Hz, 2H), 8.16 (d, J = 2.3 Hz, 2H), 10.64 (brs, 2H). 
13
C NMR (100 MHz, CDCl3) δ 
52.1 (2C), 52.4 (2C), 109.0 (2C), 110.1 (2C), 115.7 (2C), 132.9 (2C), 143.8 (2C), 154.0 
(2C), 160.9 (2C), 168.0 (2C). 5,5’-Isomer: 1H NMR (400 MHz, CDCl3) δ 3.79 (s, 6H), 
3.88 (s, 6H), 7.21 (dd, J = 9.2, 3.0 Hz, 2H), 7.59 (d, J = 3.0 Hz, 2H), 8.41 (d, J = 9.2 Hz, 
2H), 10.33 (brs, 2H). 
13
C NMR (100 MHz, CDCl3) δ 52.1 (2C), 52.3 (2C), 110.1 (2C), 
120.2 (2C), 120.6 (2C), 125.2 (2C), 137.5 (2C), 151.0 (2C), 154.1 (2C), 167.7 (2C). IR 
(KBr) 3290, 1741, 1694, 1595, 1526, 1436, 1249 cm
–1
. MS (APCI) calcd for 
C20H21N2O9 [M+H]
+
 433.1242, found 433.1239. 
 
N-(Methoxycarbonyl)-β-alanine methyl ester (5a): 1H NMR (400 MHz, CDCl3) δ 
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2.55 (t, J = 6.1 Hz, 2H), 3.45 (q, J = 6.1 Hz, 2H), 3.66 (s, 3H), 3.70 (s, 3H), 5.23 (brs, 
1H). 
13
C NMR (100 MHz, CDCl3) δ 34.2, 36.5, 51.8, 52.1, 156.9, 172.8.  R ( e t) 3346, 
1725, 1533, 1441, 1256 cm
–1
. MS (ESI) calcd for C6H11NO4Na [M+Na]
+
 184.0580, 
found 184.0580. 
 
Methyl [(methoxycarbonyl)amino]methylpropanoate (5b, 2- and 3-isomers): In 
Table 3, 2-:3- = 56:44. 2-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 1.18 (d, J = 7.3 Hz, 
3H), 2.67-2.75 (m, 1H), 3.26-3.42 (m, 2H), 3.66 (s, 3H), 3.70 (s, 3H), 5.24 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 14.6, 39.8, 43.3, 51.7, 52.0, 157.0, 175.6. 3-Isomer: 
1
H 
NMR (400 MHz, CDCl3) δ 1.24 (d, J = 6.8 Hz, 3H), 2.48-2.58 (m, 2H), 3.66 (s, 3H), 
3.69 (s, 3H), 4.01-4.18 (m, 1H), 5.07 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 20.3, 
40.2, 44.0, 51.5, 51.9, 156.1, 171.8. IR (neat) 3342, 1727, 1532, 1440, 1255 cm
–1
. MS 
(ESI) calcd for C7H14NO4 [M+H]
+
 176.0917, found 176.0920. 
 
Methyl butyl-[(methoxycarbonyl)amino]propanoate (5c, 2- and 3-isomers): In 
Table 3, 2-:3- = 59:41. 2-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 0.89 (t, J = 7.0 Hz, 3H), 
1.23-1.39 (m, 4H), 1.44-1.56 (m, 2H), 2.57-2.67 (m, 1H), 3.25-3.34 (m, 1H), 3.37-3.46 
(m, 1H), 3.66 (s, 3H), 3.70 (s, 3H), 5.14 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 13.8, 
22.4, 28.2, 29.1, 42.0, 45.4, 51.7, 52.0, 157.0, 175.5. 3-Isomer: 
1
H NMR (400 MHz, 
CDCl3) δ 0.89 (t, J = 7.0 Hz, 3H), 1.24-1.39 (m, 5H), 1.56-1.67 (m, 1H), 2.54 (t, J = 5.2 
Hz, 2H), 3.66 (s, 3H), 3.68 (s, 3H), 3.89-4.00 (m, 1H), 5.19 (brs, 1H). 
13
C NMR (100 
MHz, CDCl3) δ 13.9, 22.3, 29.3, 34.0, 38.8, 48.0, 51.6, 51.9, 156.4, 172.0. IR (neat) 
3342, 1729, 1533, 1441, 1254 cm
–1
. MS (ESI) calcd for C10H20NO4 [M+H]
+
 218.1387, 
found 218.1389. 
 
Methyl benzyl-[(methoxycarbonyl)amino]propanoate (5d, 2- and 3-isomers): In 
Table 3, 2-:3- = 57:43. 2-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 2.77-2.84 (m, 1H), 
2.90-2.99 (m, 2H), 3.27-3.35 (m, 1H), 3.36-3.46 (m, 1H), 3.61 (s, 3H), 3.65 (s, 3H), 
5.32 (brs, 1H), 7.12-7.32 (m, 5H). 
13
C NMR (100 MHz, CDCl3) δ 35.6, 41.7, 47.0, 51.6, 
51.9, 126.4, 128.3(2C), 128.6(2C), 138.0, 156.1, 174.4. 3-Isomer: 
1
H NMR (400 MHz, 
CDCl3) δ 2.42-2.55 (m, 2H), 2.77-2.84 (m, 1H), 2.90-2.99 (m, 1H), 3.61 (s, 3H), 3.63 (s, 
3H), 4.16-4.25 (m, 1H), 5.43 (brs, 1H), 7.12-7.32 (m, 5H). 
13
C NMR (100 MHz, CDCl3) 
δ 37.2, 40.0, 49.2, 51.5, 51.8, 126.5, 128.3(2C), 129.1(2C), 137.4, 156.8, 171.8. IR 
(neat) 3341, 1728, 1532, 1442, 1259 cm
–1
. MS (ESI) calcd for C13H18NO4 [M+H]
+
 
252.1230, found 252.1230. 
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Methyl 3-[(methoxycarbonyl)amino]-2-methylbutanoate (5e): 
1
H NMR (400 MHz, 
CDCl3) δ 1.16 (d, J = 6.8 Hz, 3H), 1.20 (d, J = 7.3 Hz, 3H), 2.59-2.68 (m, 1H), 3.36 (s, 
3H), 3.70 (s, 3H), 3.85-3.98 (m, 1H), 5.36 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
14.3, 19.3, 43.9, 48.8, 51.6, 51.9, 156.6, 175.5. IR (neat) 3336, 1724, 1530, 1453, 1246 
cm
–1
. MS (ESI) calcd for C8H16NO4 [M+H]
+
 190.1074, found 190.1075. 
 
Methyl [(methoxycarbonyl)amino]dimethylpropanoate (5f, 2- and 3-isomers): In 
Table 3, 2-:3- = 70:30. 2-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 1.20 (s, 6H), 3.30 (d, J 
= 6.6 Hz, 2H), 3.66 (s, 3H), 3.69 (s, 3H), 5.21 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
22.9 (2C), 44.0, 48.7, 51.4, 51.9, 157.3, 177.4. 3-Isomer: 
1
H NMR (400 MHz, CDCl3) δ 
1.40 (s, 6H), 2.69 (s, 2H), 3.62 (s, 3H), 3.68 (s, 3H), 5.21 (brs, 1H). 
13
C NMR (100 
MHz, CDCl3) δ 27.2 (2C), 43.5, 51.2, 51.4, 52.0, 155.5, 171.6. IR (neat) 3358, 1725, 
1530, 1469, 1257 cm
–1
. MS (ESI) calcd for C8H16NO4 [M+H]
+
 190.1074, found 
190.1076. 
 
Methyl 4-[(methoxycarbonyl)amino]butanoate (5g): 
1
H NMR (400 MHz, CDCl3) δ 
1.80-1.88 (m, 2H), 2.37 (t, J = 7.3 Hz, 2H), 3.23 (q, J = 6.5 Hz, 2H), 3.66 (s, 3H), 3.68 
(s, 3H), 4.93 (brs, 1H). 
13
C NMR (100 MHz, CDCl3) δ 25.1, 31.2, 40.3, 51.6, 52.0, 
157.1, 173.7. IR (neat) 3345, 1724, 1535, 1442, 1260 cm
–1
. MS (ESI) calcd for 
C7H14NO4 [M+H]
+
 176.0917, found 176.0917. 
 
Methyl 3-{[(methoxycarbonyl)amino]methyl}-5-methylhexanoate (5h): 
1
H NMR 
(400 MHz, CDCl3) δ 0.88 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H), 1.07-1.23 (m, 
2H), 1.65 (sep, J = 6.6 Hz, 1H), 2.08-2.19 (m, 1H), 2.29 (d, J = 6.6 Hz, 2H), 2.96-3.12 
(m, 1H), 3.16-3.32 (m, 1H), 3.36 (s, 3H), 3.67 (s, 3H), 5.02 (brs, 1H). 
13
C NMR (100 
MHz, CDCl3) δ 22.5(2C), 25.1, 33.5, 37.1, 41.4, 44.7, 51.5, 51.9, 157.2, 173.6. IR 
(neat) 3347, 1731, 1536, 1439, 1254 cm
–1
. MS (ESI) calcd for C11H22NO4 [M+H]
+
 
232.1543, found 232.1543. 
 
Phenyliodine (III) bis[phthalimidate] (7): 
1
H NMR (400 MHz, DMSO-d6) δ 7.23 (t, J 
= 8.0 Hz,2H), 7.44 (t, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 2H), 7.87 (s, 8H). 
13
C NMR 
(100 MHz, DMSO) δ 122.9 (5C), 127.7, 130.7 (2C), 132.6 (4C), 134.3 (4C), 137.1 (2C), 
169.2 (4C). IR (Nujol) 1736, 1692, 1670, 1611, 1279, 1117 cm
–1
. MS (ESI) calcd for 
C14H9INO2 [M–Phthalimidate]
+
 349.9668, found 349.9672. 
 
3. General procedure for Methoxycarbonylation of Methyl anthranilate 3a. 
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To a solution of methyl anthranilate 3a (37.8 mg, 0.25 mmol) in toluene (1 mL) was 
added  ethyl chl   f    te (38.4 μL, 0.50    l)  t      te pe  t  e   de    g   
atomosphere, and the solution was refluxed for 8 h. After removal of the solvent under 
reduced pressure, the pure methyl 2-[(methoxycarbonyl)amino]benzoate 2a was 
obtained as a colorless crystal (51.0 mg, >99% yield) without further purification by 
collumn chromatography. 
 
4. In Situ HRMS-ESI Study. 
To the solution of PhI(OH)(OTs) (39.1 mg, 0.10 mmol) and phthalimide 1a (14.7 mg, 
0.10 mmol) in MeCN (1 mL) was added K2CO3 (13.8 mg, 0.10 mmol), and the mixture 
stirred at room temperature for 3 h. The reaction mixture was diluted with 
MeCN/MeOH prior to the injection into the mass spectrometer. 
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Chapter 2 
Preparation of Novel Imide-combined Hypervalent Iodines: Heteroaryl(aryl)- 
iodonium Imides 
 
Abstract 
(Heteroaryl)(aryl)iodonium imides were prepared from various heteroaromatics with 
(diacetoxyiodo)benzene (DIB) and bis(sulfonyl)imides. These novel hypervalent 
iodines were stable as white solid, and the unique structure was observed from two 
types of iodane (III), imide-combined -iodane and asymmetric diaryliodonium salt 
containing heterocycles. 
 
Introduction 
Heteroaryl-contained hypervalent iodine is attractive reagent to obtain various 
heteroaryl substituted compounds
1,2
. In particular, C-N bond formation with hetroaryl 
hypervalent iodine is much important to use for synthesis of amino-heteroaryl rings, 
which are included in a lot of biological active and medicinal compounds
3
. Nevertheless, 
synthesis of heteroaryliodane containing I-N bond had been less studied. Recently, Suna 
group reported (indolyl)(phenyl)iodonium azide and azidation of indole
4
, however, the 
iodonium azide was not stable and required heavy metal for C-N bond formation.  
On the other hands, imide-combined hypervalent iodine was used as oxidative C-N 
bond formation. Muñis group reported useful C-N bond introduction to alkene, alkyne, 
and so on, using imide-combined hypervalent iodine
5
, and the author also reported 
Hofmann-type rearrangement via imide-combined hypervalent iodine (Chapter 1)
6
. 
Here, the author reported preparation of novel imide-combined hypervalent iodines, 
heteroaryl(aryl)iodinum imides, which were stable as white solid and easily obtained 
from heteroaryl compounds. 
 
Results and Discussion 
First, the author used indole as a model compound, and screened the reaction conditions 
for preparation of (indolyl)(aryl)iodonium imide (2) (Table 1). MeCN and a mixture of 
MeCN/DCE(2:1) were effective solvents (entries 1-8), however, PhI(OAc)NR2 
generated in situ from hypervalent iodines and bis(sulfonyl)imids were sometimes 
precipitated in MeCN and the yield was not reproducible. DIB is the best hypervalent 
iodine reagent (entries 9, 10). Using t-butoxycalbonyl (Boc), benzoyl (Bz), and tosyl 
(Ts) as a N-protecting group, desired products (2) were obtained in good yield (entries 
11-13). On the other hands, BzTsNH and PhTsNH instead of Ts2NH did not give 2 
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(entries 14, 15). From these results, the author believed that the active hypervalent 
iodine compound, PhI(OAc)NR2, is not formed from the reaction with BzTsNH or 
PhTsNH, and treatment of N-Pivalpylindole (1) with DIB(1.2 equiv.) and Ts2NH (1.2 
equiv.) in MeCN/DCE(2:1) at 50 ˚C (entry 7) is the best conditions.  
 
 
 
Next, the author examined the preparation of (indolyl)(aryl)iodonium imides (2) from 
various substituted N-protected indoles (1) under optimized reaction conditions (Table 
2). The reaction of 5-substituted indole bearing Me (1b), MeO (1c), F (1d), Cl (1e), 
PivO (1i), and PhthN (1j) groups gave the corresponding 5-substituted 
(indolyl)(aryl)iodonium imides (2b-2e, 2i, 2j) in high yields, respectively. 
(Indolyl)(aryl)iodonium imides bearing an electron-withdrawing group, such as Br (1f), 
CO2Me (1g), and CN (1h), were also converted into desire products in good yields 
(2f-2h), respectively. (Indolyl)(aryl)iodonium imides bearing other monosubstituted 
indoles at different position were also transformed into the corresponding products in 
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good to high yields (2k-2m), respectively. In all substrates that the author examined, 
iodonium imides bonded at 3-position of indoles were observed and those imides 
bonded at 2-position of indoles were not observed at all. 
 
 
Then, the author also screened various bis(sulfonyl)imides and (diacetoxyiodo)arenes to 
optimized reaction conditions (Table 3). The formation of 2 proceeded with high 
conversion and the desired products were obtained in high yields (2n-2ac), respectively. 
In addition, the product 2 with methyl 1-pivaloylindole-2-carboxylate, Ms2NH or 
(BnSO2)2NH could be isolated using 1-(diaceetoxyiodo)-3,5-dichlorobenzene or 
1-(diacetoxyiodo)-2-methoxybenzene instead of DIB, although 2 with DIB could not be 
isolated
7
 (2ae-af). 
 
38 
 
 
 
The crystal structure of (indolyl)(phenyl)iodonium imide (2a) is depicted in Figure 1. It 
displays that the bond distance of I-N, I-C (aryl) and I-C (het) are 2.831 Å, 2.111 Å, and 
2.085 Å, respectively. Both I-C bond lengths are the same as I-C (aryl) bond length of 
the previously reported hypervalent iodines
4
.
 
I-N bond length is similar to that of OTf, 
OCOCF3, N3 group in diaryliodonium salt
3h,8
.
 
The author believes as follows, the above 
result suggest that Ts2N group may be easily removable, electron density on iodine atom 
is extremely low, and therefore, nucleophilic attack to iodine atom followed by 
amination with imide may occur smoothly.   
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Moreover, the author succeeded in the preparation of heteroaryl(aryl)iodonium imide 
with heteroaromatic derivatives instead of indole derivatives (Table 4). The treatment of 
pyrrole derivatives, such as 4,5,6,7-tetrahydroindole (3a) and 
3,5-dimethyl-1-ethoxycarbonylpyrrole (3b), with DIB and Ts2NH gave desired products 
(4a,b) in high yields, respectively. The same treatment of 3,5-dimethylpyrrazole 
provided heteroaryl(aryl)iodonium imide (4c) in high yield using 
1-(diacetioxyiodo)-2-methoxybenzene. Indazole (3d) was transformed to 4d without 
any N-protection group. Sulfur-containing heteroaryl(aryl)iodonium imides (4e,f) were 
also obtained from thiophene derivatives (3e,f), respectively. In addition, the same 
treatment of 1,3,6-trimethyluracil (3g) and 2-methyl-4-quinolinol (3h) provided desired 
products (4g,h) in high yields, respectively. 
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In conclusion, the author succeeded in the preparation of heteroaryl(aryl)iodonium 
imides from heteroaromatics, (diacetoxyiodo)arene, and bis(sulfonyl)imides. These 
novel imide-combined hypervalent iodines were easily prepared, isolated, and stable 
solid at room temperature in air. The author believes that those heteroaryl(aryl)iodonium 
imide possesses high reactivity for new C-N bond formation at the heteroaryl group. 
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Experimental 
1. General Methods. 
1
H NMR spectra were measured on a JEOL ECA-500 (500 MHz) 
spectrometer at ambient temperature. Data were recorded as follows: chemical shift in 
ppm from internal tetramethylsilane on the δ sc le,  lt pl c ty (s = s  glet; d = d  blet; 
t = triplet; q = quartet; sep = septet; m = multiplet; br = broad), coupling constant (Hz), 
integration, and assignment. 
13
C NMR spectra were measured on a JEOL ECA-500 
(125 MHz) spectrometer. Chemical shifts were recorded in ppm from the solvent 
resonance employed as the internal standard (deuterochloroform at 77.0 ppm). 
High-resolution mass spectra were recorded by Thermo Fisher Scientific Exactive 
Orbitrap mass spectrometers. Infrared (IR) spectra were recorded on a JASCO FT/IR 
4100 spectrometer. Single crystal X-ray diffraction data were collected at 173 K on a 
   ke  SMART APEX    CCD d ff  ct  ete  w th M  Kα (λ = 0.71073) radiation and 
graphite monochrometer. For thin-layer chromatography (TLC) analysis throughout this 
work, Merck precoated TLC plates (silica gel 60GF254 0.25 mm) were used. 
Visualization was accomplished by UV light (254 nm), anisaldehyde, KMnO4, and 
phosphomolybdic acid.  
 
2. 1 General Procedure Using Method A for Preparation of Indolyl(aryl)iodonium 
Imides (2)  
To prepare PhI(OAc)NTs2 were used DIB (96.6 mg, 0.30 mmol) and Ts2NH (97.6 mg, 
0.3 mmol) in MeCN (1.4 ml) and dichloroethane (0.7 ml). The mixture was stirred at 
room temperature for 30 min. under argon atmosphere. Then, N-pivaloylindole (50.3 mg, 
0.25 mmol) was added, and the solution was stirred at 50 ˚C for 3 h. The solvent was 
removed under reduced pressure. Then, AcOEt (5 ml) and ether (3 ml) were added. The 
mixture was sonicated until precipitation occurred as the white solid, and ether (3 ml) 
was added to the mixture. The solid was filtrated and washed with AcOEt/ether (2:1) 
(15 ml), to give desired product 2a (163.9 mg, 90 % yield). 
 
2. 2 General Procedure Using Method B for Preparation of Indolyl(aryl)iodonium 
Imides (2)  
To prepare PhI(OAc)NTs2 were used DIB (96.6 mg, 0.30 mmol) and Ts2NH (97.6 mg, 
0.3 mmol) in MeCN (1.4 ml) and dichloroethane (0.7 ml). The mxture was stirred at 
room temperature for 30 min. under argon atmosphere. Then, 
5-methoxy-N-pivaloylindole (57.8 mg, 0.25 mmol) was added, and the solution was 
stirred at 50 ˚C for 7 h. The solvent was removed under reduced pressure. Then, AcOEt 
(5 ml) and ether (3 ml) were added. The mixture was sonicated until precipitation 
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occurred as the white solid, and and ether (3 ml) was added to the mixture. The solid 
was filtrated and washed with AcOEt/ether (2:1) (15 ml). The crude product was 
purified by recrystalization from CHCl3/AcOEt, to give desired product 2c (174.5 mg, 
92 % yield). 
 
2. 3 General Procedure Method C for Preparation of Indolyl(aryl)iodonium Imides 
(2) 
To prepare PhI(OAc)NTs2 were used DIB (96.6 mg, 0.30 mmol) and Ts2NH (97.6 mg, 
0.3 mmol) in MeCN (1.4 ml) and dichloroethane (0.7 ml) The mixture was stirred at 
room temperature for 30 min. under argon atmosphere. Then, 6-chloro-N-pivaloylindole 
(58.9 mg, 0.25 mmol) was added, and the solution was stirred at 50 ˚C for 7 h. The 
solvent was removed under reduced pressure. Then, AcOEt (5 ml) and ether (3 ml) were 
added. The mixture was sonicated until precipitation occurred as the white solid, and 
ether (3 ml) was added to the mixture. The solid was filtrated and washed with 
AcOEt/ether (2:1) (15 ml). The crude product was purified by recrystalization from 
acetone/hexane, to give desired product 2k (133.6 mg, 70 % yield). 
 
2. 4 General Procedure Using Method D for Preparation of 
4-Methyl-N-((4-methoxyphenyl)(1-pivaloyl-1H-indol-3-yl)-3-iodanyl)-N-tosylbenz
enesulfonamide (2r)  
To prepare ArI(OAc)NTs2 were used 1-(diacetoxyiodo)-4-methoxybenzene (105.6 mg, 
0.3 mmol) and Ts2NH (97.6 mg, 0.3 mmol) in MeCN (1.4 ml) and dichloroethane (0.7 
ml). The mixture was stirred at room temperature for 30 min. under argon atmosphere. 
Then, N-pivaloylindole (50.3 mg, 0.25 mmol) was added, and the solution was stirred at 
50 ˚C for 7 h. The solvent was removed under reduced pressure. Then, AcOEt (3 ml) 
was added. The mixture was added dropwise to ether until the solvent changed clear 
solution to pale white, followed by sonication. Then, ether (1 ml) was added to the 
mixture. The solid was filtrated and washed with AcOEt/ether (1:1) (15 ml), to give 
desired product 2r (141.2 mg, 74 % yield). 
 
2. 5 General Procedure Using Method E for Preparation of 
N-((1-Benzoyl-1H-indol-3-yl)(phenyl)-3-iodanyl)-4-methyl-N-tosylbenzenesulfona
mide (2ah) 
To prepare PhI(OAc)NTs2 were used DIB (96.6 mg, 0.30 mmol) and Ts2NH (97.6 mg, 
0.3 mmol) in MeCN (1.4 ml) and dichloroethane (0.7 ml). The mixtue was stirred at 
room temperature for 30 min. under argon atmosphere. Then, N-benzoylindole (55.3 mg, 
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0.25 mmol) was added, and the solution was stirred at 50 ˚C for 7 h. The solvent was 
removed under reduced pressure. Then, AcOEt (3 ml) was added. The mixture was 
added dropwise to ether /hexane (1:1) until the solvent changed clear solution to pale 
white, followed by sonication. Then, ether (1 ml) was added to the mixture. The solid 
was filtrated and washed with AcOEt/hexane (2:1) (15 ml), to give desired product 2ah 
(127.3 mg, 68 % yield). 
 
2. 6 General Procedure Using Method F for Preparation of 
4-Methyl-N-(1-pivaloyl-(3-trifluoromethylphenyl)-1H-indol-3-yl)-3-iodanyl)-N-tos
ylbenzenesulfonamide (2aa)  
To prepare ArI(OAc)NTs2 were used 1-(diacetoxyiodo)-3-trifluoromethylbenzene 
(117.0 mg, 0.3 mmol) and Ts2NH (97.6 mg, 0.3 mmol) in MeCN (1.4 ml) and 
dichloroethane (0.7 ml). The mixture was stirred at room temperature for 30 min. under 
argon atmosphere. Then, N-pivaloylindole (50.3 mg, 0.25 mmol) was added, and the 
solution was stirred at 50 ˚C for 7 h. The solvent was removed under reduced pressure. 
Then, AcOEt (3 ml) was added. The mixture was added dropwise to ether /hexane (1:1) 
until the solvent changed clear solution to pale white. The solution was stored overnight 
at -10 ˚C. The solid was filtrated and washed with AcOEt/hexane (2:1) (15 ml), to give 
desired product 2aa (159.1 mg, 85 % yield). 
 
2. 7 General Procedure Using Method G for Preparation of 
N-((5-(1,3-Dioxyindolin-2-yl)-1-pivaloyl-1H-indol-3-yl)(phenyl)-λ3-iodanyl)-4-meth
yl-Ntosylbenzenesulfonamide (2j)  
To prepare ArI(OAc)NTs2 were used DIB (96.6 mg, 0.30 mmol) and Ts2NH (97.6 mg, 
0.3 mmol) in MeCN (1.4 ml) and dichloroethane (0.7 ml). The mixture was stirred at 
room temperature for 30 min. under argon atmosphere. Then, 
2-(N-pivaloyl-1H-indol-5-yl)isoindoline-1,3-dione (86.6 mg, 0.25 mmol) was added, 
and the solution was stirred at 50 ˚C for 7 h. The solvent was removed under reduced 
pressure. Then, AcOEt (5 ml) was added, and the mixture was filtrated and washed with 
AcOEt (5 ml). The filtrate was evaporated. Then AcOEt (3 ml) was added. The mixture 
was added dropwise to ether until the solvent changed clear solution to pale white, 
followed by sonicated. Then, ether (1 ml) was added to the mixture. The solid was 
filtrated and washed with AcOEt/ether (1:1) (15 ml), to give desired product 2j (166.0 
mg, 76 % yield). 
 
4-Methyl-N-(phenyl(1-pivaloyl-1H-indol-3-yl)-3-iodanyl)-N-tosylbenzenesulfonam
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ide (2a) (Isolated Method : A) : mp. 164 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) 
δ1.44 (s, 9H), 2.20 (s, 6H), 6.87 (d, J=8.0 Hz, 4H), 7.27 (t, J=7.5 Hz, 2H), 7.33 (t, J=7.5 
Hz, 1H), 7.39-7.48 (m, 7H), 8.03 (d, J=7.5 Hz, 2H), 8.45 (d, J=8.3 Hz, 1H), 8.85(s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.4 (3C), 41.7, 86.0, 115.4, 117.6, 119.4, 
125.1, 126.76 (4C), 126.81, 127.7, 128.5 (4C), 131.5 (3C), 134.9 (2C), 135.5, 136.3, 
140.8 (2C), 141.0 (2C), 177.1. IR (neat) 1703, 1444, 1281, 1134, 1281, 1077, 1034 cm
–1
. 
MS (ESI) calcd for C33H33N2O5INaS2 [M+Na]
+
 751.0768, found 751.0754. 
 
Crystal data for 2a: Formula C33H33N2O5S2·2CHCl3, colorless, crystal dimensions 
0.30 × 0.20 × 0.10 mm
3
, prismatic, space group P2 (1), a = 18.254(3) Å, b = 9.5283(15) 
Å, c = 23.967(4) Å, α = 90.00 °, β = 97.187(2) °, γ = 90.00 °, V = 4157.7(11) Å3, Z = 4, 
ρcalc = 1.545 g cm
-3
, F(000) = 1944, μ(M Kα) = 1.298 mm-1, T = 173 K. 22389 
reflections collected, 9335 independent reflections with I > 2σ(I) (2θmax = 27.56°), and 
539 parameters were used for the solution of the structure. The non-hydrogen atoms 
were refined anisotropically. R1 = 0.0678 and wR2 = 0.1797. GOF = 1.061. 
Crystallographic data (excluding structure factors) for the structure reported in this 
paper have been deposited with the Cambridge Crystallographic Data Centre as 
supplementary publication no. CCDC-1023214. Copies of the data can be obtained free 
of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. 
code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
 
 
Figure 1. OPTEP drawing of 2a. 
 
4-Methyl-N-(phenyl(5’-methyl-1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylbenz
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enesulfonamide (2b) (Isolated Method : A) : mp. 173 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.44 (s, 9H), 2.23 (s, 6H), 2.43 (s, 3H), 6.88 (d, J=8.0Hz,4H), 7.19 (s, 
1H), 7.24 (d, J=8.6 Hz, 1H), 7.42-7.48 (m, 1H), 7.45 (d, J=8.0 Hz,4H), 8.06 (d, J=7.8 
Hz, 2H), 8.32 (d, J=8.6 Hz, 1H), 8.78 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.26 
(2C), 21.33, 28.4 (3C), 41.7, 85.4, 115.4, 117.4, 119.0, 126.8 (4C), 127.8, 128.4, 128.5 
(4C), 131.6, 131.7 (2C), 134.5, 134.6 (2C), 135.2, 135.4, 140.7 (2C), 140.9 (2C), 176.9. 
IR (neat) 1699, 1489, 1294, 1131, 1078, 1037, 1014, 806, 760 cm
–1
. MS (ESI) calcd for 
C34H35N2O5INaS2 [M+Na]
+
 765.0924, found 765.0908. 
 
N-((5’-Methoxy-1’-pivaloyl-1’H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4-methyl-N-tosylb
enzenesulfonamide (2c) (Isolated Method : B) : mp. 199 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ1.43 (s, 9H), 2.20 (s, 6H), 3.80 (s, 3H), 6.86 (s, 5H), 6.87 (d, J=8.3 
Hz,4H), 6.99 (dd, J=9.2, 2.3 Hz, 1H), 7.27 (t, J=7.7 Hz, 2H), 7.36-7.48 (m, 5H), 8.09 (d, 
J=7.7 Hz, 2H), 8.33(d, J=9.2 Hz, 1H), 8.79 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 
(2C), 28.4 (3C), 41.6, 55.9, 85.7, 101.6, 115.4, 115.8, 118.6, 126.7 (4C), 128.4 (4C), 
128.8, 130.7, 131.50 (2C), 131.54, 134.9 (2C), 135.6, 140.8 (2C), 141.2 (2C), 176.8. IR 
(neat) 1711, 1471, 1434, 1260, 1201, 1128, 1075, 1039, 802, 737, 664 cm
–1
. MS (ESI) 
calcd for C34H35N2O5INaS2 [M+Na]
+
 781.0873, found 781.0867. 
 
N-((5’-Fluoro-1’-pivaloyl-1’H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4-methyl-N-tosylben
zenesulfonamide (2d) (Isolated Method : A) : mp. 178 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.42 (s, 9H), 2.22 (s, 6H), 6.90 (d, J=8.2 Hz, 4H), 7.05 (dd, J=9.2, 2.3 
Hz, 1H), 7.13 (td, J=9.2, 2.3 Hz, 1H), 7.28 (t, J=7.5 Hz, 1H), 7.43 (d, J=8.2 Hz, 4H) 
7.46 (t, J=7.5 Hz, 1H), 8.06 (d, J=7.5 Hz, 2H), 8.42 (dd, J=9.2, 4.6 Hz, 1H), 8.91 (s, 
1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.4 (3C), 41.7, 85.7, 105.2 (d, 
JC-F=25.0 Hz), 114.7 (d, JC-F=25.0 Hz), 115.6, 119.2, 126.7 (4C), 128.5 (4C), 129.1 (d, 
JC-F=10.7 Hz), 131.56 (2C), 131.63, 132.6 135.1 (2C), 136.9, 141.06 (2C), 141.13 (2C), 
160.2 (d, JC-F=243.2 Hz), 177.0. 
19
F NMR (471 MHz, CDCl3) δ -115.8. IR (neat) 1716, 
1469, 1440, 1280, 1179, 1133, 1077, 1031, 1011, 813, 761, 738, 671 cm
–1
. MS (ESI) 
calcd for C33H32N2O5FINaS2 [M+Na]
+
 769.0674, found 769.0662. 
 
N-((5’-Chloro-1’-pivaloyl-1’H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4-methyl-Ntosylben
zenesulfonamide (2e) (Isolated Method : A) : mp. 186 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.42 (s, 9H), 2.21 (s, 6H), 6.88 (d, J=8.1 Hz, 4H), 7.28 (t, J=7.8 Hz, 
2H), 7.32-7.38 (m, 3H), 7.40 (d, J=8.1 Hz, 4H), 7.47 (t, J=7.8 Hz, 1H), 8.07 (d, J=9.8 
Hz, 2H), 8.37 (d, J=9.8 Hz, 1H), 8.91 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 
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28.3 (3C), 41.7, 85.4, 115.8, 118.8, 118.9, 126.7 (4C), 126.9, 128.5 (4C), 129.2, 130.7, 
131.5 (2C), 131.6, 134.6, 135.1 (2C), 136.7, 141.0 (2C), 141.1 (2C), 177.0. IR (neat) 
1715, 14742, 1260, 1129, 1076, 1044, 810, 763, 735, 665 cm
–1
. MS (ESI) calcd for 
C32H32N2O5ClINaS2 [M+Na]
+
 785.0378, found 785.0367. 
 
N-((5’-Bromo-1’-pivaloyl-1’H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4-methyl-N-tosylben
zenesulfonamide (2f) (Isolated Method : A) : mp. 194 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.43 (s, 9H), 2.22 (s, 6H), 6.87 (d, J=8.1 Hz, 4H), 7.28(t, J=7.8 Hz, 2H), 
7.41 (d, J=8.1 Hz, 4H), 7.46-7.62 (m, 3H), 8.06 (d, J=7.8 Hz, 2H), 8.30 (d, J=7.1 Hz, 
1H), 8.89 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.3 (3C), 41.8, 85.1, 115.7, 
118.4, 119.1, 121.9, 126.7 (4C), 128.5 (4C), 129.5, 129.6, 131.6 (2C), 131.7, 135.1 (3C), 
136.6, 140.87 (2C), 140.93 (2C), 177.0. IR (neat) 1714, 1441, 1281, 1163, 1133, 1081, 
1040, 808, 763, 672 cm
–1
. MS (ESI) calcd for C35H32N2O5BrINaS2 [M+Na]
+
 828.9873, 
found 828.9861. 
 
Methyl 
3-(((4’-methyl-N-tosylphenyl)sulfonamido)(phenyl)-3-iodanyl)-1-pivaloyl-1H-indo
le-5-carboxylate (2g) (Isolated Method : A) : mp. 189 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.45 (s, 9H), 2.23 (s, 6H), 3.95 (s, 3H), 6.91 (d, J=8.1 Hz, 4H), 7.30 (t, 
J=7.8 Hz, 2H), 7.44-7.50 (m, 1H), 7.46 (d, J=8.1 Hz,4H), 8.06-8.14 (m, 3H), 8.50 (d, 
J=7.5 Hz, 1H), 8.97 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.3 (2C), 28.3 (3C), 41.9, 
52.4, 86.5, 115.6, 117.6, 121.2, 126.8 (4C), 127.0, 127.7, 127.8, 128.6 (4C), 131.7 (2C), 
131.8, 135.0 (2C), 137.0, 138.9, 140.7 (2C), 141.3 (2C), 166.4, 177.1. IR (neat) 1718, 
1434, 1291, 1263, 1130, 1075, 1041, 764, 738, 665 cm
–1
. MS (ESI) calcd for 
C35H35N2O7INaS2 [M+Na]
+
 809.0823, found 809.0807. 
 
3-(((4’-Methyl-N-tosylphenyl)sulfonamido)(phenyl)-3-iodanyl)-1-pivaloyl-1H-indo
l-5-yl pivalate (2h) (Isolated Method : B) : mp. 195 °C (decomp.) 
1
H NMR (500 MHz, 
CDCl3) δ 1.37 (s, 9H), 1.45 (s, 9H), 2.21 (s, 6H), 6.90 (d, J=8.1 Hz, 4H), 7.11 (dd, J=9.2, 
2.3 Hz, 1H), 7.16 (d, J=7.8 Hz, 1H), 7.31 (t, J=7.8 Hz, 2H), 7.44 (d, J=8.1 Hz, 4H), 
7.48 (t, J=7.8 Hz, 1H), 8.08 (d, J=7.8 Hz, 2H), 8.45 (d, J=9.2 Hz, 1H), 8.83 (s, 1H). 
13
C 
NMR (125 MHz, CDCl3) δ 21.2 (2C), 27.2 (3C), 28.3 (3C), 39.1, 41.7, 85.8, 111.9, 
115.8, 118.5, 120.9, 126.7 (4C), 128.5 (4C), 128.7, 129.7, 131.5 (2C), 133.7, 135.1 (2C), 
136.5, 140.8 (2C), 141.3 (2C), 148.4, 176.97, 177.0. IR (neat) 1748, 1712, 1459, 1276, 
1133, 1113, 1078, 1034, 822, 770, 741, 671 cm
–1
. MS (ESI) calcd for C38H41N2O7INaS2 
[M+Na]
+
 851.1292, found 851.1279. 
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N-((5’-Cyano-1’-pivaloyl-1’H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4-methyl-N-tosylben
zenesulfonamide (2i) (Isolated Method : A) : mp. 188 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.43 (s, 9H), 2.23 (s, 6H), 6.87 (d, J=8.0 Hz, 4H), 7.31 (t, J=7.8 Hz, 
2H), 7.35 (d, J=8.0 Hz, 4H), 7.49 (t, J=7.8 Hz, 1H), 7.63 (dd, J=8.9,1.4 Hz,1H), 7.72 (d, 
J=1.4 Hz, 1H), 8.09 (d, J=7.8 Hz, 2H), 8.51 (d, J=8.9 Hz,1H), 9.02 (s,1H). 
13
C NMR 
(125 MHz, CDCl3) δ 21.3 (2C), 28.2 (3C), 41.9, 86.3, 108.5, 115.8, 118.58, 118.62, 
124.1, 126.6 (4C), 128.2, 128.5 (4C), 129.4, 131.7 (2C), 131.9, 135.3 (2C), 137.6, 138.1, 
140.8 (2C), 141.0 (2C), 177.1. IR (neat) 2223, 1721, 1447, 1280, 1133, 1078, 1039, 821, 
763, 672 cm
–1
. MS (ESI) calcd for C34H32N3O5INaS2 [M+Na]
+
 776.0720, found 
776.0707. 
 
N-((5’-(1”,3”-dioxyindolin-2”-yl)-1’-pivaloyl-1’H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4
-methyl-N-tosylbenzenesulfonamide (2j) (Isolated Method : G) : mp. 190 °C 
(decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.43 (s, 9H), 2.19 (s, 6H), 6.85 (d, J=8.1 Hz, 
4H), 7.29 (t, J=7.8 Hz, 2H), 7.38 (d, J=8.1 Hz, 4H), 7.41-7.50 (m, 2H), 7.62 (d, J=1.8 
Hz, 1H), 7.76-7.82 (m, 2H), 7.86-7.94 (m, 2H) , 8.17 (d, J=7.8 Hz, 2H), 8.51 (d, J=8.9 
Hz, 1H), 8.91 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.3 (3C), 41.7, 86.6, 
116.0, 117.7,118.3, 123.7 (2C), 125.0, 126.6 (4C), 128.3, 128.4 (4C), 128.6, 129.8, 
131.6 (4C), 134.5 (2C), 135.2, 135.4 (2C), 136.3, 140.8 (2C), 141.3 (2C), 167.1 (2C), 
177.0.. IR (neat) 1719, 1468, 1377, 1279, 1132, 1077, 1036, 814, 751, 716, 669 cm
–1
. 
MS (ESI) calcd for C27H22N2O3I [M-Ts2N
-
]
+
 549.0670, found 549.0657. 
 
N-((6’-Chloro-1’-pivaloyl-1’H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4-methyl-N-tosylben
zenesulfonamide (2k) (Isolated Method : C) : mp. 143 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.42 (s, 9H), 2.21 (s, 6H), 6.87 (d, J=8.2 Hz, 4H), 7.24-7.30 (m, 3H), 
7.33 (d, J=8.3 Hz, 1H), 7.38 (d, J=8.2 Hz, 4H), 7.46 (t, J=7.5 Hz, 1H), 8.10 (d, J=7.5 
Hz, 2H), 8.48 (d, J=1.7 Hz,1 H), 8.83 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 
28.3 (3C), 41.7, 86.3, 115.7, 117.8, 120.2, 125.6, 126.4, 126.6 (4C), 128.4 (4C), 131.5 
(2C), 131.6, 133.0, 135.1 (2C), 135.9, 136.4, 141.0 (2C), 141.2 (2C), 177.0. IR (neat) 
1714, 1421, 1265, 1161, 1131, 1077, 1042, 805, 766, 670 cm
–1
. MS (ESI) calcd for 
C33H32N2O5ClINaS2 [M+Na]
+
 785.0378, found 785.0364. 
 
N-((7’-Methyl-1-pivaloyl-’1H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4-methyl-N-tosylben
zenesulfonamide (2l) (Isolated Method : A) : mp. 171 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.46 (s, 9H), 2.19 (s, 6H), 2.29 (s, 3H), 6.86 (d, J=8.1 Hz, 4H), 7.20 (d, 
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J=6.9 Hz, 1H), 7.21-7.31 (m, 5H), 8.04 (d, J=7.5 Hz, 2H), 8.63 (s, 1H). 
13
C NMR (125 
MHz, CDCl3) δ 21.0, 21.2 (2C), 28.8 (3C), 42.7, 84.0, 115.8, 117.4, 124.8, 125.7, 126.8 
(4C), 128.4 (4C), 128.7, 128.9, 131.4, 131.5 (2C), 134.6 (2C), 135.3, 135.6, 140.7 (2C), 
141.3 (2C), 178.8. IR (neat) 1724, 1442, 1276, 1131, 1077, 1035, 811, 762, 738, 672 
cm
–1
. MS (ESI) calcd for C34H35N2O5INaS2 [M+Na]
+
 765.0924, found 765.0913. 
 
N-((2’-Methyl-1’-pivaloyl-1’H-indol-3’-yl)(phenyl)-λ3-iodanyl)-4-methyl-N-tosylbe
nzenesulfonamide (2m) (Isolated Method : D) : mp. 142 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.32 (s, 9H), 2.25 (s, 6H), 2.68 (s, 3H), 6.91 (d, J=8.0 Hz, 4H), 7.24 (d, 
J=7.6 Hz, 1H), 7.27-7.34 (m, 4H), 7.42-7.48 (m, 1H), 7.45 (d, J=8.2 Hz, 4H), 7.51 (d, 
J=7.6 Hz, 1H), 7.89 (d, J=8.5 Hz, 2H). 
13
C NMR (125 MHz, CDCl3) δ 14.4, 21.3 (2C), 
27.9 (3C), 44.8, 82.0, 112.2, 115.9, 119.4, 123.5, 124.5, 126.7 (4C), 127.6, 128.4 (4C), 
131.4, 131.7 (2C), 133.5 (2C), 135.8, 140.5 (2C), 141.2 (2C), 143.1, 185.2. IR (neat) 
1730, 1451, 1263, 1131, 1082, 1035 cm
–1
. MS (ESI) calcd for C34H35N2O5INaS2 
[M+Na]
+
 765.0924, found 765.0908. 
 
N-(Phenyl(1-pivaloyl-1H-indol-3-yl)-3-iodanyl)-N-(phenylsulfonyl)benzenesulfona
mide (2n) (Isolated Method : A) : mp. 180 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 
1.43 (s, 9H), 7.10 (t, J=8.0 Hz, 4H), 7.22 (t, J=7.7 Hz, 2H), 7.28 (t, J=8.0 Hz, 2H), 7.35 
(t, J=7.7 Hz, 1H), 7.40-7.49 (m, 3H), 7.55 (d, J=8.0 Hz,4H), 8.07 (d, J=7.7 Hz, 2H), 
8.46 (d, J=8.1 Hz, 1H), 8.84 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 28.3 (3C), 41.7, 
85.9, 115.3, 117.7, 119.3, 125.2, 126.6 (4C), 126.9, 127.7, 127.9 (4C), 130.6 (3C), 131.6 
(2C), 131.7, 134.9 (2C), 135.4, 136.3, 143.9 (2C), 177.1. IR (neat) 1712, 1444, 1279, 
1131, 1078, 1038, 793, 744, 720, 688 cm
–1
. MS (ESI) calcd for C31H29N2O5INaS2 
[M+Na]
+
 723.0455, found 723.0444. 
 
4-Fluoro-N-((4’-fluorophenyl)sulfonyl)-N-(phenyl(1”-pivaloyl-1”H-indol-3”-yl)-3-i
odanyl)benzenesulfonamide (2o) (Isolated Method : E) : mp. 155 °C (decomp.) 
1
H 
NMR (500 MHz, CDCl3) δ 1.43 (s, 9H), 6.77 (dd, J=7.6, 7.2, Hz, 4H), 7.31 (t, J=8.1 Hz, 
2H), 7.36 (t, J=8.1 Hz, 1H), 7.40-7.53 (m, 7H), 8.05 (d, J=8.1 Hz, 2H), 8.47 (d, J=8.3 
Hz, 1H), 8.78 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 28.3 (3C), 41.7, 85.7, 114.9 (d, 
JC-F=22.7 Hz, 4C), 115.0, 117.7, 119.2, 125.3, 127.1, 127.6, 129.2 (d, JC-F=9.5 Hz, 4C), 
131.7 (2C), 131.8, 134.8 (2C), 135.3, 136.3, 140.0 (2C), 163.9 (d, JC-F=250.4 Hz, 2C), 
176.9. 
19
F NMR (471 MHz, CDCl3) δ -108.9. IR (neat) 1712, 1444, 1280, 1219, 1133, 
1081, 1039 cm
–1
. MS (ESI) calcd for C31H27N2O5F2INaS2 [M+Na]
+
 759.0266, found 
759.0273. 
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N-(Phenyl(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-(propylsulfonyl)propane-1-su
lfonamide (2p) (Isolated Method : E) : mp. 97 °C (decomp.) 
1
H NMR (500 MHz, 
CDCl3) δ 0.87 (t, J=7.5 Hz, 6H), 1.56 (s, 9H), 1.60-1.70 (m, 4H), 2.95-3.00 (m, 4H), 
7.36-7.50 (m, 2H), 7.54 (t, J=7.5Hz, 1H), 8.11 (d, J=7.5 Hz, 2H), 8.49 (d, J=8.6 Hz, 1H), 
8.65 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 13.0 (2C), 17.5 (2C), 28.5 (3C), 41.8, 56.1 
(2C), 86.8, 115.3, 116.6, 117.8, 119.3, 125.4, 127.3 (4C), 127.5, 131.9 (2C), 132.0, 
134.46 (2C), 134.53, 136.4, 176.7. IR (neat) 1706, 1442, 1303, 1270, 1095, 1046, 948, 
822, 741, 608 cm
–1
. MS (ESI) calcd for C25H33N2O5INaS2 [M+Na]
+
 655.0768, found 
655.0771. 
 
4-Methyl-N-(methylsulfonyl)-N-(phenyl(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)be
nzenesulfonamide (2q) (Isolated Method : A) : mp. 150 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.48 (s, 9H), 2.23 (s, 3H), 2.80 (s, 3H), 6.99 (d, J=7.5 Hz, 2H), 
7.30-7.38 (m, 3H), 7.40-7.52 (m, 3H), 7.56 (d, J=7.5 Hz, 2H), 8.07 (d, J=8.3 Hz, 2H), 
8.47 (d, J=8.6 Hz, 1H), 8.75 (d, J=8.3 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.3, 
28.4 (3C), 41.7, 42.7, 86.2, 115.7, 117.7, 119.3, 125.2, 126.7 (2C), 127.0, 127.6, 128.7 
(2C), 131.67 (2C), 131.73, 134.7 (2C), 135.1, 136.3, 141.2, 141.6, 177.0. IR (neat) 1710, 
1443, 1267, 1120, 1080, 1051, 823, 747, 717 cm
–1
. MS (ESI) calcd for 
C27H29N2O5INaS2 [M+Na]
+
 675.0455, found 675.0450. 
 
4-Methyl-N-((4”-methoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylb
enzenesulfonamide (2r) (Isolated Method : D) : mp. 180 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.43 (s, 9H), 2.20 (s, 6H), 3.74 (s, 3H), 6.75 (d, J=9.2Hz, 2H), 6.88 (d, 
J=8.0Hz, 4H), 7.34 (t, J=7.5 Hz, 1H), 7.38-7.48 (m, 2H), 7.43 (d, J=8.0 Hz, 4H), 8.02 
(d, J=9.2Hz, 2H), 8.45 (d, J=7.5 Hz, 1H), 8.83 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 
21.2 (2C), 28.4 (3C), 41.9, 55.5, 86.6, 103.9, 117.2 (2C), 117.7, 119.4, 125.0, 126.67, 
126.71 (4C), 127.7, 128.4 (4C), 135.0, 136.2, 137.1 (2C), 140.8 (2C), 141.4 (2C), 162.2, 
177.1. IR (neat) 1702, 1443, 1292, 1259, 1138, 1078, 1031, 1113, 814, 746, 671 cm
–1
. 
MS (ESI) calcd for C33H34N2O6INaS2 [M+Na]
+
 781.0873, found 781.0865. 
 
4-Methyl-N-((4”-chlorphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylbenz
enesulfonamide (2s) (Isolated Method : A) : mp. 190 °C (decomp.) 
1
H NMR (500 MHz, 
CDCl3) δ 1.40 (s, 9H), 2.20 (s, 6H), 6.87 (d, J=8.1 Hz, 4H), 7.17 (d, J=8.6 Hz, 2H), 
7.31-7.40 (m, 5H), 8.04 (d, J=8.6 Hz, 2H), 8.45 (d, J=9.2 Hz, 1H), 8.87 (s, 1H). 
13
C 
NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.3 (3C), 41.7, 86.6, 112.7, 117.7 119.3, 125.1, 
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126.6 (4C), 126.8, 127.7, 128.5 (4C), 131.5 (2C), 135.6, 136.2, 136.6 (2C), 138.4, 141.0 
(2C), 141.2 (2C), 177.1. IR (neat) 1703, 1443, 1281, 1136, 1077, 1029, 813, 754, 670 
cm
–1
. MS (ESI) calcd for C33H32N2O5ClINaS2 [M+Na]
+
 785.0378, found 785.0361. 
 
4-Methyl-N-((4”-cyanophenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylbenz
enesulfonamide (2t) (Isolated Method : D) : mp. 167 °C (decomp.) 
1
H NMR (500 MHz, 
CDCl3) δ 1.36 (s, 9H), 2.22 (s, 6H), 6.84 (d, J=8.3 Hz, 4H), 7.28 (d, J=8.3 Hz, 4H), 7.34 
(t, J=8.5 Hz, 1H), 7.39-7.49 (m, 4H), 8.24 (d, J=8.6 Hz, 2H), 8.46 (d, J=8.5 Hz, 1H), 
8.90 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.3 (3C), 41.7, 86.5, 115.3, 
117.0, 117.7, 119.2, 120.0, 125.3, 126.5 (4C), 127.0, 127.7, 128.5 (4C), 134.2 (2C), 
135.7 (2C), 136.0, 136.2, 140.7 (2C), 141.2 (2C), 177.0. IR (neat) 2232, 1714, 1445, 
1269, 1133, 1078, 1036, 814, 749, 671 cm
–1
. MS (ESI) calcd for C34H32N3O5INaS2 
[M+Na]
+
 776.0720, found 776.0701. 
 
4-Methyl-N-((4”-nitrophenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylbenz
enesulfonamide (2u) (Isolated Method : A) : mp. 179 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.38 (s, 9H), 2.21 (s, 6H), 6.84 (d, J=8.1 Hz, 4H), 7.31 (d, J=8.1 Hz, 
4H), 7.35 (t, J=7.5 Hz, 1H), 7.42-7.49 (m, 2H), 8.28 (dt, J=9.2, 2.0 Hz, 2H), 8.47 (d, 
J=7.5 Hz, 1H), 8.92 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.3 (3C), 41.7, 
86.5, 117.8, 119.2, 125.3, 125.8 (2C), 126.6 (4C), 127.0, 127.6, 128.5 (4C), 136.08, 
136.14 (2C), 136.3, 140.7 (2C), 141.4 (2C), 149.3, 177.1. IR (neat) 1706, 1525, 1289, 
1137, 1078, 1028, 1009, 819, 768, 671 cm
–1
. MS (ESI) calcd for C33H32N3O7INaS2 
[M+Na]
+
 796.0619, found 796.0603. 
 
4-Methyl-N-((2”-methoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylb
enzenesulfonamide (2v) (Isolated Method : A) : mp. 204 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.45 (s, 9H), 2.25 (s, 6H), 3.97 (s, 3H), 6.85-6.93 (m, 5H), 6.99 (dd, 
J=8.3, 1.5 Hz, 1H), 7.38 (t, J=8.6 Hz, 1H), 7.40-7.52 (m, 7H), 7.59 (dd, J=8.3, 1.5 Hz, 
1H), 8.51 (d, J=8.6 Hz, 1H), 8.87 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.3 (2C), 
28.4 (3C), 41.8, 57.0, 82.8, 103.9, 112.2, 117.7, 119.6, 124.0, 125.2, 126.6 (4C), 127.0, 
127.6, 128.4 (4C), 133.8, 134.0, 136.3, 136.5, 140.7 (2C), 141.2 (2C), 156.3, 177.0. IR 
(neat) 1712, 1474, 1277, 1127, 1079, 1014, 751, 671 cm
–1
. MS (ESI) calcd for 
C34H35N2O6INaS2 [M+Na]
+
 781.0873, found 781.0853. 
 
4-Methyl-N-((2”-n-butoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylb
enzenesulfonamide (2w) (Isolated Method : E): mp. 165 °C (decomp.) 
1
H NMR (500 
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MHz, CDCl3) δ 1.00 (t, J=7.5 Hz, 3H), 1.44 (s, 9H), 1.53 (sext, J=7.5 Hz, 2H), 1.87 
(quin, J=7.5 Hz, 2H), 2.26 (s, 6H), 4.14 (t, J=7.5 Hz, 2H), 6.82-6.88 (m, 1H), 6.89 (d, 
J=8.0 Hz, 4H), 6.98 (d, J=7.5 Hz, 1H), 7.37 (t, J=7.5 Hz, 1H), 7.40-7.52 (m, 4H), 7.44 
(d, J=8.0 Hz,4H), 8.52 (d, J=8.6 Hz, 1H), 8.88 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 
13.8, 19.1, 21.3 (2C), 28.4 (3C), 30.8, 41.8, 70.1, 82.4, 103.9, 113.0, 117.7, 119.5, 124.0, 
125.2, 126.9 (4C), 127.0, 127.6, 128.3 (4C), 133.6 (3C), 136.3, 136.4 (2C), 140.6, 141.4, 
155.8, 177.1. IR (neat) 1710, 1461, 1281, 1129, 1076, 1029, 1010 cm
–1
. MS (ESI) calcd 
for C37H41N2O6INaS2 [M+Na]
+
 823.1343, found 823.1335. 
 
N-((2”-isobutoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methyl-N-tosyl
benzenesulfonamide (2x) (Isolated Method : C) : mp. 156 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ1.12 (d, J=6.6 Hz, 6H), 1.44 (s, 9H), 2.19-2.32 (m, 7H), 3.94 (d, J=6.6 
Hz, 1H), 6.87-6.94 (m, 5H), 7.01 (d, J=8.5 Hz, 1H), 7.36-7.48 (m, 8H), 7.51 (d, J=8.5 
Hz, 1H), 8.55 (d, J=8.3 Hz, 1H), 8.92 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 19.4 (2C), 
21.3 (2C), 28.1, 28.4 (3C), 41.8, 76.5, 82.2, 103.7, 113.1, 117.8, 119.4, 124.1, 125.3, 
126.6 (4C), 127.1, 127.5, 128.4 (4C), 133.0, 133.5, 136.3, 136.3, 140.7 (2C), 141.5 (2C), 
155.8, 177.1. IR (neat) 1712, 1446, 1281, 1132, 1078, 1012, 757, 669 cm
–1
. MS (ESI) 
calcd for C37H41N2O6INaS2 [M+Na]
+
 823.1343, found 823.1324. 
 
N-((2”-(octyloxy)phenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methyl-N-tosyl
benzenesulfonamide (2y) (Isolated Method : A) : mp. 136 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 0.89 (t, J=7.2 Hz, 3H), 1.22-1.52 (m, 19H), 1.90 (quin, J=7.2 Hz, 2H), 
2.27 (s, 6H), 4.14 (t, J=7.2 Hz, 2H), 6.86-6.94 (m, 5H), 6.99 (dd, J=8.3, 1.2 Hz, 1H), 
7.38 (t, J=8.6 Hz, 1H), 7.41-7.53 (m, 8H), 8.54 (d, J=8.6 Hz, 1H), 8.89 (s, 1H). 
13
C 
NMR (125 MHz, CDCl3) δ 14.3, 21.3 (2C), 22.6, 25.8, 28.4 (3C), 28.8, 29.1, 29.3, 31.8, 
41.7, 70.4, 82.6, 103.9, 113.0, 117.8, 119.5, 123.9, 125.2, 126.6 (4C), 127.0, 127.6, 
128.4 (4C), 133.6 (2C), 136.3, 136.4, 140.7 (2C), 141.4 (2C), 155.8, 177.0. IR (neat) 
1707, 1474, 1292, 1135, 1080, 1032, 759, 671 cm
–1
. MS (ESI) calcd for 
C41H49N2O6INaS2 [M+Na]
+
 879.1969, found 879.1974. 
 
N-((2”-(2’”-methoxyethoxy)phenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-met
hyl-N-tosylbenzenesulfonamide (2z) (Isolated Method : A) : mp. 78-82 °C 
1
H NMR 
(500 MHz, CDCl3) δ 1.46 (s, 9H), 2.26 (s, 6H), 3.47 (s, 3H), 3.82-3.92 (m, 2H), 
4.28-4.40 (m, 2H), 6.84-6.96 (m, 5H), 7.07 (dd, J=8.3, 1.2 Hz, 1H), 7.38 (t, J=8.6 Hz, 
1H), 7.41-7.52 (m, 7H), 7.58 (dd, J=8.3, 1.2 Hz, 1H), 8.51 (d, J=8.6 Hz, 1H), 8.89 (s, 
1H). 
13
C NMR (125 MHz, CDCl3) δ21.3 (2C), 28.4 (3C), 41.7, 59.3, 70.2, 70.6, 83.4, 
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99.9, 105.6, 114.3, 117.7, 119.6, 124.5, 125.2, 126.6 (4C), 126.9, 127.7, 128.3 (4C), 
133.7, 133.7, 134.0, 136.3, 140.7 (2C), 141.3 (2C), 156.0, 177.1. IR (neat) 1706, 1474, 
1294, 1135, 1080, 1033, 759, 672 cm
–1
. MS (ESI) calcd for C36H40N2O7INaS2 [M+Na]
+
 
825.1136, found 825.1121. 
 
4-Methyl-N-(1’-pivaloyl-(3”-trifluoromethylphenyl)-1’H-indol-3’-yl)-3-iodanyl)-N
-tosylbenzenesulfonamide (2aa) (Isolated Method : E): mp. 139 °C (decomp.) 
1
H 
NMR (500 MHz, CDCl3) δ 1.42 (s, 9H), 2.20 (s, 6H), 6.85 (d, J=8.1 Hz, 4H), 7.31-7.42 
(m, 2H), 7.42-7.48 (m, 2H), 7.67 (d, J=7.9 Hz, 1H), 8.34 (d, J=7.9 Hz, 1H), 8.38 (s,1H), 
8.46 (d, J=8.3 Hz, 1H), 8.88 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.3 
(3C), 41.7, 87.1, 115.9, 117.7, 119.3, 120.3 (q, JC-F=271.8 Hz, 1C), 125.2, 125.2, 126.6 
(4C), 127.7, 128.2 (2C), 128.5 (4C), 131.7, 132.9 (q, JC-F=33.4 Hz, 1C), 135.7, 136.2, 
138.6, 140.9 (2C), 141.0 (2C), 177.1.
 19
F NMR (471 MHz, CDCl3) δ -62.6. IR (neat) 
1706, 1443, 1292, 1136, 1077, 1033, 800, 748, 671 cm
–1
. MS (ESI) calcd for 
C34H32N2O5F3INaS2 [M+Na]
+
 819.0642, found 819.0634. 
 
4-Methyl-N-((3”,5”-dichlorophenlyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tos
ylbenzenesulfonamide (2ab) (Isolated Method : A) : mp. 183 °C (decomp.) 
1
H NMR 
(500 MHz, CDCl3) δ 1.44 (s, 9H), 2.23 (s, 6H), 6.90 (d, J=8.0 Hz, 4H), 7.35-7.45 (m, 
3H), 7.39 (d, J=8.6 Hz, 1H), 7.47 (td, J=8.6, 1.5 Hz, 1H), 7.95 (d, J=1.8 Hz, 2H), 8.48 
(d, J=8.6, Hz, 1H), 8.87 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.3 (2C), 28.4 (3C), 
41.8, 87.1, 115.4, 117.7, 119.3, 125.3, 126.7 (4C), 127.0, 127.7, 128.6 (4C), 132.0, 
132.7 (2C), 135.9, 136.3, 136.6 (2C), 140.8 (2C), 141.2 (2C), 177.1. IR (neat) 1714, 
1444, 1283, 1135, 1077, 1031, 1012, 800, 745, 672 cm
–1
. MS (ESI) calcd for 
C33H31N2O5Cl2INaS2 [M+Na]
+
 818.9988, found 818.9987. 
 
4-Methyl-N-((3”,5”-bis(trifluoromethyl)phenlyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iod
anyl)-N-tosylbenzenesulfonamide (2ac) (Isolated Method : E) : mp. 156 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.42 (s, 9H), 2.20 (s, 6H), 6.83 (d, J=8.0 Hz, 4H), 7.26 (d, 
J=8.0 Hz, 4H), 7.40 (t, J=7.8 Hz, 1H), 7.45-7.52 (m, 2H), 7.86 (s,1H), 8.47 (d, J=7.8 
Hz,1H), 8.59 (s, 1H), 8.90 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2 (2C), 28.3 (3C), 
41.7, 87.8, 116.9, 117.7, 119.2, 121.8 (q, JC-F=271.9 Hz, 2C), 125.1, 125.3, 126.5 (4C), 
127.1, 127.6, 128.5 (4C), 133.5 (q, JC-F=34.6 Hz, 2C), 135.1 (2C), 136.0, 136.2, 140.4 
(2C), 141.2 (2C), 177.1.
 19
F NMR (471 MHz, CDCl3) δ -62.8. IR (neat) 1715, 1342, 
1273, 1152, 1129, 1077, 1038, 812, 753, 658 cm
–1
. MS (ESI) calcd for 
C35H31N2O5F6INaS2 [M+Na]
+
 887.0515, found 887.0511. 
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Methyl 
3-((3”,5”-dichlorophenyl)((4’-methyl-N-tosylphenyl)sulfonamido)-3-iodanyl)-1-piv
aloyl-1H-indole-2-carboxylate (2ad) (Isolated Method : A) : mp. 178 °C (decomp.) 
1
H 
NMR (500 MHz, CDCl3) δ 1.25 (s, 9H), 2.26 (s, 6H), 4.09 (s, 3H), 6.88 (d, J=8.1, Hz, 
4H), 7.28 (d, J=8.1 Hz, 4H), 7.34 (d, J=8.3 Hz, 1H), 7.37-7.42 (m, 2H), 7.50 (t, J=8.3, 
Hz, 1H), 7.77 (d, J=8.3 Hz, 1H), 7.98 (d, J=2.0 Hz, 2H), 8.89 (s, 1H). 
13
C NMR (125 
MHz, CDCl3) δ21.3 (2C), 27.9 (3C), 45.5, 53.9, 87.9, 112.6, 117.4, 122.1, 124.8, 126.7 
(4C), 127.8, 128.2, 128.4 (4C), 130.2, 132.0, 132.5 (2C), 136.3, 136.6 (2C), 140.2 (2C), 
140.8 (2C), 159.5, 182.7. IR (neat) 1739, 1710, 1510, 1273, 1156, 1134, 1079, 1030, 
761, 652 cm
–1
. MS (ESI) calcd for C35H33N2O7INaS2 [M+Na]
+
 877.0043, found 
877.0025. 
 
N-((2”-methoxyphenlyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-mesylmethanes
ulfonamide (2ae) (Isolated Method : F) : mp. 178 °C (decomp.) 
1
H NMR (500 MHz, 
CDCl3) δ 1.58 (s, 9H), 2.81 (s, 6H), 4.02 (s, 3H), 6.95 (t, J=8.3 Hz, 1H), 7.03 (d, J=8.3 
Hz, 1H), 7.40 (t, J=8.0 Hz, 1H), 7.45-7.54 (m, 3H), 7.62 (d, J=8.3 Hz, 1H), 8.51 (d, 
J=8.0 Hz, 1H), 8.73 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.3 (2C), 28.5 (3C), 41.8, 
42.2 (2C), 57.0, 83.6, 104.6, 112.4, 117.7, 119.5, 124.0, 125.3, 127.2, 127.4, 134.2, 
135.9, 136.2, 156.3, 176.8. IR (neat) 1710, 1474, 1284, 1105, 1037, 832, 756, 701 cm
–1
. 
MS (ESI) calcd for C22H27N2O6INaS2 [M+Na]
+
 629.0247, found 629.0263. 
 
N-(benzylsulfonyl)-N-((2”-methoxyphenlyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl
)- 1-phenylmethanesulfonamide (2af) (Isolated Method : E) : mp. 139 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.54 (s, 9H), 4.37 (s, 4H), 6.80 (t, J=8.3 Hz, 1H), 6.90 (d, 
J=8.3 Hz, 1H), 6.95 (t, J=7.5 Hz, 2H), 7.10 (t, J=7.5 Hz, 4H), 7.21 (d, J=8.3 Hz, 1H), 
7.32 (t, J=8.0 Hz, 1H), 7.36 (d, J=8.0 Hz, 1H), 7.38-7.49 (m, 6H), 8.39 (s, 1H), 8.45 (d, 
J=8.0 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 28.5 (3C), 41.7, 56.7, 59.6 (2C), 83.8, 
104.1, 112.1, 117.7, 119.6, 123.6, 124.9, 126.8, 127.1, 127.3 (2C), 127.8 (4C), 131.5 
(4C), 132.0 (2C), 133.9, 134.7, 135.4, 136.1, 156.3, 176.6. IR (neat) 1712, 1474, 1442, 
1281, 1106, 1027, 748, 697 cm
–1
. MS (ESI) calcd for C34H35N2O6INaS2 [M+Na]
+
 
781.0873, found 781.0874. 
 
N-((1’-t-butoxylcarbonyl-1’H-indol-3’-yl)(phenyl)-3-iodanyl)-4-methyl-N-tosylben
zenesulfonamide (2ag) (Isolated Method : A) : mp. 104 °C (decomp.) 
1
H NMR (500 
MHz, CDCl3) δ 1.67 (s, 9H),2.26 (s, 6H),6.94 (d, J=8.0 Hz,4H), 7.30-7.39 (m, 3H), 
7.40-7.55 (m, 7H), 8.07 (d, J=7.5 Hz, 2H), 8.20 (d, J=8.3 Hz, 1H), 8.42 (s, 1H). 
13
C 
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NMR (125 MHz, CDCl3) δ 21.3 (2C), 28.0 (3C), 84.7, 86.2, 115.8, 116.1, 119.8, 124.7, 
126.5, 126.8 (4C), 128.5 (4C), 128.6, 131.6, 131.7 (2C), 134.5 (2C), 135.1, 135.3, 141.0 
(4C), 147.8. IR (neat) 1743, 1450, 1255, 1134, 1080, 1036 cm
–1
. MS (ESI) calcd for 
C33H33N2O6INaS2 [M+Na]
+
 767.0717, found 767.0718. 
 
N-((1’-Benzoyl-1’H-indol-3’-yl)(phenyl)-3-iodanyl)-4-methyl-N-tosylbenzenesulfo
namide (2ah) (Isolated Method : E) : mp. 161 °C (decomp.) 
1
H NMR (500 MHz, 
CDCl3) δ 2.21 (s, 6H), 6.85 (d, J=8.1 Hz, 4H), 7.26 (t, J=7.7 Hz, 2H),7.37 (d, J=8.0 
Hz,4H), 7.34-7.55 (m, 10H), 7.61 (t, J=7.5 Hz, 1H), 7.69 (d, J=7.2 Hz, 2H), 8.00 (d, 
J=7.7 Hz, 2H), 8.22 (s, 1H), 8.38 (d, J=8.4 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 
21.2 (2C), 86.7, 115.6, 116.7, 119.9, 125.5, 126.7 (4C), 128.4 (4C), 128.9, 129.2 (2C), 
129.9 (2C), 131.5 (2C), 132.0, 133.2, 134.7 (2C), 135.7, 136.8, 140.7 (2C), 141.1 (2C), 
167.9. IR (neat) 1695, 1445, 1282, 1133, 1081, 1029, 1010, 808, 761, 664 cm
–1
.MS 
(ESI) calcd for C35H29N2O5INaS2 [M+Na]
+
 771.0455, found 771.0448. 
 
4-Methyl-N-(phenyl(1’-tosyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylbenzenesulfonami
de (2ai) (Isolated Method : A) : mp. 151 °C (decomp.) 
1
H NMR (500 MHz, DMSO-d6) 
δ2.29 (s,9H), 7.12 (d, J=8.0 Hz, 4H), 7.40 (t, J=8.0 Hz, 2H), 7.43-7.49 (m, 4H), 7.52 (d, 
J=8.0 Hz, 4H), 7.58 (d, J=7.2 Hz, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.92 (d, J=8.0 Hz, 2H), 
8.00 (d, J=8.4 Hz, 1H), 8.26 (d, J=7.8 Hz, 2H), 9.03 (s, 1H). 
13
C NMR (125 MHz, 
CDCl3) δ 20.8 (2C), 21.1, 90.3, 113.7, 117.3, 120.8, 125.2, 126.1 (4C), 126.9, 127.1 
(2C), 128.2 (4C), 128.6, 130.6 (2C), 131.7 (2C), 132.0, 133.1, 133.4, 134.7 (2C), 135.0, 
139.5 (2C), 143.8 (2C), 146.6. IR (neat) 1384, 1283, 1136, 1081, 1030, 1010, 812, 762, 
672 cm
–1
. MS (ESI) calcd for C35H31N2O6INaS3 [M+Na]
+
 821.0267, found 821.0267. 
 
4-Methyl-N-(phenyl(1-pivaloyl-4’,5’,6’,7’-tetrahydro-1’H-indol-3’-yl)-3-iodanyl)-
N-tosylbenzenesulfonamide (4a) (Isolated Method : E) : mp. 129 °C (decomp.) 
1
H 
NMR (500 MHz, CDCl3) δ 1.38 (s, 9H), 1.63-1.73 (m, 4H), 2.24-2.29 (m, 2H), 2.28 (s, 
6H), 2.77-2.83 (m, 2H), 6.97 (d, J=8.0 Hz, 4H), 7.36 (t, J=7.8 Hz, 2H),7.49 (d, J=8.0 
Hz, 4H), 7.52 (t, J=7.8 Hz, 1H), 7.95 (d, J=7.8 Hz, 2H), 8.17 (s, 1H). 
13
C NMR (125 
MHz, CDCl3) δ 21.3 (2C), 22.0, 22.6, 22.9, 25.4, 28.4 (3C), 41.8, 89.3, 122.4, 126.8 
(4C), 128.2, 128.4 (4C), 131.5, 131.6 (2C), 134.3, 134.4 (2C), 140.6 (2C), 141.6 (2C), 
177.1. IR (neat) 1709, 1279, 1139, 1079, 1032, 1012 cm
–1
. MS (ESI) calcd for 
C33H37N2O5INaS2 [M+Na]
+
 755.1081, found 755.1060. 
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Ethyl 
4-(((4’-methyl-N-tosylphenyl)sulfonamido)(phenyl)-3-iodanyl)-3,5-dimethyl-1-piv
aloyl-pyrrole-2-carboxylate (4b) (Isolated Method : F) : mp. 144-147 °C 
1
H NMR 
(500 MHz, CDCl3) δ 1.21 (s, 9H), 1.34 (t, J=7.2 Hz, 3H), 2.27 (s, 6H), 2.46 (s, 2H), 
6.97 (br, 2H), 6.95 (d, J=8.0 Hz, 4H), 7.34 (t, J=7.5 Hz, 2H), 7.45-7.52 (m, 5H), 7.81 (d, 
J= 7.5 Hz, 2H). 
13
C NMR (125 MHz, CDCl3) δ 13.7, 14.3, 21.3 (2C), 27.9 (3C), 45.3, 
61.5, 93.4, 115.5, 122.3, 126.8 (4C), 128.4 (4C), 130.5, 131.4, 133.5 (2C), 139.2, 140.6 
(2C), 141.0 (2C), 160.9, 183.5. IR (neat) 1754, 1697, 1408, 1283, 1130, 1039, 822, 750, 
665 cm
–1
. MS (ESI) calcd for C34H39N2O7INaS2 [M+Na]
+
 801.1136, found 801.1133. 
 
4-Methyl-N-((3’,5’-dimethyl-1’-pivaloyl-pyrrazol-4’-yl)(phenyl)-3-iodanyl)-N-tosy
lbenzenesulfonamide (4c) (Isolated Method : F) : mp. 91-95 °C
 1
H NMR (500 MHz, 
CDCl3) δ 1.46 (s, 9H), 2.29 (s, 6H), 2.40 (s, 3H), 2.74 (s, 3H), 3.93 (s, 3H), 6.93-6.99 
(m, 5H), 7.01 (d, J=8.0 Hz, 1H), 7.47 (d, J=8.3 Hz, 4H), 7.52 (t, J=8.0 Hz, 1H), 7.71 (d, 
J= 8.0 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 13.6, 15.9, 21.3 (2C), 27.7 (3C), 42.6, 
57.0, 89.6, 104.5, 112.5, 123.8, 126.7 (4C), 128.4 (4C), 134.3, 134.9, 140.7 (2C), 141.0 
(2C), 151.3 (2C), 156.4, 177.8. IR (neat) 1727, 1476, 1266, 1126, 1078, 812, 771, 665 
cm
–1
. MS (ESI) calcd for C31H36N2O6INaS2 [M+Na]
+
 760.0982, found 760.0981. 
 
4-Methyl-N-((indazol-3’-yl)(phenyl)-3-iodanyl)-N-tosylbenzenesulfonamide (4d) 
(Isolated Method : E) : mp. 175 °C (decomp.) 
1
H NMR (500 MHz, DMSO-d6) δ 2.31 (s, 
6H), 3.46 (br, 1H), 7.49 (d, J=8.0 Hz, 2H), 7.50-7.57 (m, 5H), 7.61 (t, J=8.0 Hz, 1H), 
7.72 (t, J=7.8 Hz, 1H), 7.99 (d, J= 8.3 Hz, 1H), 8.26 (d, J= 8.0 Hz, 2H). 
13
C NMR (125 
MHz, DMSO-d6) δ 20.9 (2C), 111.5, 114.7, 117.1, 119.6, 123.4, 124.4 (4C), 126.1 (4C), 
131.8 (2C), 132.0, 135.0 (2C), 140.5 (2C), 143.9. IR (neat) 3174, 1259, 1126, 1077, 
1037, 763, 677, 556 cm
–1
. MS (ESI) calcd for C27H24N3O4INaS2 [M+Na]
+
 668.0145, 
found 668.0128. 
 
4-Methyl-N-((2’,5’-dimethylthiophen-3’-yl)(phenyl)-3-iodanyl)-N-tosylbenzenesulf
onamide (4e) (Isolated Method : A) : 188 °C (decomp.) 
1
H NMR (500 MHz, 
DMSO-d6) δ 2.31 (s, 6H), 2.40 (s, 3H), 2.62 (s, 3H), 7.15 (d, J=8.0 Hz, 4H), 7.26 (s, 
1H), 7.48-7.56 (m, 6H), 7.66 (t, J=7.4 Hz, 1H), 8.16 (d, J= 7.4 Hz, 2H). 
13
C NMR (125 
MHz, DMSO-d6) δ 14.9, 16.5, 20.8 (2C), 101.5, 116.8, 126.1 (4C), 128.2 (4C), 129.3, 
131.8 (2C), 131.9, 134.8 (2C), 139.5, 141.1, 143.9 (2C), 144.4 (2C). IR (neat) 1279, 
1133, 1079, 1032, 810, 766, 742, 663 cm
–1
. MS (ESI) calcd for C26H26NO4INaS3 
[M+Na]
+
 661.9961, found 661.9971. 
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4-Methyl-N-((2’-methylbenzo[b]thiophen-3’-yl)(phenyl)-3-iodanyl)-N-tosylbenzen
esulfonamide (4f) (Isolated Method : A) : 181-184 °C 
1
H NMR (500 MHz, DMSO-d6) 
δ 2.31 (s, 6H), 2.94 (s, 3H), 7.14 (d, J=8.0 Hz, 4H), 7.44-7.57 (m, 8H), 7.61 (t, J=7.5 Hz, 
1H), 8.02-8.09 (m, 2H), 8.21 (d, J= 7.5 Hz, 2H). 
13
C NMR (125 MHz, DMSO-d6) δ 
17.8, 20.8 (2C), 102.0, 116.5, 123.1, 123.4, 126.0, 126.1 (4C), 126.5, 128.1 (4C), 131.8 
(2C), 132.0, 134.8 (2C), 137.7, 137.9, 139.5 (2C), 143.9 (2C), 149.9. IR (neat) 1429, 
1276, 1129, 1078, 1010, 758, 664 cm
–1
. MS (ESI) calcd for C29H27NO4INaS3 [M+Na]
+
 
697.9961, found 697.9966. 
 
4-Methyl-N-(phenyl(1’,3’,6’-trimethyl-uracil-5’-yl)-3-iodanyl)-N-tosylbenzenesulf
onamide (4g) (Isolated Method : E): 172 °C (decomp.) 
1
H NMR (500 MHz, DMSO-d6) 
δ 2.31 (s, 6H), 2.87 (s, 3H), 3.24 (s, 3H), 3.50 (s, 3H), 7.14 (d, J=8.0 Hz, 4H), 7.47-7.56 
(m, 6H), 7.65 (t, J=8.0 Hz, 1H), 8.09 (d, J=8.0 Hz, 2H). 
13
C NMR (125 MHz, 
DMSO-d6) δ 20.8 (2C), 24.4, 30.0, 34.1, 95.4, 116.4, 126.1 (4C), 128.1 (4C), 131.5 
(2C), 131.9, 134.7 (2C), 139.5 (2C), 143.8 (2C), 150.7, 158.7, 161.4. IR (neat) 1706, 
1651, 1583, 1281, 1230, 1149, 1084, 814, 743, 684 cm
–1
. MS (ESI) calcd for 
C27H27N3O6INaS2 [M+Na]
+
 704.0341, found 704.0356. 
 
N-((3”,5”-dichlorophenyl)(2’-methyl-4’-oxo-1’,4’-dihydroquinolin-3’-yl)-3-iodanyl
)-4-methyl-N-tosylbenzenesulfonamide (4h) (Isolated Method : A) : 162 °C (decomp.) 
1
H NMR (500 MHz, DMSO-d6) δ 2.30 (s, 6H), 2.92 (s, 3H), 3.51 (br, 1H), 7.14 (d, 
J=7.7 Hz, 4H), 7.44-7.56 (m, 5H), 7.68 (t, J=8.0 Hz, 1H), 7.81 (t, J= 8.0 Hz, 1H), 7.91 
(br, 1H), 8.25 (s, 2H). 
13
C NMR (125 MHz, DMSO-d6) δ 20.8 (2C), 24.1, 105.4, 115.6, 
118.7, 121.9, 126.1 (4C), 128.2 (4C), 131.7, 133.0 (2C), 133.7, 135.3 (2C), 139.3 (2C), 
139.6 (2C), 143.8, 156.8, 171.5. IR (neat) 3114, 1276, 1129, 1073, 1031, 1010, 796, 763, 
677 cm
–1
. MS (ESI) calcd for C30H25N2O5Cl2INaS2 [M+Na]
+
 776.9519, found 
776.9515. 
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Chapter 3-5 
Regio-controlled aminations of Indoles via (Indolyl)(aryl)iodonium Imide 
 
Abstract 
Three different aminations were performed by one hypervalent iodine, 
(indolyl)(aryl)iodonium imide. These reactions induced transformation of C-H bond to 
C-N bond regioselectively, and gave 2-, 3- or benzylic aminoindoles from indole 
derivatives.  
 
Introduction 
Amino indole is very important structure for medicinal or biologically active 
compounds
1
. Therefore, direct C-N bond formation of indoles is attractive for synthetic 
organic chemists, and various types of reactions using heavy metals
2 
and without 
metals
3
, were reported. Direct nitrogen introduction requires high regioselectivity, 
however, some reports were applied to limited indoles where reactive positions are 
blocked by substituents, such as 2-,3-alkyl, and carboxylindoles, or requires complex 
ligands. On the other hands, halo-amination is useful strategy for regioselective and 
direct C-N bond formation. Nicholas group reported 3,2-bromo-amination of indoles 
with benzophenone O-acetyloxime and CuBr
4
, and Liu group succeeded in 
chloro-amination of indoles with Chloramine-T
®
 and Cu/Pd catalysts
5
. However, both 
methods require stoichiometric amount of heavy metal reagents.  
On the other hands, hypervalent iodine is effective reagent for functionalization of 
indoles. Recently, Suna group reported azidation of indole derivatives via 
(indolyl)(phenyl)iodonium azide with copper catalyst
2g
. However, the reaction was 
applied to only methyl indole-2-carboxylate derivatives, and the azidoiodane 
intermediate was unstable and careful experimental operation was required. Similarly, 
imide-combined hypervalent iodines are also useful reagents for C-N bond formation
6
. 
The author also developed novel imide and indole-combined hypervalent iodine, 
(indolyl)(aryl)iodonium imide
7
. This reagent is stable solid and easily prepared and able 
to isolate. Here, the author reported the new synthetic strategy for C-N bond formation 
of indole from (indolyl)(aryl)iodonium imide as substrate. This methodology contains 
three different atom-economy amination reactions, and the controled introduction of 
imide group by designing structures of the hypervalent iodines can be achieved. 
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Chapter 3 
 
Regioselective Bromo-amination of Indoles via (Indolyl)(aryl)iodonium Imides 
N-(3’-Bromo-1’-pivaloyl-1’H-indol-2’-yl)-4-methyl-N-tosylbenzenesulfonamides were 
obtained by bromo-amination of (indolyl)(phenyl)iodonium imides using brominating 
reagents. This reaction is C-H dual-functionalization on one-step with complete 
regioselectivity. 
 
Introduction 
Direct oxidative transformation of C-H bond to C-N bond is attractive on organic 
chemistry
1
. Moreover, direct and regioselective C-H dual-functionalization
2
 is greatly 
ambitious, and possesses much possibility to reduce synthetic step, and therefore 
environmental load. Nevertheless, the study of regioselective C-H 
dual-functionalization of indole is lacked. On the best of the author’s knowledge, 
Nicholas
3
 group and Liu group
4
 reported regioselective intermolecular 
2,3-halo-amination of indoles. However, these methods required stoichiometric amount 
of heavy metal reagents. Recently, Yuan and Liu group
5
 reported metal-free 
3,3-dichloro-2-amination of indole with Chloramine-B
®
. However, the products require 
reduction process of halogen to give indole structure. Here, the author showed first 
metal-free 3,2-bromo-amination of indoles via (indolyl)(aryl)iodonium imide
6
 with 
bromination reagent. This reaction forms both C-N and C-Br bonds regioselectively 
without any metal reagents. 
 
Results and Discussion 
First, the author screened a series of bromination reagents and solvent for the 
3,2-bromo-amination of (indolyl)(phenyl)iodonium imides 2a (Table 1). The treatment 
with N-Bromosuccinimide (NBS) and N-bromoacetamide transformed 2a into 
2-bis(tosyl)imidyl-3- bromoindole derivative (3a) in good yields (entries 1, 2), however, 
treatment with pyrridinium tribromide provided desired product (3a) in low yield (entry 
3). Use of 1,3-dibromo-5,5-dimethylhydantin (DBH) increased the yield of 3a (entry 4). 
On the other hands, both 1,3-dichloro-5,5-dimethylhydantin (DCH) and 
1,3-diiodo-5,5-dimethylhydantin (DIH) were not effective at all (entries 4, 5). Then, 
other solvents were screened with DBH (entries 6-8). Solvents, such as CHCl3, THF, 
and DMF, were not effective. Warming reaction temperature to 40 ˚C improved the 
yield of 3a (entry 10). 
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To research the scope of substrate on redioselective 3,2-bromo-amination of 
(indolyl)(aryl)iodonium imides, various indoles and bis(sulfonyl)imides were examined 
(Table 2). The conditions for equivalent of DBH, solvent, and temperature had to be 
changed by the substituent group on indole group (Table 5, conditions A-E). The 
reaction of 5-substituted indoles bearing Me (2b), F (2d), Cl (2e), Br (2f), CO2Me (2g), 
CN (2h), PivO (2i), and PhthN (2j) groups gave the corresponding monosubstituted 
N-(3-bromo-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (3b, 
3d-3j) in high yields, respectively. The substrate bearing strong electron-donating group, 
such as MeO (2c), was converted into 3,4-dibromo product in high yield (3c). Other 
(indolyl)(aryl)iodonium imides bearing mono-substituted indole at other position were 
also transformed into the corresponding products in high yields (3m, 3n), respectively. 
The same reaction of (indolyl)(aryl)iodonium imides having various bis(sulfonyl)imides 
2 was carried out with high conversion and the desired products were obtained in high 
yields (3p-3s), respectively. Moreover, (indolyl)(aryl)iodonium imides bearing N-Ts or 
N-Bz groups instead of N-Piv group as a protecting group were also transformed into 
desired products in good yields (3t, and 3u), respectively. 
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The author also searched direct conversion of 1-pivaloylindole 1 into 
N-(3-bromo-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (3) 
(Scheme 1). 3,2-Bromo-amination of (indolyl)(aryl)iodonium imide was carried out in 
high yield, however, isolation of 2 reduced the total yield of 3 from 1. In addition, this 
method could not be used when (indolyl)(aryl)iodonium imides could not be isolated. 
The author examined two methods for one-pot synthesis of 3 from 1 (Scheme 2). 
Addition of DBH and 1a at the same time (eq. 2) proceeded smoothly to give the the 
product in higher yield than that in addition of DBH after preparation of compound 2a 
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(eq. 3).  
 
 
Then, the author examined direct conversion of various indoles into 
(indolyl)(aryl)iodonium imide (2) with bis(sulfonyl)imides, DIB, and DBH (Table 3). 
The conditions for equivalent of DBH, solvent, and temperature had to be changed by 
substituent groups on indoles, respectively (Table 6, conditions A-E). Treatment of 
monosubstuted indole 1(2b-2n) and N-Ts or N-Bz protected indole (2t, 2u) with various 
bis(sulfonyl)imides (2o-2s) gave the corresponding 
2-bis(sulfonyl)imidyl-3-bromoindoles (2b-2u) in high yields, respectively. Direct 
conversion procedure improved the yield of the most products 3, as compound with 
isolation method of (indolyl)(aryl)iodonium imide 2. Especially, indoles, such as 5-NO2 
(1l), 4-Br (1m), and Ms2NH (1r), where the isolation of 2 was impossible, were also 
transformed into compounds 3 bearing 5-NO2 (3l), 4-Br (3m), and Ms2NH (3r) in high 
yields using one-pot method. 
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Next, the author investigated the reaction mechanism of the regioselective 
3,2-bromo-amination of indole via (indolyl)(aryl)iodonium imide (Scheme 2). The 
reaction with 1-pivaloylindole (1a), bis(sulfonyl)imide, and DBH, without DIB 
proceeded to generate desired product (3a) in 4 % yield, and 3-bromo indole derivative 
4 in 96 % yield, respectively. Moreover, 4 did not react with DIB and Ts2NH under the 
present reaction conditions. These results suggested that generation of 
(indolyl)(aryl)iodonium imide 2 was necessary for the formation of 3. In addition, the 
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reaction of 2a with DBH (0.6 equiv.) and (PrSO2)NH (1.0 equiv.) gave 
N-(3-bromo-1-pivaloyl-1H-indol-2-yl)- 4-methyl-N-tosylbenzenesulfonamide (3a) 
(60 % yield) and N-(3-bromo-1-pivaloyl-1H-indol-2-yl)-N-(propanesulfonyl)- 
propanesulfonamide (3q) (32 % yield), respectively. However, ligand exchange on the 
iodine atom was not observed by the treatment of 2a with (PrSO2)2NH in DCE. The 
treatment of 1:1 mixture of 2e and 2q with DBH (0.6 equiv.) provided four 
3,2-bromo-amination products (3a, 3e, 3q, 3v). These observations indicate that 
3,2-bromo-amination of indole derivatives with DBH is intermolecular reaction via 
exchange for bis(sulfonyl)imide group on the iodine atom. 
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The proposed reaction mechanism is showed in Scheme 3. N-pivaloylndole 1 reacts 
with PhI(OAc)NTs2 generated in situ from DIB and Ts2NH, to give 
(indolyl)(aryl)iodonium imide 2 via deprotonation. Then, treatment of 2 with DBH 
gives intermediate A. At this step, reactivity of DBH is promoted by Lewis acidity of 
hypervalent iodine, and the Ts2N group on the hypervalent iodine is substituted by 
5,5-dimethylhydantoin derived from DBH to form A. Then, A is attacked by Ts2N anion 
followed by aromatization to produce dual-functionalized indole 3 together with 
iodobenzene and 5,5-dimethylhydantoin.  
 
 
Then, the author demonstrated derivatization of 3,2-bromo-amination product 3a (Table 
4). Various 3-functionalized indoles (5a-10a) were obtained by halogen-lithium and 
-magnesium exchange of 3 with tBuLi and MgCl2, followed by reaction with 
electrophiles, respectively.  
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Moreover, the author also succeeded in synthesis of polycyclic indole derivatives from 
3a (Scheme 4). Thus, -unsaturated imine (12a) was generated by reduction of 3a 
with Raney Ni, followed by condensation with benzaldehyde (Scheme 4). 12a is useful 
compounds for forming a part of medicinally important indoline derivatives. Treatment 
12a with 2,3-dimethylbutadiene under heating conditions gave Diels-Alder adduct 13a, 
and with N-(2-bromoethyl)methansulfonamide and 2-bromoethanol with base provided 
spiro-hetero cyclic compounds 14a and 15a, respectively. New ionic 6-membered ring 
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formation by reaction of 12a with benzaldehyde, pyrroridine, and 4-nitrobenzoic acid 
was also successfully obtained. These transformations showed easy preparation of 
various indole derivatives from 12a, and with synthetic utility of 12a for application to 
medicinally important indole derivatives. 
 
 
In conclusion, the author succeeded in regioselective 3,2-bromo-amination of indoles 
using indolyl(aryl)iodonium imides and bromination reagent. This is the first metal-free 
regioselective dual-functionalization of indoles, and it was applied to direct 
functionalization of N-pivaloylindole. The 3,2-bromo-amination product was easily 
transformed to various 3-substituted 2-aminoindole derivatives, and tricyclic 
compounds.   
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Experimental 
1. General Methods. 
1
H NMR spectra were measured on a JEOL ECA-500 (500 MHz) 
spectrometer at ambient temperature. Data were recorded as follows: chemical shift in 
ppm from internal tetramethylsilane    the δ sc le,  lt pl c ty (s = s  glet; d = d  blet; 
t = triplet; q = quartet; sep = septet; m = multiplet; br = broad), coupling constant (Hz), 
integration, and assignment. 
13
C NMR spectra were measured on a JEOL ECA-500 
(125 MHz) spectrometer. Chemical shifts were recorded in ppm from the solvent 
resonance employed as the internal standard (deuterochloroform at 77.0 ppm). 
High-resolution mass spectra were recorded by Thermo Fisher Scientific Exactive 
Orbitrap mass spectrometers. Infrared (IR) spectra were recorded on a JASCO FT/IR 
4100 spectrometer. Single crystal X-ray diffraction data were collected at 173 K on a 
   ke  SMART APEX    CCD d ff  ct  ete  w th M  Kα (λ = 0.71073) radiation and 
graphite monochrometer. For thin-layer chromatography (TLC) analysis throughout this 
work, Merck precoated TLC plates (silica gel 60GF254 0.25 mm) were used. The 
products were purified by column chromatography on neutral silica-gel (Kanto 
Chemical Co., Inc. silica gel 60N, Prod. No. 37560-84; Merck silica gel 60, Prod. No. 
1.09385.9929). Visualization was accomplished by UV light (254 nm), anisaldehyde, 
KMnO4, and phosphomolybdic acid.  
 
1. General Procedure for Preparation of 
N-(3-Bromo-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (3a) 
from 4-Methyl-N-(phenyl(1-pivaloyl-1H-indol-3-yl)-3-iodanyl)-N- 
tosylbenzenesulfonamide (2a) (Table 4, entry 10) 
To a solution of 4-methyl-N-(phenyl(1-pivaloyl-1H-indol-3-yl)-3-iodanyl)-N- 
tosylbenzenesulfonamide 2a (72.9 mg, 0.10 mmol) in 1,2-dichloroethane (1mL) was 
added 1,3-dibromo-5,5-dimethylhydantoin (17.2 mg, 0.060 mmol). The mixture was 
stirred at 40 ºC for 7 h under argon atmosphere. Saturated Na2SO3 aqueous solution (10 
mL) was added to the reaction mixture, and the product was extracted with AcOEt (15 
mL × 3). The combined extracts were washed by water (10 mL) and brine (10 mL) and 
dried over Na2SO4. The organic phase was concentrated under reduced pressure and the 
crude product was purified by column chromatography on silica-gel (eluent: 
hexane/AcOEt = 5/1), to give the desired product 3a (55.4 mg, 92 % yield). 
 
2. General Procedure for Preparation of 
N-(3-Bromo-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (3a) 
from 1-Pivaloylindole (1a) (scheme 2) 
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To prepare PhI(OAc)NTs2 were used DIB (38.7 mg, 0.12 mmol), Ts2NH (39.1 mg, 0.12 
mmol) in 1,2-dichloroethane (1mL. The mixture was stirred at room temperature for 30 
min. under argon atmosphere. Then, N-pivaloylindole (1a) (20.1 mg, 0.10 mmol) and 
1,3-dibromo-5,5-dimethylhydantoin (17.2 mg, 0.060 mmol) were added, and the 
solution was stirred at 40 ºC for 7 h. Saturated Na2SO3 aqueous solution (10 mL) was 
added to the reaction mixture, and the product was extracted with AcOEt (15 mL × 3). 
The combined extracts were washed by water (10 mL), brine (10 mL) and dried over 
Na2SO4. The organic phase was concentrated under reduced pressure and the crude 
product was purified by column chromatography on silica-gel (eluent: hexane/AcOEt = 
5/1), to give the desired product 3a (52.4 mg, 87 % yield). 
 
N-(3-Bromo-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (3a): 
1
H NMR (500 MHz, CDCl3) δ 1.50 (s, 9H), 2.48 (s, 6H), 7.24-7.30 (m, 1H), 7.33 (d, 
J=8.0 Hz, 4H), 7.41 (t, J=7.5 Hz, 1H), 7.52 (d, J=7.5 Hz, 1H), 7.55 (d, J=7.5 Hz, 1H), 
7.98 (d, J=8.0 Hz, 4H), 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 28.1 (3C), 43.2, 
103.4, 113.8, 121.0, 122.2, 125.6, 125.9, 126.1, 129.1 (4C), 130.4 (4C), 133.7, 135.5 
(2C), 145.4 (2C), 181.2. IR (neat) 1716, 1373, 1295, 1167, 660 cm
–1
. MS (ESI) calcd 
for C27H27N2O5BrNaS2 [M+Na]
+
 625.0437, found 625.0428. 
Crystal data for 3a: Formula C27H27BrN2O5S2, colorless, crystal dimensions 0.40 × 
0.30 × 0.30 mm
3
, prismatic, space group Pbca, a = 11.3613(5) Å, b = 15.8902(15) Å, c 
= 29.9856(4) Å, α = 90.00 °, β = 90.00 °, γ = 90.00 °, V = 5413.74(4) Å3, Z = 8, ρcalc = 
1.481 g cm
–3
, F(000) = 2480, μ(M Kα) = 1.713 mm–1, T = 173 K. 28834 reflections 
collected, 5143 independent reflections with I > 2σ(I) (2θmax = 27.51°), and 539 
parameters were used for the solution of the structure. The non-hydrogen atoms were 
refined anisotropically. R1 = 0.0292 and wR2 = 0.0767. GOF = 1.105. Crystallographic 
data (excluding structure factors) for the structure reported in this paper have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary 
publication no. CCDC-1023213. Copies of the data can be obtained free of charge on 
application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. code + 
44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
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Figure 2. OPTEP drawing of 3a. 
 
N-(3-Bromo-5-methyl-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonami
de (3b): 
1
H NMR (500 MHz, CDCl3) δ 1.49 (s, 9H), 2.46 (s, 3H), 2.47 (s, 6H), 7.23 (d, 
J=8.6 Hz, 1H), 7.29 (s, 1H), 7.32 (d, J=8.3 Hz, 4H), 7.45 (d, J=8.6 Hz, 1H), 7.96 (d, 
J=8.3 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.2, 21.8 (2C), 28.1 (3C), 43.1, 103.2, 
113.7, 120.4, 125.7, 125.9, 127.5, 129.2 (4C), 130.4 (5C), 132.0, 135.5 (2C), 145.4 (2C), 
181.0. IR (neat) 1712, 1374, 1282, 1164, 662 cm
–1
. MS (ESI) calcd for C27H25N2O5BrS2 
[M-H
+
]
-
 678.9577, found 678.9586. 
 
N-(3,4-Dibromo-5-methoxy-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulf
onamide (3c): 
1
H NMR (500 MHz, CDCl3) δ 1.46 (s, 9H), 2.48 (s, 6H), 3.94 (s, 3H), 
7.09 (d, J=9.2 Hz, 1H), 7.33 (d, J=8.3 Hz, 4H), 7.43 (d, J=9.2 Hz, 1H), 7.98 (d, J=8.3 
Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 28.2 (3C), 43.4, 57.7, 102.3, 104.2, 
112.1, 113.3, 122.9, 128.6, 129.2 (4C), 129.9, 130.6 (4C), 135.6 (2C), 145.6 (2C), 151.9, 
181.0. IR (neat) 1723, 1382, 1277, 1175, 1084, 648 cm
–1
. MS (ESI) calcd for 
C28H28N2O5BrS2 [M-H
+
]
-
 615.0628, found 615.0639. 
 
N-(3-Bromo-5-fluoro-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonami
de (3d): 
1
H NMR (500 MHz, CDCl3) δ 1.48 (s, 9H), 2.48 (s, 6H), 7.12-7.21 (m, 2H), 
7.33 (d, J=8.2 Hz, 4H), 7.49 (dd, J=8.5, 3.8 Hz, 1H), 7.96 (d, J=8.2 Hz, 4H). 
13
C NMR 
(125 MHz, CDCl3) δ 21.8 (2C), 28.1 (3C), 43.2, 102.8 (d, JC-F=9.5 Hz), 106.0 (d, 
JC-F=25.0 Hz), 114.5 (d, JC-F=26.2 Hz), 115.2 (d, JC-F=8.3 Hz), 126.5 (d, JC-F=9.5 Hz), 
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127.5, 129.2 (4C), 130.1, 130.4 (5C), 135.3 (2C), 145.6 (2C), 158.7 (d, JC-F=239.7 Hz), 
180.8.
 19
F NMR (471 MHz, CDCl3) δ -119.8. IR (neat) 1723, 1373, 1300, 1171, 662 
cm
–1
. MS (ESI) calcd for C27H25N2O5BrFS2 [M-H
+
]
-
 619.0378, found 619.0392. 
 
N-(3-Bromo-5-chloro-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonami
de (3e): 
1
H NMR (500 MHz, CDCl3) δ 1.48 (s, 9H), 2.48 (s, 6H), 7.33 (d, J=8.1 Hz, 
4H), 7.36 (dd, J=8.9, 2.3 Hz, 1H), 7.47 (d, J=8.9 Hz, 1H), 7.50 (d, J=2.3 Hz, 1H), 7.95 
(d, J=8.1 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 28.1 (3C), 43.2, 102.4, 
115.1, 120.4, 126.3, 126.7, 127.3, 128.2, 129.3 (4C), 130.4 (4C), 131.9, 135.3 (2C), 
145.6 (2C), 180.7. IR (neat) 1721, 1373, 1297, 1164, 1130, 661 cm
–1
. MS (ESI) calcd 
for C27H25N2O5BrClS2 [M-H
+
]
-
 635.0082, found 635.0097. 
 
N-(3,5-Dibromo-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide 
(3f): 
1
H NMR (500 MHz, CDCl3) δ 1.47 (s, 9H), 2.48 (s, 6H), 7.33 (d, J=8.3 Hz, 4H), 
7.42 (d, J=8.9 Hz, 1H), 7.50 (dd, J=8.9, 1.8 Hz, 1H), 7.66 (d, J=1.8 Hz, 1H), 7.95 (d, 
J=8.3 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 28.1 (3C), 43.2, 102.2, 115.3, 
123.5, 127.2, 128.8 (2C), 129.3, 130.4 (4C), 132.2, 135.3 (2C), 145.6 (2C), 180.7. IR 
(neat) 1725, 1373, 1299, 1165, 661 cm
–1
. MS (ESI) calcd for C27H25N2O5Br2S2 [M-H
+
]
-
 
678.9577, found 678.9586. 
 
Methyl 3-bromo-2-((4-methyl-N-tosylphenyl)sulfonamido)-1-pivaloyl-1H-indole- 
5-carboxylate (3g): 
1
H NMR (500 MHz, CDCl3) δ 1.50 (s, 9H), 2.48 (s, 6H), 3.96 (s, 
3H), 7.33 (d, J=8.4 Hz, 4H), 7.57 (dd, J=8.9, 0.60 Hz, 1H), 7.96 (d, J=8.4 Hz, 4H), 8.10 
(dd, J=8.9, 1.7 Hz, 1H), 8.25 (dd, J=1.7, 0.60 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 
21.8 (2C), 28.1 (3C), 43.3, 104.1, 113.6, 123.6, 124.3, 125.3, 126.8, 127.5, 129.3 (4C), 
130.4 (4C), 135.2 (2C), 135.8, 145.7 (2C), 166.7, 180.7. IR (neat) 1720, 1379, 1289, 
1166, 650 cm
–1
. MS (ESI) calcd for C29H28N2O5BrS2 [M-H
+
]
-
 659.0527, found 
659.0530. 
 
N-(3-Bromo-5-cyano-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonami
de (3h): 
1
H NMR (500 MHz, CDCl3) δ 1.48 (s, 9H), 2.49 (s, 6H), 7.34 (d, J=8.3 Hz, 
4H), 7.60 (d, J=8.6 Hz, 1H), 7.64 (dd, J=8.6, 1.7 Hz, 1H), 7.88 (d, J=1.7 Hz, 1H), 7.95 
(d, J=8.3 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 28.0 (3C), 43.4, 102.8, 
105.9, 114.6, 118.9, 125.4, 126.4, 128.2, 128.6, 129.3 (4C), 130.4 (4C), 134.9, 135.0 
(2C), 145.9 (2C), 180.6. IR (neat) 2225, 1728, 1372, 1308, 1165, 664 cm
–1
. MS (ESI) 
calcd for C28H25N3O5BrS2 [M-H
+
]
-
 626.0424, found 626.0411. 
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3-Bromo-2-((4-methyl-N-tosylphenyl)sulfonamido)-1-pivaloyl-1H-indol-5-yl 
pivalate (3i): 
1
H NMR (500 MHz, CDCl3) δ 1.39 (s, 9H), 1.48 (s, 9H), 2.47 (s, 6H), 
7.10 (dd, J=8.9, 2,8 Hz, 1H), 7.21 (d, J=2.8 Hz, 1H), 7.33 (d, J=8.2 Hz, 4H), 7.53 (d, 
J=8.9 Hz, 1H), 7.96 (d, J=8.2 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 27.2 
(3C), 28.1 (3C), 39.1, 43.2, 103.1, 113.1, 114.6, 120.3, 126.2, 127.1, 129.2 (4C), 130.4 
(4C), 131.2, 135.4 (2C), 145.5 (2C), 146.3, 177.5, 180.9. IR (neat) 1744, 1723, 1384, 
1272, 1166, 652 cm
–1
. MS (ESI) calcd for C32H34N2O7BrS2 [M-H
+
]
-
 701.0996, found 
701.1014. 
 
N-(3-Bromo-5-(1,3-dioxoisoindolin-2-yl)-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosy
lbenzenesulfonamide (3J): 
1
H NMR (500 MHz, CDCl3) δ 1.51 (s, 9H), 2.48 (s, 6H), 
7.34 (d, J=8.3 Hz, 4H), 7.45 (dd, J=8.9, 2.0 Hz, 1H), 7.60 (d, J=2.0 Hz, 1H), 7.67 (d, 
J=8.9 Hz, 1H), 7.79-7.85 (m, 2H), 7.94-8.03 (m, 6H). 
13
C NMR (125 MHz, CDCl3) δ 
21.8 (2C), 28.1 (3C), 43.2, 103.4, 114.5, 119.7, 123.8 (2C), 124.7, 126.1, 126.2, 127.5, 
129.5 (4C), 130.5 (4C), 131.7 (2C) 132.8, 134.5 (2C), 135.4 (2C), 145.4 (2C), 167.5 
(2C), 180.8. IR (neat) 1718, 1479, 1376, 1307, 1166, 1079, 661 cm
–1
. MS (ESI) calcd 
for C35H29N3O7BrS2 [M-H
+
]
-
 746.0641, found 746.0641. 
 
N-(3-Bromo-5-nitro-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamid
e (3k): 
1
H NMR (500 MHz, CDCl3) δ 1.50 (s, 9H), 2.50 (s, 6H), 7.35 (d, J=8.3 Hz, 4H), 
7.61 (d, J=9.3 Hz, 1H), 7.95 (d, J=8.3 Hz, 4H), 8.30 (dd, J=9.3, 2.3 Hz, 1H), 8.48 (d, 
J=2.3 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 28.1 (3C), 43.5, 104.0, 114.1, 
118.0, 120.8, 125.3, 129.4 (4C), 130.4 (5C), 135.0 (2C), 136.0, 143.1, 146.0 (2C), 180.6. 
IR (neat) 1730, 1523, 1348, 1308, 1166, 873, 650 cm
–1
. MS (ESI) calcd for 
C27H25N3O7BrS2 [M-H
+
]
-
 646.0323, found 646.0328. 
 
N-(3,4-Dibromo-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide 
(3l): 
1
H NMR (500 MHz, CDCl3) δ 1.46 (s, 9H), 2.48 (s, 6H), 7.20 (dd, J=8.3, 7.8 Hz, 
1H), 7.34 (d, J=8.5 Hz, 4H), 7.44 (d, J=7.8 Hz, 1H), 7.46 (d, J=8.3 Hz, 1H), 7.99 (d, 
J=8.5, Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 28.2 (3C), 43.6, 102.2, 113.0, 
115.6, 121.9, 125.9, 127.4, 127.9, 129.2 (4C), 130.6 (5C), 134.7, 135.6 (2C), 145.6 (2C), 
181.4. IR (neat) 1718, 1377, 1310, 1165, 662 cm
–1
. MS (ESI) calcd for 
C27H25N2O5Br2S2 [M-H
+
]
-
 678.9577, found 678.9598. 
 
N-(3-Bromo-6-chloro-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonami
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de (3m): 
1
H NMR (500 MHz, CDCl3) δ 1.49 (s, 9H), 2.47 (s, 6H), 7.25 (dd, J=8.6, 1.5 
Hz, 1H), 7.33 (d, J=8.2 Hz, 4H), 7.44 (d, J=8.6 Hz, 1H), 7.54 (d, J=1.5 Hz, 1H), 7.96 (d, 
J=8.2 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 28.1 (3C), 43.2, 103.1, 113.7, 
122.0, 123.1, 124.1, 126.7, 129.3 (4C), 130.4 (4C), 132.0, 133.6, 135.3 (2C), 145.6 (2C), 
180.7. IR (neat) 1726, 1374, 1292, 1165, 1072, 648 cm
–1
. MS (ESI) calcd for 
C27H25N2O5BrClS2 [M-H
+
]
-
 635.0082, found 635.0094. 
 
N-(3-Bromo-7-methyl-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonami
de (3n): 
1
H NMR (500 MHz, CDCl3) δ 1.32 (s, 9H), 2.36 (s, 3H), 2.48 (brs, 6H), 
7.14-7.21 (m, 2H), 7.22-7.46 (m, 5H), 7.76 (br, 2H), 8.14 (br, 2H). 
13
C NMR (125 MHz, 
CDCl3) δ 20.8, 21.8 (2C), 28.6 (3C), 44.7, 102.7, 118.7, 122.3, 122.4, 125.4, 127.6, 
128.9, 129.3 (4C), 130.5 (br, 4C), 131.3 (br, 2C), 136.1, 145.9 (br, 2C), 181.2. IR (neat) 
1736, 1379, 1264, 1173 662 cm
–1
. MS (ESI) calcd for C28H28N2O5BrS2 [M-H
+
]
-
 
615.0628, found 615.0644. 
 
N-(3-Bromo-1-pivaloyl-1H-indol-2-yl)-N-(benzenesulfonyl)benzenesulfonamide 
(3o): 
1
H NMR (500 MHz, CDCl3) δ1.49 (s, 9H), 7.27 (t, J=7.7 Hz, 1H), 7.42 (t, J=7.7 
Hz, 1H), 7.49-7.59 (m, 6H), 7.68 (tt, J=7.5, 1.2 Hz, 2H), 8.09 (d, J=8.6, 1.2 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 28.0 (3C), 43.2, 103.7, 113.9, 121.0, 122.3, 125.5, 125.8, 
126.1, 128.6 (4C), 130.4 (4C), 133.6, 133.4 (2C), 138.3 (2C), 181.1. IR (neat) 1714, 
1379, 1298, 1168, 685 cm
–1
. MS (ESI) calcd for C25H22N2O5BrS2 [M-H
+
]
-
 573.0159, 
found 573.0175. 
 
N-(3-Bromo-1-pivaloyl-1H-indol-2-yl)-N-(4-fluorobenzenelsulfonyl)-4-fluorobenze
nesulfonamide (3p): 
1
H NMR (500 MHz, CDCl3) δ1.48 (s, 9H), 7.19-7.27 (m, 4H), 
7.30 (t, J=7.7 Hz, 1H), 7.44 (t, J=7.7 Hz, 1H), 7.52-7.59 (m, 2H), 8.14 (dd, J=8.9, 5.2 
Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 28.0 (3C), 43.2, 103.7, 113.9, 115.9 (d, 
JC-F=9.5 Hz, 4C), 121.2, 122.5, 125.5, 125.6, 126.2, 133.5 (d, JC-F=9.5 Hz, 4C), 133.6, 
134.1 (d, JC-F=2.4 Hz, 2C), 166.4 (d, JC-F=256.3 Hz, 2C), 181.2.
 19
F NMR (471 MHz, 
CDCl3) δ -102.0. IR (neat) 1712, 1387, 1285, 1238, 1176, 1154 cm
–1
. MS (ESI) calcd 
for C25H20N2O5BrF2S2 [M-H
+
]
-
 608.9971, found 608.9988.  
 
N-(3-Bromo-1-pivaloyl-1H-indol-2-yl)-N-(propanesulfonyl)propanesulfonamide 
(3q): 
1
H NMR (500 MHz, CDCl3) δ 1.13 (t, J=7.4 Hz, 6H), 1.52 (s, 9H), 1.93-1.99 (m, 
4H), 3.68-3.80 (m, 2H), 3.92-4.06 (m, 2H), 7.31 (t, J=8.0 Hz, 1H), 7.42 (t, J=8.0 Hz, 
1H), 7.51 (d, J=8.0 Hz, 1H), 7.63 (d, J=7.8 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 
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13.1 (2C), 16.9 (2C), 28.0 (3C), 43.4, 58.5 (2C), 102.8, 113.9, 120.9, 122.7, 125.36, 
125.41, 126.1, 133.4, 182.7. IR (neat) 1712, 1374, 1299, 1163, 619 cm
–1
. MS (ESI) 
calcd for C19H26N2O5BrS2 [M-H
+
]
-
 505.0472, found 505.0487. 
 
N-(3-Bromo-1-pivaloyl-1H-indol-2-yl)-N-(methanesulfonyl)methanesulfonamide 
(3r): 
1
H NMR (500 MHz, CDCl3) δ 1.51 (s, 9H), 3.63 (s, 6H), 7.32 (t, J=7.8 Hz, 1H), 
7.43 (t, J=7.8 Hz, 1H), 7.51 (d, J=7.8 Hz, 1H), 7.63 (d, J=7.8 Hz, 1H). 
13
C NMR (125 
MHz, CDCl3) δ 28.0 (3C), 43.4, 43.8 (2C), 102.5, 121.0, 122.8, 125.0, 125.4, 126.3, 
133.4, 182.7. IR (neat) 1714, 1357, 1290, 1161, 621 cm
–1
. MS (ESI) calcd for 
C15H18N2O5BrS2 [M-H
+
]
-
 448.9846, found 448.9858. 
 
N-(3-Bromo-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-(methanesulfonyl)benzenesulfon
amide (3s): 
1
H NMR (500 MHz, CDCl3) δ1.60 (s, 9H), 2.44 (s, 3H), 3.83 (s, 3H), 7.27 
(t, J=8.0 Hz, 1H), 7.30 (d, J=8.1 Hz, 2H), 7.41 (t, J=8.0 Hz, 1H), 7.50 (d, J=8.0 Hz, 1H), 
7.56 (d, J=8.0 Hz,1H), 7.82 (d, J=8.1 Hz, 2H). 
13
C NMR (125 MHz, CDCl3) δ 21.8, 
28.1 (3C), 43.3, 44.0, 103.8, 114.0, 121.0, 122.5, 125.4, 125.6, 126.1, 129.7 (2C), 129.8 
(2C), 133.4, 134.5, 146.0, 182.3. IR (neat) , 1718, 1361, 1300, 1171, 663 cm
–1
. MS 
(ESI) calcd for C21H22N2O5BrS2 [M-H
+
]
-
 525.0159, found 525.0170. 
 
N-(1-Benzoyl-3-bromo-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (3t): 
1
H NMR (500 MHz, CDCl3) δ 2.44 (s, 6H), 6.47 (d, J=8.6 Hz, 1H), 7.10 (t, J=8.6 Hz, 
1H), 7.23 (t, J=7.7 Hz, 1H), 7.30 (d, J=8.0 Hz, 4H), 7.44 (t, J=7.7 Hz, 2H), 7.55 (d, 
J=8.6 Hz, 1H), 7.61 (t, J=8.6 Hz, 1H), 7.68 (d, J=7.7 Hz, 2H), 8.01 (d, J=8.0 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 105.8, 114.4, 120.8, 123.0, 126.0, 126.1, 
126.4, 128.6 (2C), 129.2 (4C), 130.2 (4C), 130.5 (2C), 133.4, 133.9, 134.7, 135.7 (2C), 
145.4(2C), 166.4. IR (neat) 1702, 1381, 1302, 1168 cm
–1
. MS (ESI) calcd for 
C29H22N2O5BrS2 [M-H
+
]
-
 621.0148, found 621.0155. 
 
N-(3-Bromo-1-tosyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (3u): 
1
H 
NMR (500 MHz, CDCl3) δ 2.33 (s, 3H), 2.47 (s, 6H), 7.20 (d, J=8.2 Hz, 2H), 7.29 (t, 
J=7.6 Hz, 1H), 7.31-7.38 (m, 5H), 7.53 (d, J=7.7 Hz, 1H), 7.65 (d, J=7.7 Hz, 1H), 7.92 
(d, J=8.2 Hz, 2H), 8.02 (d, J=8.3 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.6, 21.8 
(2C), 114.4, 121.1, 123.9, 126.5, 126.9, 127.4, 128.1 (2C), 129.3 (4C), 129.6 (2C), 
130.4 (4C), 134.3, 135.99, 136.02 (2C), 145.0, 145.6 (2C). IR (neat) 1595, 1378, 1176, 
1161, 1082, 658 cm
–1
. MS (ESI) calcd for C29H24N2O6BrS3 [M-H
+
]
-
 670.9974, found 
670.9990. 
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N-(3-Bromo-5-chloro-1-pivaloyl-1H-indol-2-yl)-N-(propanesulfonyl)propanesulfon
amide (3v): 
1
H NMR (500 MHz, CDCl3) δ 1.13 (t, J=7.4 Hz, 6H), 1.50 (s, 9H), 
1.93-2.08 (m, 4H), 3.64-3.79 (m, 2H), 3.92-4.04 (m, 2H), 7.36 (dd, J=8.9, 2.3 Hz, 1H), 
7.43 (d, J=8.9 Hz, 1H), 7.61 (d, J=2.3 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 13.1 
(2C), 16.9 (2C), 28.1 (3C), 43.4, 58.6 (2C), 101.7, 115.1, 120.4, 126.47, 126.54, 126.63, 
128.7, 131.6, 182.3. IR (neat) 1714, 1375, 1302, 1158, 862, 802 cm
–1
. MS (ESI) calcd 
for C19H27N2O5BrClS2 [M+Na]
+
 563.0047, found 563.0052. 
 
3. Transformation of 2a into Various 2-Amino Indole Derivatives. 
3.1. General Procedure for Electrophilic Addition of 3a with t-BuLi. 
To a solution of 2a (60.2 mg, 0.10 mmol) in THF (1.0 mL) was added dropwise the 
cooled t-BuLi (0.12 mL, 0.21 mmol, 1.8 M in pentane) at -96 ºC over 10 min. The 
solution was stirred at –96 ºC for 20 min. under argon atmosphere. Then, dried MgCl2 
(20.0 mg, 0.21 mmol) was added. After the obtained mixture was stirred at –96 ºC for 
20 min, electrophiles were added and the reaction solution was kept at –96 ºC 
(electrophile: PhCHO, TMSOTf) or –60 ºC (electrophile: Piv2O, 1-formylmorphorine, 
Me2SO4) for 1-2 h. Saturated NH4Cl aqueous solution (10 mL) was added to the 
reaction mixture, and the product was extracted with AcOEt (15 mL × 3). The 
combined extracts were washed by brine (10 mL) and dried over Na2SO4. The organic 
phase was concentrated under reduced pressure and the crude product was purified by 
silica-gel column chromatography (eluent: hexane/AcOEt = 8/1), to give the desired 
product 5a-10a. 
 
4-Methyl-N-(1-pivaloyl-1H-indol-2-yl)-N-tosylbenzenesulfonamide (5a): 
1
H NMR 
(500 MHz, CDCl3) δ 1.49 (s, 9H), 2.48 (s, 6H), 6.15 (s, 1H), 7.18 (t, J = 7.6 Hz, 1H), 
7.29-7.37 (m, 5H), 7.47-7.53 (m, 2H), 7.91 (d, J = 8.6 Hz, 4H). 
13
C NMR (125 MHz, 
CDCl3) δ 21.8 (2C), 28.0 (3C), 43.4, 110.3, 113.6, 121.6, 121.8, 124.7, 125.5, 127.2, 
129.1 (4C), 130.0 (4C), 134.6, 134.8 (2C), 145.4 (2C), 182.3. IR (neat) 1713, 1370, 
1294, 1171 cm
–1
. MS (ESI) calcd for C27H29N2O5S2 [M+H]
+
 525.1512, found 525.1508. 
 
N-(3-(Hydroxy(phenyl)methyl)-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzene
sulfonamide (6a): 
1
H NMR (500 MHz, CDCl3) δ 1.48 (s, 9H), 2.22 (s, 3H), 2.50 (s, 
3H), 2.86 (d, J = 2.3 Hz, 1H), 5.45 (d, J = 2.3 Hz, 1H), 6.96 (d, J = 8.0 Hz, 2H), 7.01 (d, 
J = 7.6 Hz, 1H), 7.19-7.28 (m, 6H), 7.28-7.33 (m, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.56 (d, 
J = 8.6 Hz, 1H), 7.86 (d, J = 8.5 Hz, 2H), 8.03 (d, J = 8.5 Hz, 2H). 
13
C NMR (125 MHz, 
CDCl3) δ 21.6, 21.8, 28.3 (3C), 43.3, 66.6, 113.8, 121.4, 123.1, 124.2, 124.3, 124.9, 
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126.2, 127.0, 127.1 (2C), 127.6 (2C), 129.1 (2C), 129.4 (2C), 129.5 (2C), 130.5 (2C), 
134.7, 135.1, 135.2, 140.1, 145.55, 145.64, 181.7. IR (neat) 2928, 1711, 1377, 1291, 
1163 cm
-1
. MS (ESI) calcd for C34H34N2NaO6S2 [M+Na]
+
 653.1750, found 653.1739. 
 
N-(3-Formyl-1-pivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (7a): 
1
H NMR (500 MHz, CDCl3) δ 1.48 (s, 9H), 2.50 (s, 6H), 7.30-7.41 (m, 1H), 7.37 (d, J = 
8.4 Hz, 4H), 7.44 (t, J = 7.8 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.97 (d, J = 8.4 Hz, 4H), 
8.37 (d, J = 7.8 Hz, 1H), 8.97 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.9 (2C), 28.0 
(3C), 43.7, 113.3, 119.3, 123.1, 123.2, 123.9, 126.0, 129.5 (4C), 130.3 (4C), 133.5 (2C), 
134.1, 134.2, 146.4 (2C), 181.9, 185.4. IR (neat) 1724, 1674, 1381, 1311, 1166 cm
-1
. 
MS (ESI) calcd for C28H28N2NaO6S2 [M+Na]
+
 575.1281, found 575.1267. 
 
N-(1,3-Dipivaloyl-1H-indol-2-yl)-4-methyl-N-tosylbenzenesulfonamide (8a): 
1
H 
NMR (500 MHz, CDCl3) δ 1.27 (s, 9H), 1.43 (s, 9H), 2.48 (s, 6H), 7.25-7.30 (m, 1H), 
7.32 (d, J = 8.4 Hz, 4H), 7.35-7.40 (m, 1H), 7.52 (d, J = 8.6 Hz, 1H), 7.73 (d, J = 8.0 Hz, 
1H), 8.00 (d, J = 8.3 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 21.8 (2C), 27.4 (3C), 28.3 
(3C), 43.6, 44.1, 113.6, 121.9, 122.5, 123.3, 123.6, 124.6, 126.3, 128.7 (4C), 130.8 (4C), 
132.9, 135.7 (2C), 145.0 (2C), 181.6, 205.6. IR (neat) 2930, 1718, 1672, 1379, 1289, 
1165 cm
-1
. MS (ESI) calcd for C32H36N2NaO6S2 [M+Na]
+
 631.1907, found 631.1896. 
 
4-Methyl-N-(3-methyl-1-pivaloyl-1H-indol-2-yl)-N-tosylbenzenesulfonamide (9a): 
1
H NMR (500 MHz, CDCl3) δ 1.50 (s, 9H), 1.51 (s, 3H), 2.47 (s, 6H), 7.20 (t, J = 8.0 
Hz, 1H), 7.30-7.39 (m, 1H), 7.33 (d, J = 7.8 Hz, 4H), 7.46 (d, J = 7.5 Hz, 1H), 7.55 (d, J 
= 8.0 Hz, 1H), 7.99 (d, J = 7.8 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 8.2, 21.8 (2C), 
28.1 (3C), 43.0, 113.8, 120.2, 120.5, 121.1, 124.6, 124.9, 126.9, 129.1 (4C), 130.2 (4C), 
134.2, 135.4 (2C), 145.2 (2C), 181.9. IR (neat) 1719, 1374, 1292, 1163 cm
-1
. MS (ESI) 
calcd for C28H30N2NaO5S2 [M+Na]
+
 561.1488, found 561.1484. 
 
4-Methyl-N-(1-pivaloyl-3-(trimethylsilyl)-1H-indol-2-yl)-N-tosylbenzenesulfonamid
e (10a): 
1
H NMR (500 MHz, CDCl3) δ 0.05 (s, 9H), 1.39 (s, 9H), 2.47 (s, 6H), 7.21 (t, J 
= 7.9 Hz, 1H), 7.30-7.37 (m, 1H), 7.32 (d, J = 8.3 Hz, 4H), 7.54 (d, J = 8.3 Hz, 1H), 
7.79 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 8.3 Hz, 4H). 
13
C NMR (125 MHz, CDCl3) δ 0.11 
(3C), 21.7 (2C), 28.3 (3C), 43.3, 113.8, 120.4, 120.9, 123.2, 124.0, 129.0 (4C), 130.4 
(4C), 130.9, 131.2, 135.4, 136.2 (2C), 144.9 (2C), 181.4. IR (neat) 2922, 1715, 1447, 
1375, 1294, 1170, 658 cm
-1
. MS (ESI) calcd for C30H36N2NaO5S2Si [M+Na]
+
 619.1727, 
found 619.1711. 
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3.2. Transformation of 3a into 2-Amino-indole Derivatives 11a-15a. 
3.2.1. Transformation of 3a into 11a. 
To a solution of Raney Nickel (300 mg) in 1,4-dioxiane (4.0 mL) and H2O (0.8 mL) 
was added 3a (120.4 mg, 0.20 mmol). The solution was refluxed for 48 h under argon 
atmosphere. Then, the mixture was filtrated and washed with CHCl3 (10 mL). The 
solution was removed under reduced pressure and the crude product was purified by 
column chromatography on silica-gel (eluent: hexane/AcOEt = 2/1), to give the desired 
product 11a (64.3 mg, 88 % yield). 
 
(Z)-N-(Indolin-2-ylidene)-4-methylbenzenesulfonamide (11a): 
1
H NMR (500 MHz, 
CDCl3/CF3CO2H) δ 2.44 (s, 3H), 4.24 (s, 2H), 7.21-7.29 (m, 2H), 7.33-7.43 (m, 4H), 
7.88 (d, J = 8.3 Hz, 2H), 11.8 (brs, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.6, 37.6, 
113.1, 124.6, 125.9, 127.3 (2C), 129.1, 130.3 (2C), 135.3, 140.6, 146.2, 170.7. IR (neat) 
2952, 1590, 1486, 1302, 1144 cm
-1
. MS (ESI) calcd for C15H15N2O2S [M+H]
+
 287.0849, 
found 287.0845.  
 
3.2.3. Transformation of 11a into 12a. 
To a solution of 11a (36.3 mg, 0.10 mmol) in CH2Cl2 (1.0 mL) were added BF3•Et2O 
(18.5 L, 0.15 mmol) and PhCHO (15.3 L, 0.15 mmol). The mixture was stirred at 
room temperature for 7 h under argon atmosphere. Then, saturated NaHCO3 aqueous 
solution (10 mL) was added to the reaction mixture, and the product was extracted with 
AcOEt (15 mL × 3). The combined extracts were washed by brine (10 mL) and dried 
over Na2SO4. The organic phase was concentrated under reduced pressure and the crude 
product was purified by silica-gel column chromatography (eluent: hexane/AcOEt = 
2/1), to give the desired product 12a (36.3 mg, 97 % yield, E:Z = 92:8). 
 
N-((Z)-3-((E)-Benzylidene)indolin-2-ylidene)-4-methylbenzenesulfonamide (12a): 
1
H NMR (500 MHz, CDCl3) δ 2.41 (s, 3H), 6.92 (t, J = 7.8 Hz, 1H), 7.04 (d, J = 8.0 Hz, 
1H), 7.21-7.28 (m, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.41-7.49 (m, 3H), 7.58-7.63 (m, 2H), 
7.65 (d, J = 7.8 Hz, 1H), 7.94 (d, J = 8.2 Hz, 2H), 8.11 (s, 1H), 10.12 (s, 1H). 
13
C NMR 
(125 MHz, CDCl3) δ 21.5, 111.3, 121.3, 122.8, 123.1, 126.5 (2C), 128.7 (2C), 129.4 
(4C), 129.5, 130.1, 130.2, 134.3, 139.1, 140.2, 141.8, 143.1, 160.6. IR (neat) 3280, 1571, 
1461, 1312, 1280, 1134, 1085 cm
-1
. MS (ESI) calcd for C22H19N2O2S [M+H]
+
 375.1162, 
found 375.1154. 
Crystal data for 12a: Formula C22H18N2O2S, yellow, crystal dimensions 0.30 × 0.10 × 
0.10 mm
3
, triclinic, space group P-1, a = 9.9285(7) Å, b = 10.1079(7) Å, c = 10.4705(7) 
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Å,  = S23 66.6900(10) °,  = 76.0070(10) °,  = 89.8540(10) °, V = 931.25(11) Å3, Z 
= 2, calc = 1.335 g cm
-3
, F(000) = 392, (MoK) = 0.193 mm–1, T = 173 K. 5301 
reflections collected, 4050 independent reflections with I > 2(I) (2max = 28.43°), and 
245 parameters were used for the solution of the structure. The non-hydrogen atoms 
were refined anisotropically. R1 = 0.0458 and wR2 = 0.1094. GOF = 1.040. 
Crystallographic data (excluding structure factors) for the structure reported in this 
paper have been deposited with the Cambridge Crystallographic Data Centre as 
supplementary publication no. CCDC-1023215. Copies of the data can be obtained free 
of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. 
code +44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
 
Figure 3. ORTEP drawing of 12a. 
 
3.2.4. Transformation of 12a into 13a. 
To the solution of 12a (37.4 mg, 0.1 mmol) in toluene (2 ml) was added 
2,3-dimethyl-1,3-butadiene (15.3μl, 0.15 mmol). The solution was stirred at 120 ºC for 
24 h. Then, the solvent was removed under reduced pressure to give the desired product 
13a (42.9 mg, 94 % yield, E/Z = 90:10) without any purifications. 
 
4,5-Dimethyl-2-phenylspiro[cyclohex-4-ene-1,3'-indoline] (13a): 
1
H NMR (500 MHz, 
CDCl3) δ 1.71 (s, 3H), 2.78 (s, 3H), 1.98 (d, J=17.2 Hz, 1H), 2.23 (dd, J=17.8, 5.5 Hz, 
1H), 2.58 (t, J=17.8 Hz, 1H), 2.97 (d, J=17.2 Hz, 1H), 3.31 (dd, J=17.8, 5.5 Hz, 1H), 
6.34 (d, J=7.7 Hz, 2H), 6.77 (t, J=7.7 Hz, 2H), 6.81 (d, J=7.5 Hz, 1H), 6.99 (t, J=7.5 Hz, 
1H), 7.13 (t, J=7.5 Hz, 1H), 7.22-7.37 (m, 4H), 7.78 (d, J=8.3 Hz, 2H), 9.51 (brs, 1H). 
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13
C NMR (125 MHz, CDCl3) δ 18.6, 18.9, 21.6, 36.5, 41.5, 47.1, 55.6, 110.6, 123.3, 
123.5, 124.7, 125.4, 126.7, 126.8 (2C), 127.6 (2C), 127.9 (2C), 128.4, 129.3 (2C), 132.2, 
140.9, 143.0, 173.0. IR (neat) 3289, 1606, 1282, 1141, 1090 cm
–1
. MS (ESI) calcd for 
C28H27N2O3S [M-H
+
]
-
 455.1799, found 455.1812. 
 
3.2.5. Transformation of 12a into 14a. 
To a solution of 12a (37.4 mg, 0.10 mmol) and 2-methanesulfonylethylamine (24.3 mg, 
0.12 mmol) in THF (1.0 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (15.6 L, 
0.105 mmol. The mixture was stirred at room temperature for 7 h under argon 
atmosphere. Then, saturated NH4Cl aqueous solution (10 mL) was added to the reaction 
mixture, and the product was extracted with AcOEt (15 mL × 3). The combined extracts 
were washed by brine (10 mL) and dried over Na2SO4. The organic phase was 
concentrated under reduced pressure and the crude product was purified by silica-gel 
column chromatography (eluent: hexane/AcOEt = 3/1), to give the desired product 13a 
(42.6 mg, 86% yield, E:Z = >99:<1). 
 
(Z)-4-Methyl-N-(1'-(methanesulfonyl)-2'-phenylspiro[indoline-3,3'-pyrrolidin]-2- 
ylidene)benzenesulfonamide (14a): 
1
H NMR (500 MHz, CDCl3)  2.20-2.28 (m, 1H), 
2.41- 2.50 (m, 1H), 2.45 (s, 3H), 2.83 (s, 3H), 3.90-3.98 (m, 2H), 4.89 (s, 1H), 5.82 (d, J 
= 7.8 Hz, 1H), 6.68 (td, J = 7.8, 1.0 Hz, 1H), 6.71-7.30 (br, 2H), 6.93 (d, J = 7.8 Hz, 
1H), 7.10-7.25 (m, 3H), 7.13 (td, J = 7.8, 1.0 Hz, 1H), 7.34 (d, J = 8.2 Hz, 2H), 7.87 (d, 
J = 8.2 Hz, 2H), 10.0 (s, 1H). 
13
C NMR (125 MHz, CDCl3)  21.6, 35.2, 35.9, 46.8, 
62.1, 69.3, 110.7 (2C), 123.4, 125.4, 126.4 (2C), 127.2 (2C), 128.1, 128.2, 129.0, 129.8 
(2C), 138.2, 139.1, 140.3 (2C), 144.0, 172.0. IR (neat) 3282, 1589, 1322, 1145, 1085 
cm
-1
. MS (ESI) calcd for C25H26N3O4S2 [M+H]
+
 496.1359, found 496.1353. 
Crystal data for 14a: Formula C25H25N3O4S2•C4H8O2, colorless, crystal dimensions 
0.20 × 0.10 × 0.10 mm
3
, triclinic, space group P-1, a = 9.5145(9) Å, b = 11.3505(10) Å, 
c = 12.4229(11) Å,  = 79.1933(10) °,  = 86.0059(12) °,  = 82.6050(12) °, V = 
1305.4(2) Å3, Z = 2, calc = 1.375 g cm
-3
, F(000) = 570, (MoK) = 0.247 mm-1, T = 
173 K. 7744 reflections collected, 5883 independent reflections with I > 2(I) (2max = 
28.74°), and 364 parameters were used for the solution of the structure. The 
non-hydrogen atoms were refined anisotropically. R1 = 0.0528 and wR2 = 0.1411. GOF 
= 1.044. Crystallographic data (excluding structure factors) for the structure reported in 
this paper have been deposited with the Cambridge Crystallographic Data Centre as 
supplementary publication no. CCDC-1023217. Copies of the data can be obtained free 
of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. 
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code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
 
 
Figure 4. ORTEP drawing of 14a. 
 
3.2.6. Transformation of 12a into 15a. 
To a solution of 12a (37.4 mg, 0.10 mmol) in THF (1.0 mL) were added 
2-bromoethanol (15.3 L, 0.15 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (15.3 L, 
0.15 mmol). The mixture was stirred at room temperature for 7 h under argon 
atmosphere. Then, saturated NH4Cl aqueous solution (10 mL) was added to the reaction 
mixture, and the product was extracted with AcOEt (15 mL × 3). The combined extracts 
were washed by brine (10 mL) and dried over Na2SO4. The organic phase was 
concentrated under reduced pressure and the crude product was purified by silica-gel 
column chromatography (eluent: hexane/AcOEt = 2/1), to give the desired product 14a 
(38.1 mg, 91% yield, E:Z = 85:15). 
 
(Z)-4-Methyl-N-(2-phenyl-4,5-dihydro-2H-spiro[furan-3,3'-indolin]-2'- 
ylidene)benzenesulfonamide (15a): 1H NMR (500 MHz, CDCl3) 2.37 (ddd, J = 
12.6, 8.3, 5.2 Hz, 1H), 2.46 (s, 3H), 2.89 (ddd, J = 12.6, 9.8, 7.2 Hz, 1H), 4.35 (td, J = 
9.8, 5.2 Hz, 1H), 4.44 (td, J = 8.3, 7.2 Hz, 1H), 5.09 (s, 1H), 6.71 (d, J = 7.5 Hz, 2H), 
6.76 (d, J = 7.8 Hz, 1H), 6.89 (t, J = 7.5 Hz, 2H), 6.94-7.01 (m, 2H), 7.07 (t, J = 7.8 Hz, 
1H), 7.24 (d, J = 7.5 Hz, 1H), 7.36 (d, J = 8.0 Hz, 2H), 7.96 (d, J = 8.0 Hz, 2H), 9.86 (s, 
1H). 13C NMR (125 MHz, CDCl3) 21.6, 39.2, 62.9, 67.1, 89.1, 110.5, 123.5, 124.6, 
125.2 (2C), 126.7 (2C), 127.49 (2C), 127.53, 128.2, 129.6 (2C), 131.2, 135.5, 138.5, 
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139.6, 143.6, 170.1. IR (neat) 3060, 1657, 1446, 1275, 1149 cm–1. MS (ESI) calcd for 
C24H23N2O3S [M+H]+ 419.1424, found 419.1416. 
Crystal data for 15a: Formula C24H22N2O3S, colorless, crystal dimensions 0.20 × 0.10 
× 0.10 mm
3
, triclinic, space group P-1, a = 6.8453(4) Å, b = 11.1232(7) Å, c = 
14.3467(9) Å,  = 95.8640(10) °,  = 94.6170(2) °,  = 106.1630(10) °, V = 
1036.91(11) Å3, Z = 2, calc = 1.340 g cm
-3
, F(000) = 440, (MoK) = 0.185 mm-1, T = 
173 K. 5925 reflections collected, 4519 independent reflections with I > 2(I) (2max = 
28.44°), and 272 parameters were used for the solution of the structure. The 
non-hydrogen atoms were refined anisotropically. R1 = 0.0437 and wR2 = 0.1124. GOF 
= 1.079. Crystallographic data (excluding structure factors) for the structure reported in 
this paper have been deposited with the Cambridge Crystallographic Data Centre as 
supplementary publication no. CCDC-1023216. Copies of the data can be obtained free 
of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. 
code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
 
 
Figure 5. ORTEP drawing of 15a. 
 
3.2.7. Transformation of 12a into 16a. 
To a solution of 12a (37.4 mg, 0.10 mmol), 4-nitrobenzoic acid (3.3 mg, 0.02 mmol), 
and pyrrolidine (1.7 L, 0.02 mol) in THF (1.0 mL) was added acetaldehyde (24.9 L, 
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0.40 mmol, ca. 90% aq.) at -78 ºC. The mixture was stirred at -78 ºC for 24 h under 
argon atmosphere. Then, saturated NaHCO3 aqueous solution (10 mL) was added to the 
reaction mixture, and the product was extracted with AcOEt (15 mL × 3). The 
combined extracts were washed by brine (10 mL) and dried over Na2SO4. The organic 
phase was concentrated under reduced pressure and the crude product was purified by 
silica-gel column chromatography (eluent: hexane/AcOEt = 2/1), to give the desired 
product 16a (35.2 mg, 82% yield). 
 
4-Phenyl-1-tosyl-2,3,4,9-tetrahydro-1H-pyrido[2,3-b]indol-2-ol (16a): 
1
H NMR (500 
MHz, CDCl3) δ 1.03-1,09 (m, 1H), 2.21 (ddd, J = 14.5, 6.0, 3.0 Hz, 1H), 2.38 (s. 3H), 
2.94 (brs, 1H), 4.18 (dd, J = 11.5, 6.0 Hz, 1H), 5.74 (s, 1H), 6.60 (d, J = 7.8 Hz, 1H), 
6.85 (t, J = 7.8 Hz, 1H), 6.87-6.93 (m, 2H), 7.11 (t, J = 7.8 Hz, 1H), 7.14-7.20 (m, 3H), 
7.26 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 8.2 Hz, 2H), 9.04 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.6, 34.0, 37.3, 79.8, 101.9, 110.7, 119.4, 119.7, 121.5, 
125.6, 126.6, 126.9 (2C), 127.8 (2C), 128.4 (2C), 129.1, 130.1 (2C), 133.5, 134.0, 143.3, 
144.8. IR (neat) 3480, 1593, 1468, 1362, 1162 cm
-1
. MS (ESI) calcd for C24H23N2O3S 
[M+H]
+
 419.1424, found 419.1424.  
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Chapter 4 
 
Regioselective Iodo-amination of 2-Methylindoles via (Indolyl)(aryl)iodonium 
Imides 
N-((3-iodo-1-pivaloyl-1H-indol-2-yl)methyl)-N-(methanesulfonyl)methanesulfonamide
s were prepared by iodo-amination of 2-methylindole derivatives via  
(2-methylindolyl)(phenyl)iodonium imides using iodinating reagents. This reaction 
transformed both sp
2 
C-H and non-activated sp
3 
C-H bonds to C-I and C-N bonds, 
respectively. 
 
Introduction 
Direct intermolecular C-H amination at non-activated sp
3
 carbon is attractive as 
functionalization of commercially available and cheep compounds, and is useful for 
synthetic chemistry
1
. Although oxidative C-H functionalization of alkylindole is also 
noticed by a lot of organic chemists to construct new synthetic process of medicinal and 
bioactive compounds
2
, direct intermolecular sp
3
 carbon amination of alkylindoles 
required azide compounds or heavy metal reagents
2a,c
. On the other hands, halogenation 
reagents are useful compounds for direct and metal-free C-N bond formation at benzylic 
carbon atom
3
, and some reports showed that hypervalent iodine is also effective for 
direct carbon-nitrogen bond construction reaction at non-activated sp
3
 carbon atom
4
.  
On chapter 2, the author developed novel imide-combined hypervalent iodine, 
(indolyl)(aryl)iodonium imide, and succeeded in C-H dual-functionalization of indole 
via (indolyl)(aryl)iodonium imide with bromination reagent in chapter 3
5
. These 
methods regioselectively transformed two C-H bonds to C-Br and C-N bond, 
respectively. Here, the author reports new regioselective dual-functionalization of 
2-methylindole derivatives via (indolyl)(aryl)iodonium imide generated in situ with 
iodination reagent. This reaction provided 2-aminomethyl-3-iodoindole derivatives 
through oxidative C-N bond formation of non-activated sp
3
 C-H bond. 
 
Results and Discussion 
First, the author screened haloganation reagents and solvents in halo-amination of 
(2-methylindolyl)(aryl)iodonium imide (Table 1). The same treatment as 
3,2-bromo-amination of (indolyl)(aryl)iodonium imide with DBH gave 
N-((3’-bromo-1’-pivaloyl-1’H-indol-2’-yl)methyl)-4-methyl-N-tosylbenzenesulfonamid
e in moderate yield (entry 1). Use of 1.2 equivalents DBH decreased the product yield 
(entry 2), however, dark conditions and use of Ts2NH (1.2 equiv.) improved the yield of 
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3a (entries 3,4). Although the author examined halo-amination with various solvents 
and bromination reagents, desire product was not obtained in high yield (entries 5-11). 
Amazingly, 3a was produced in high yield by use of NIS or DIH instead of DBH 
(entries 12,13). Those iodination reagents were not effective for dual-functionalization 
of indole derivatives (see chapter 3), however, DIH was the best reagent for C-N bond 
formation of 2-methylindole derivatives. 
 
 
 
Although the desire product (3a) was obtained in high yield from 2a, various 
(alkylindolyl)(aryl)iodonium imides 2 generated from substituted 2-alkylindole 
derivatives (1) could not be isolated from the reaction mixture of 1 with DIB and Ts2NH. 
Then, the author studied one-pot preparation method for iodo-amination of 1a (Scheme 
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1). The yield of product was 78 %, when DIB, Ts2NH and DIH were added at same time. 
The condition of DIH and additional Ts2NH adde after 1st step, generation of 
(indolyl)(aryl)iodonium imide intermediate, did not improve the yield of 3a. Then, the 
author examined addition of bases after 1st step, followed by stirring for 10 minutes 
(Table 2). Use of 1.2 equivalent of NaHCO3 was not affected in the yield of 3a (entry 2), 
however, the product was formed in 96 % yield by using NaHCO3 (2.4 equiv.) (entry 3). 
Other bases were not effective for iodo-amination of 2-methylindole derivatives (entries 
4-7). 
 
 
 
 
Next, the author examined screening various bis(sulfonyl)imides and N-protecting 
groups of 2-methylindole for iodo-amination (Table 3). Although both arene- and 
bis(alkanesulfonyl)imide gave -amino-3-iodoindole derivatives (3a-3f) in high yield, 
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use of Ms2NH was the best conditions for dual-functionalization of 2-methylindole with 
DIH. In addition, indole bearing Bz (1h) and Ts (1g) groups were also applied for 
effective to give desire products in 91 % and 52 % yields, respectively.   
 
 
 
To research the range of substrates for redioselective iodo-amination of 2-methylindole, 
various 2-methylindoles were examined (Table 4). NIS was used instead of DIH for 
some substrates, and equivalent of iodination reagent depended on substitutent of 
2-methylindole derivatives. 3,5-dimethylindole (2j) derivative gave 
N-((3’-bromo-5’-methyl-1’-pivaloyl-1’H-indol-2’-yl)methyl)-4-methyl-N-tosylbenzenes
ulfonamide (3j) in high yield. The substrate bearing strong electron-donating group, 
MeO (2q), was converted into 3,6-diiodo product (3k) in high yield by using 2.4 
equivalent of NIS. The reaction of 5 or 6-monosubstituted indoles bearing 5-F (2k), 
5-Cl (2l), 5-Br (2m), 5-CO2Me (2n), 5-CN (2o), 6-Me (2r), 6-MeO (2s), 6-Cl (2t), and 
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6-CO2Ne (2u) groups, gave the corresponding monosubstituted products (3k-3o, 3r-3u) 
in high yields, respectively. 5- or 6-NO2 indole derivative were also transformed to 
desire products in high yield in the presence of Na2SO4 (2.0 equiv.) without base. 4-Me 
(1w) indole derivative was also converted into 2-Ms2NCH2-3-iodo indole derivative 
(3w) in high yields, respectively. In addition, the same treatment of di-substituted 
indoles (1x, 1y) and 3H-benzo[e]indole derivatives (1z) gave corresponding products in 
good to high yields, respectively. Unfortunately, 3-ethylindole derivative was not 
transformed to iodo-amination product. 
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The author then examined some experimental studies to determine reaction mechanism 
for iodo-amination of 2-methylindole derivatives (Scheme 2). Reducing equivalent of 
DIH from 0.6 to 0.5, the desired product 3e was obtained in only 7 % yield and 
3-iodoindole derivative was formed in 91 % as a byproduct. Moreover, when DIH (0.1 
equiv.) was added to the reaction mixture of (indolyl)(aryl)iodonium imide (2e) 
generated in situ from 1a with DIH (0.5equiv.) stirring for 2h, the yield of 3e was 
increased to 75 %. These results suggested that 4 is one of the intermediates for 
dual-functionalization of 2-methylindole derivatives. In addition, reaction of 4 with DIB 
(1.2 equiv.) and Ms2NH (1.2 equiv.) in DCM for 7 h under dark conditions gave 3e in 
35 %, together with recovered 4 in 56 %. Surprisingly, the treatment of 1a with only 
DIH (0.6 equiv.) and Ms2NH (1.2 equiv.) also gave 3e in 56 % yield. However, both 
methods provided 3e in moderate yield less than that in the optimized conditions. On 
the other hands, treatment of 4 with DBH (0.5 equiv.), DIB (1.0 equiv.), and Ms2NH 
(1.2 equiv.) provided 3-iodo-product 3e and 3-bromo-product 5e in 6 % and 53 % yields, 
respectively. Since 5a was not produced by the reaction of 3e with DBH (0.5 equiv.), 5e 
was directly transformed from 4 with DBH. These observations suggest that both DIB 
and DIH separately gave iodo-amination product 3e. 
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The proposed mechanism for iodo-amination is shown in Scheme 3. First, 
2-methylindole derivative 1a reacts with PhI(OAc)NMs2 generated in situ from DIB 
and Ms2NH to form (indolyl)(phenyl)iodonium imide 2e.  
2e generates 2-methyl-3-iodoindole derivative 4 and hypervalent iodine species by 
using DIH. 4 is transformed to 3e via two pathways. In the first pathway, 4 is 
re-oxidized with hypervalent iodine compound and enamine intermediate A is formed 
via dehydrogenation. Then, Ms2N anion attacks intermediate A to give 3e (Path A). In 
the second pathway, 4 reacts with iodination reagent again followed by dehydrogenation, 
and enamine intermediate B is formed. Intermediate B is converted into 3e by the 
reaction with Ms2N anion and the subsequent elimination of iodide ion. Iodide ion is 
re-oxidized by hypervalent iodine to regenerate iodination species (Path B). The author 
believed that both pathways are included under the optimized conditions. 
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The author also found removal of one methanesulfonyl group from the product 3e by 
using K2CO3 (Scheme 4). The deprotection proceeded under mild conditions to give 6e, 
which can be converted into various medicinal compounds via nucleophilic reactions. 
 
 
 
In conclusion, the author developed first regioselective dual-fuctionalization of 
2-methylindole derivatives via (indolyl)(aryl)iodonium imides with DIH or NIS. This 
reaction directly converted non-activated sp
3
 C-H bond into C-N bond, and the product 
possesses synthetic utility for medicinal and biologically active compounds. 
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Experimental 
1. General Methods. 
1
H NMR spectra were measured on a JEOL ECA-400 (400 MHz) 
spectrometer at ambient temperature. Data were recorded as follows: chemical shift in 
ppm f      te   l tet   ethyls l  e    the δ sc le,  lt pl c ty (s = s  glet; d = d  blet; 
t = triplet; q = quartet; sep = septet; m = multiplet; br = broad), coupling constant (Hz), 
integration, and assignment. 
13
C NMR spectra were measured on a JEOL ECA-400 
(100 MHz) spectrometer. Chemical shifts were recorded in ppm from the solvent 
resonance employed as the internal standard (deuterochloroform at 77.0 ppm). 
High-resolution mass spectra were recorded by Thermo Fisher Scientific Exactive 
Orbitrap mass spectrometers. Infrared (IR) spectra were recorded on a JASCO FT/IR 
4100 spectrometer. Single crystal X-ray diffraction data were collected at 173 K on a 
   ke  SMART APEX    CCD d ff  ct  ete  w th M  Kα (λ = 0.71073) radiation and 
graphite monochrometer. For thin-layer chromatography (TLC) analysis throughout this 
work, Merck precoated TLC plates (silica gel 60GF254 0.25 mm) were used. The 
products were purified by column chromatography on neutral silica-gel (Kanto 
Chemical Co., Inc. silica gel 60N, Prod. No. 37560-84; Merck silica gel 60, Prod. No. 
1.09385.9929). Visualization was accomplished by UV light (254 nm), anisaldehyde, 
KMnO4, and phosphomolybdic acid. 
 
1. General Procedure for Preparation of N-((3’-iodo-1’-pivaloyl-1’H-indol-2’-yl)- 
methyl)-4-methyl-N-tosylbenzenesulfonamide (3a) from 4-Methyl-N-(phenyl(1’- 
pivaloyl-2’-methyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylbenzenesulfonamide 2a 
(Table 1, entry 13) 
To a solution of 4-methyl-N-(phenyl(1-pivaloyl-2-methyl-1H-indol-3-yl)-3-iodanyl)- 
N-tosylbenzenesulfonamide 2a (74.3 mg, 0.10 mmol) in dichloromethane (1mL) was 
added 1,3-diiodo-5,5-dimethylhydantoin (22.2 mg, 0.060 mmol). The mixture was 
stirred at room temperature for 7 h under argon atmosphere. Then, saturated Na2SO3 
aqueous solution (10 mL) was added to the reaction mixture, and the product was 
extracted with AcOEt (15 mL × 3). The combined extracts were washed by water (10 
mL), brine (10 mL) and dried over Na2SO4. The organic phase was concentrated under 
reduced pressure and the crude product was purified by column chromatography on 
silica-gel (eluent: hexane/AcOEt = 5/1), to give the desired product 3a (61.1 mg, 92 % 
yield). 
 
2. General Procedure for One-pot Preparation of 
N-((3’-iodo-1’-pivaloyl-1’H-indol-2’-yl)-methyl)-4-methyl-N-tosylbenzenesulfonam
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ide (3a) from 1-Pivaloyl-2-methylindole 1a (Table 2, entry 3) 
To prepare PhI(OAc)NTs2 were used DIB (38.7 mg, 0.12 mmol), and Ts2NH (39.1 mg, 
0.12 mmol) in dichloromethane (1mL). The solution was stirred at room temperature for 
30 min. under argon atmosphere. Then, 1-pivaloyl-2-methylindole (1a) (22.2 mg, 0.10 
mmol) was added, and the obtained mixture was stirred at room temperature for 2 h. 
Then, NaHCO3 (22.1 mg, 0.24 mmol) was added, and the obtained mixture was stirred 
at room temperature for 10 min, followed by addition of 
1,3-diiodo-5,5-dimethylhydantoin (22.2 mg, 0.060 mmol). The mixture was stirred at 
room temperature for 5 h under argon atmosphere. Then, saturated Na2SO3 aqueous 
solution (10 mL) was added to the reaction mixture, and the product was extracted with 
AcOEt (15 mL × 3). The combined extracts were washed by water (10 mL), brine (10 
mL) and dried over Na2SO4. The organic phase was concentrated under reduced 
pressure and the crude product was purified by column chromatography on silica-gel 
(eluent: hexane/AcOEt = 5/1), to give the desired product 3a (63.8 mg, 96 % yield). 
 
N-((3’-iodo-1’-pivaloyl-1’H-indol-2’-yl)-methyl)-4-methyl-N-tosylbenzenesulfonam
ide (3a): 
1
H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H), 2.31 (s, 6H), 5.27 (s, 2H), 7.05 (d, 
J=8.2 Hz, 4H), 7.17-7.32 (m, 4H), 7.63 (d, J=8.2 Hz, 4H). 
13
C NMR (100 MHz, CDCl3) 
δ 21.5 (2C), 28.1 (3C), 44.5, 46.8, 72.1, 112.7, 121.7, 122.1, 124.9, 127.8 (4C), 129.1 
(4C), 130.2, 130.7, 135.7, 136.8, 136.8 (2C), 144.5 (2C), 183.6. IR (neat) 1715, 1378, 
1166, 832, 750 cm
–1
. MS (ESI) calcd for C28H30N2O5IS2 [M+H]
 +
 665.0635, found 
665.0641. 
 
N-((3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(benzenesulfonyl)benzenesulfonam
ide (3b): 
1
H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H), 5.30 (s, 2H), 7.17-7.34 (m, 9H), 
7.46 (t, J=7.6 Hz, 2H), 7.75 (dd, J=8.4, 1.2 Hz, 4H). 
13
C NMR (100 MHz, CDCl3) δ 
28.1 (3C), 44.4, 46.9, 72.5, 112.8, 121.9, 122.2, 125.0, 127.9 (4C), 128.5 (4C), 130.1, 
130.7, 130.7, 135.5 (2C), 135.6, 139.6 (2C), 183.7. IR (neat) 1731, 1374, 1167, 999, 
806, 741 cm
–1
. MS (ESI) calcd for C26H27N2O5IS2 [M+H]
 +
 637.0333, found 637.0334. 
 
4-Fluoro-N-(4”-fluorobenzenesulfonyl)-N-((3’-iodo-1’-pivaloyl-1’H-indol-2’-yl)-me
thyl)benzenesulfonamide (3c): 
1
H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 5.27 (s, 
2H), 6.90-7.00 (m, 4H), 7.20-7.37 (m, 4H), 7.72-7.81 (m, 4H). 
13
C NMR (100 MHz, 
CDCl3) δ 28.0 (3C), 44.5, 47.0, 72.3, 112.7, 115.8 (d, JC-F=23.0 Hz, 4C), 121.8, 122.5, 
125.2, 130.0, 130.2, 130.9 (d, JC-F=9.6 Hz, 4C), 135.5 (d, JC-F=3.8 Hz, 2C), 135.7, 165.6 
(d, JC-F=257.7 Hz, 2C), 183.7. 
19
F NMR (390 MHz, CDCl3) δ -102.9. IR (neat) 1745, 
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1590, 1492, 1384, 1240, 1173, 837 cm
–1
. MS (ESI) calcd for C26H25N2O5F2IS2 [M-H
+
]
-
 
673.0130, found 673.0132. 
 
N-((3’-iodo-1’-pivaloyl-1’H-indol-2’-yl)-methyl)-4-methyl-N-(methanesulfonyl)ben
zenesulfonamide (3d): 
1
H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H), 2.27 (s, 3H), 3.36 (s, 
3H), 5.19 (s, 2H), 6.97 (d, J=8.8 Hz, 2H), 7.20-7.27 (m, 1H), 7.29-7.33 (m, 2H), 7.34 (d, 
J=8.0 Hz, 1H), 7.55 (d, J=8.8 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ 21.5, 28.1 (3C), 
44.4, 44.6, 46.1, 76.7, 113.0, 121.9, 122.3, 124.9, 128.1 (2C), 129.0 (2C), 130.2, 131.5, 
135.5, 135.6, 144.8, 184.0. IR (neat) 1686, 1364, 1163, 962, 841, 734 cm
–1
. MS (ESI) 
calcd for C22H26IN2O5S2 [M+H]
 +
 589.0322, found 589.0326. 
 
N-((3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methanesulfona
mide (3e): 
1
H NMR (400 MHz, CDCl3) δ 1.48 (s, 9H), 3.23 (s, 6H), 5.18 (s, 2H), 7.28 
(t, J=8.0 Hz, 1H), 7.34 (t, J=8.0 Hz, 1H), 7.42 (d, J=8.0 Hz, 1H), 7.49 (d, J=8.0 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 28.2 (3C), 43.7 (2C), 44.2, 45.6, 70.6, 113.4, 122.2, 
122.5, 125.0, 130.2, 132.7, 135.6, 184.4. IR (neat) 1692, 1363, 1154, 967, 753 cm
–1
. MS 
(ESI) calcd for C16H21N2O5ClIS2 [M+Cl]
-
 546.9631, found 546.9641. 
 
N-((3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(propanesulfonyl)propanesulfona
mide (3f): 
1
H NMR (400 MHz, CDCl3) δ 0.96 (t, J=7.5 Hz, 6H), 1.47 (s, 9H), 1.82 
(sext, J=7.5 Hz, 1H), 3.21-3.31 (m, 4H), 5.17 (s, 2H), 7.27 (t, J=8.0 Hz, 1H), 7.34 (t, 
J=8.0 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 7.50 (d, J=8.0 Hz, 1H). 
13
C NMR (100 MHz, 
CDCl3) δ 12.7 (2C), 16.6 (2C), 28.1 (3C), 44.2, 46.2, 58.5 (2C), 70.8, 113.2, 122.2, 
122.4, 125.1, 130.1, 132.9, 135.7, 184.2. IR (neat) 1703, 1370, 1151, 999, 805, 741 
cm
–1
. MS (ESI) calcd for C20H31N2O5IS2 [M+H]
+
 569.0635, found 569.0641. 
 
N-(benzylsulfonyl)-N-((3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-1-phenylmethanes
ulfonamide (3g): 
1
H NMR (400 MHz, CDCl3) δ 1.37 (s, 9H), 4.28 (br, 2H), 4.52 (s, 
4H), 7.21-7.42 (m, 13H), 7.46 (d, J=7.8 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 28.0 
(3C), 44.0, 47.3, 62.9 (4C), 113.0, 122.1, 122.4, 125.1, 126.7 (2C), 128.9 (4C), 129.4 
(2C), 130.0, 131.2 (4C), 132.6, 135.5, 183.9. IR (neat) 1691, 1377, 1158, 744, 694 cm
–1
. 
MS (ESI) calcd for C28H30N2O5IS2 [M+H]
+
 665.0635, found 665.0644. 
 
N-((1-benzoyl-3-iodo-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methanesulfona
mide (3h): 
1
H NMR (400 MHz, CDCl3) δ 3.28 (s, 6H), 5.53 (s, 2H), 6.46 (d, J=7.6 Hz, 
1H), 7.06 (td, J=8.0, 1.4 Hz, 1H), 7.23 (t, J=7.6 Hz, 1H), 7.47 (d, J=7.6 Hz, 1H), 7.53 (d, 
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J=8.0 Hz, 2H), 7.69 (t, J=7.6 Hz, 1H), 7.83 (dd, J=8.0, 1.4 Hz, 2H). 
13
C NMR (100 
MHz, CDCl3) δ 42.7 (2C), 44.9, 75.2, 114.1, 122.1, 123.3, 125.3, 129.0 (2C), 130.46 
(2C), 130.54, 133.8, 134.1, 134.9, 136.7, 169.5. IR (neat) 1685, 1375, 1158, 817, 745 
cm
–1
. MS (ESI) calcd for C18H18N2O5INaS2 [M+Na]
+
 554.9516, found 554.9519. 
 
N-((3-iodo-1-tosyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methanesulfonamid
e (3i): 
1
H NMR (500 MHz, CDCl3) δ 2.34 (s, 3H), 3.49 (s, 6H), 5.46 (s, 2H), 7.20 (d, 
J=8.2 Hz, 2H), 7.28-7.35 (m, 1H), 7.326-7.43(m, 2H), 7.65 (d, J=8.2 Hz, 2H), 8.06 (d, 
J=8.2 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.6, 42.8 (2C), 45.5, 80.8, 115.3, 122.5, 
124.7, 126.5 (2C), 126.9, 130.1 (2C), 131.5, 132.8, 134.8, 136.7, 145.5. IR (neat) 1359, 
1154, 996, 798, 754 cm
–1
. MS (ESI) calcd for C28H20N2O5IS2Na [M+Na]
+
 604.9342, 
found 604.9348. 
 
N-((3-iodo-5-methyl-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methan
esulfonamide (3j): 
1
H NMR (400 MHz, CDCl3) δ 1.48 (s, 9H), 2.47 (s, 3H), 3.22 (s, 
6H), 5.17 (s, 2H), 7.15 (dd, J=8.5, 1.4 Hz, 1H), 7.26 (m, 1H), 7.32 (d, J=8.5 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 21.1, 28.2 (3C), 43.7 (2C), 43.9, 45.6, 70.6, 113.3, 121.8, 
126.6, 130.4, 132.3, 132.7, 133.8, 184.2. IR (neat) 1728, 1362, 1157, 957, 761 cm
–1
. MS 
(ESI) calcd for C17H23N2O5ClIS2 [M+Cl]
-
 560.9787, found 560.9801. 
 
N-((3,6-diiodo-5-methyoxy-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)
methanesulfonamide (3k): 
1
H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 3.23 (s, 6H), 
3.97 (s, 3H), 5.14 (s, 2H), 6.83 (s, 1H), 7.84 (s, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
28.3 (3C), 43.7 (2C), 44.1, 45.5, 56.7, 70.0, 83.8, 102.2, 124.2, 131.1, 131.4, 134.5, 
154.1, 183.6. IR (neat) 1694, 1365, 1161, 1036, 840 cm
–1
. MS (ESI) calcd for 
C17H22N2O6ClIS2 [M+Cl]
-
 702.8703, found 702.8722. 
 
N-((5-fluoro-3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methan
esulfonamide (3l): 
1
H NMR (400 MHz, CDCl3) δ 1.47 (s, 9H), 3.24 (s, 6H), 5.15 (s, 
2H), 7.07 (ddd, J=9.2, 9.0, 2.5 Hz, 1H), 7.17 (dd, J=8.7, 2.5 Hz, 1H), 7.35 (dd, J=9.2, 
4.1 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 28.2 (3C), 43.7 (2C), 44.2, 45.5, 69.5, 
107.5 (d, JC-F=24.9 Hz), 113.4 (d, J C-F=25.9 Hz), 114.5 (d, J C-F=8.6 Hz), 131.4 (d, J 
C-F=10.5 Hz), 132.0, 134.4, 159.1 (d, J C-F=241.4 Hz), 184.0.
 19
F NMR (390 MHz, 
CDCl3) δ -120.1. IR (neat) 1698, 1366, 1160, 979, 762 cm
–1
. MS (ESI) calcd for 
C16H20N2O5FClIS2 [M+Cl]
-
 564.9536, found 564.9548. 
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N-((5-chloro-3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methan
esulfonamide (3m): 
1
H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 3.24 (s, 6H), 5.15 (s, 
2H), 7.28 (dd, J=9.2, 2.0 Hz, 1H), 7.33 (dd, J=9.2, 0.48 Hz, 1H), 7.48 (dd, J=2.0. 0.48 
Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 28.2 (3C), 43.7 (2C), 44.3, 45.4, 68.9, 114.4, 
121.7, 125.3, 128.5, 131.5, 134.0, 134.1, 183.9. IR (neat) 1730, 1362, 1159, 947, 846 
cm
–1
. MS (ESI) calcd for C16H20N2O5Cl2IS2 [M+Cl]
-
 580.9241, found 580.9254. 
 
N-((5-bromo-3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methan
esulfonamide (3n): 
1
H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H), 3.24 (s, 6H), 5.15 (s, 
2H), 7.27 (d, J=8.9 Hz, 1H), 7.42 (dd, J=8.9, 2.0 Hz, 1H), 7.64 (d, J=2.0 Hz, 1H). 
13
C 
NMR (100 MHz, CDCl3) δ 28.2 (3C), 43.7 (2C), 44.3, 45.4, 68.7, 114.7, 115.9, 124.8, 
127.9, 132.0, 133.9, 134.3, 183.9. IR (neat) 1729, 1362, 1159, 938, 846 cm
–1
. MS (ESI) 
calcd for C16H20N2O5ClBrIS2 [M+Cl]
-
 624.8736, found 624.8746. 
 
Methyl 
3-iodo-2-((N-(methanesulfonyl)methylsulfonamido)methyl)-1-pivaloyl-1H-indole-5-
carboxylate (3o): 
1
H NMR (400 MHz, CDCl3) δ 1.50 (s, 9H), 3.26 (s, 6H), 3.96 (s, 3H), 
5.18 (s, 2H), 7.73 (d, J=8.4 Hz, 1H), 7.94 (dd, J=8.4, 1.2 Hz, 1H), 8.19 (d, J=1.2 Hz, 
1H). 
13
C NMR (100 MHz, CDCl3) δ 28.3 (3C), 43.6 (2C), 44.3, 45.3, 52.4, 69.5, 115.3, 
121.9, 123.3, 126.7, 133.6, 135.0, 135.8, 167.0, 184.0. IR (neat) 1719, 1343, 1236, 1155, 
979, 756 cm
–1
. MS (APCI) calcd for C18H23N2O7ClIS2 [M+Cl]
-
 604.9685, found 
604.9692. 
 
N-((5-cyano-3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methane
sulfonamide (3p): 
1
H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 3.26 (s, 6H), 5.15 (s, 
2H), 7.44 (d, J=8.7 Hz, 1H), 7.57 (dd, J=8.7, 1.6 Hz, 1H), 7.86 (d, J=1.6 Hz, 1H). 
13
C 
NMR (100 MHz, CDCl3) δ 28.1 (3C), 43.6 (2C), 44.7, 45.2, 68.9, 106.1, 114.0, 119.1, 
127.56, 127.59, 130.3, 135.1, 137.3, 183.7. IR (neat) 2230, 1709, 1347, 1156, 1067, 
1005, 843 cm
–1
. MS (ESI) calcd for C17H20N3O5ClIS2 [M+Cl]
-
 571.9583, found 
571.9599. 
 
N-((3-iodo-5-nitro-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methanes
ulfonamide (3q): 
1
H NMR (400 MHz, CDCl3) δ 1.47 (s, 9H), 3.27 (s, 6H), 5.15 (s, 2H), 
7.45 (d, J=9.2 Hz, 1H), 8.23 (dd, J=9.2, 2.0 Hz, 1H), 8.46 (d, J=2.0 Hz, 1H). 
13
C NMR 
(100 MHz, CDCl3) δ 28.1 (3C), 43.6 (2C), 44.8, 45.2, 69.9, 113.3, 119.1, 120.0, 130.2, 
136.0, 138.4, 143.5, 183.6. IR (neat) 1714, 1520, 1361, 1154, 974, 836 cm
–1
. MS (ESI) 
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calcd for C16H20N3O7ClIS2 [M+Cl]
-
 591.9481, found 591.9485. 
 
N-((3-iodo-6-methyl-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methan
esulfonamide (3r): 
1
H NMR (400 MHz, CDCl3) δ 1.47 (s, 9H), 2.49 (s, 3H), 3.21 (s, 
6H), 5.16 (s, 2H), 7.09 (d, J=8.2 Hz, 1H), 7.19 (s, 1H), 7.35 (d, J=8.2 Hz, 1H). 
13
C 
NMR (100 MHz, CDCl3) δ 22.0, 28.2 (3C), 43.7 (2C), 44.2, 45.7, 70.6, 113.3, 121.7, 
124.2, 128.1, 131.7, 135.2, 136.0, 184.4. IR (neat) 1706, 1358, 1153, 965, 761 cm
–1
. MS 
(ESI) calcd for C17H23N2O5ClIS2 [M+Cl]
-
 560.9787, found 560.9794. 
 
N-((3,5-diiodo-6-methoxyl-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)
methanesulfonamide (3s): 
1
H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H), 3.20 (s, 6H), 
3.91 (s, 3H), 5.13 (s, 2H), 6.83 (s, 1H), 7.87 (s, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
28.2 (3C), 43.7 (2C), 44.6, 45.7, 56.7, 68.8, 80.9, 95.5, 126.1, 131.6, 132.4, 136.3, 155.9, 
183.9. IR (neat) 1702, 1360, 1151, 1041, 824, 763 cm
–1
. MS (ESI) calcd for 
C17H22N2O6ClIS2 [M+Cl]
-
 702.8703, found 702.8712. 
 
N-((6-chloro-3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methan
esulfonamide (3t): 
1
H NMR (400 MHz, CDCl3) δ 1.47 (s, 9H), 3.23 (s, 6H), 5.14 (s, 
2H), 7.24 (dd, J=8.5, 1.8 Hz, 1H), 7.37-7.44 (m, 2H). 
13
C NMR (100 MHz, CDCl3) δ 
28.2 (3C), 43.7 (2C), 44.3, 45.5, 69.8, 113.2, 123.1, 123.2, 128.8, 131.1, 133.3, 135.7, 
183.8. IR (neat) 1712, 1358, 1153, 1072 962, 804, 760 cm
–1
. MS (ESI) calcd for 
C16H20N2O5Cl2IS2 [M+Cl]
-
 580.9241, found 580.9251. 
 
Methyl 
3-iodo-2-((N-(methanesulfonyl)methylsulfonamido)methyl)-1-pivaloyl-1H-indole-6-
carboxylate (3u): 
1
H NMR (400 MHz, CDCl3) δ 1.51 (s, 9H), 3.19 (s, 6H), 3.94 (s, 3H), 
5.10 (s, 2H), 7.49 (d, J=8.5 Hz, 1H), 7.87 (d, J=1.4 Hz, 1H), 7.92 (dd, J=8.5, 1.4 Hz, 
1H). 
13
C NMR (100 MHz, CDCl3) δ 27.2 (3C), 39.3, 43.9 (2C), 44.5, 52.3, 63.0, 110.8, 
122.3, 123.1, 127.0, 130.2, 134.5, 134.8, 166.9, 176.5. IR (neat) 1781, 1716, 1351, 1248, 
1159, 1072, 966, 825 cm
–1
. MS (APCI) calcd for C18H23N2O7IS2 [M]
+
 569.9986, found 
569.9991. 
 
N-((3-iodo-6-nitro-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methanes
ulfonamide (3v): 
1
H NMR (400 MHz, CDCl3) δ 1.53 (s, 9H), 3.22 (s, 6H), 5.11 (s, 2H), 
7.58 (d, J=8.9 Hz, 1H), 8.08 (d, J=1.8 Hz, 1H), 8.14 (dd, J=8.9, 1.8 Hz, 1H). 
13
C NMR 
(100 MHz, CDCl3) δ 27.2 (3C), 39.4, 43.8 (2C), 44.3, 62.4, 105.3, 117.4, 123.1, 131.1, 
101 
 
133.7, 136.8, 145.4, 176.3. IR (neat) 1793, 1514, 1335, 1159, 1050, 802, 747 cm
–1
.  
 
N-((3-iodo-4-methyl-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methan
esulfonamide (3w): 
1
H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 3.23 (s, 6H), 5.18 (s, 
2H), 6.96 (d, J=7.3 Hz, 1H), 7.15 (t, J=7.3 Hz, 1H), 7.25 (d, J=7.3 Hz, 1H). 
13
C NMR 
(100 MHz, CDCl3) δ 20.3, 28.3 (3C), 43.6 (2C), 44.9, 46.3, 66.8, 111.3, 124.0, 125.8, 
131.3, 132.0, 136.1, 184.7. IR (neat) 1732, 1366, 1158, 961, 729 cm
–1
. MS (ESI) calcd 
for C17H24N2O5IClS2 [M+Cl]
-
 560.9787, found 560.9762. 
 
N-((5,6-dichloro-3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)met
hanesulfonamide (3x):
 1
H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 3.24 (s, 6H), 5.12 (s, 
2H), 7.52 (s, 1H), 7.58 (s, 1H), 
13
C NMR (100 MHz, CDCl3) δ 28.2 (3C), 43.6 (2C), 
44.3, 45.4, 68.3, 114.8, 123.2, 127.1, 129.3, 130.1, 134.0, 134.7 183.4 IR (neat) 1712, 
1353, 1156, 970, 844, 765 cm
–1
. MS (ESI) calcd for C16H19N2O5Cl3IS2 [M+Cl]
-
 
614.8851, found 614.8857. 
 
N-((5,7-dimethyl-3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)met
hanesulfonamide (3y): 
1
H NMR (400 MHz, CDCl3) δ 1.12 (s, 9H), 2.39 (s, 3H), 2.43 
(s, 3H), 3.20 (s, 6H), 5.12 (s, 2H), 6.92 (s, 1H), 7.12 (s, 1H). 
13
C NMR (100 MHz, 
CDCl3) δ 18.3, 21.1, 27.7 (3C), 43.6 (2C), 46.0, 47.1, 61.2, 119.8, 122.5 (2C), 129.3, 
130.6, 132.4, 141.1, 189.0. IR (neat) 1740, 1368, 1157, 958, 838, 764 cm
–1
. MS (ESI) 
calcd for C18H25N2O5ClIS2 [M+Cl]
-
 574.9944, found 574.9950. 
 
N-((1-iodo-3-pivaloyl-3H-benzo[e]indol-2-yl)methyl)-N-(methanesulfonyl)methanes
ulfonamide (3z): 
1
H NMR (400 MHz, CDCl3) δ 1.39 (s, 9H), 3.19 (s, 6H), 5.28 (s, 2H), 
7.42 (d, J=9.1 Hz, 1H), 7.52 (t, J=8.2 Hz, 1H), 7.64-7.74 (m, 2H), 7.92 (d, J=8.2 Hz, 
1H), 9.61 (d, J=8.2 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 28.2 (3C), 43.8 (2C), 45.5, 
46.5, 66.7, 112.9, 120.2, 121.4, 124.8, 125.9, 126.2, 127.9, 128.8, 129.2, 130.2, 133.3, 
184.6. IR (neat) 1731, 1361, 1154, 960, 795 cm
–1
. MS (ESI) calcd for C20H24N2O5IClS2 
[M+Cl]
-
 596.9787, found 596.9794. 
 
N-((3-bromo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methanesulfon
amide (5e): 
1
H NMR (400 MHz, CDCl3) δ 1.51 (s, 9H), 3.23 (s, 6H), 5.16 (s, 2H), 7.28 
(t, J=8.5 Hz, 1H), 7.35 (t, J=8.5 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 7.59 (d, J=8.5 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 28.2 (3C), 43.6 (2C), 43.9, 44.1, 100.1, 113.6, 120.0, 
122.5, 125.0, 137.3, 130.2, 134.7, 184.2. IR (neat) 1697, 1366, 1159, 1048, 841, 762 
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cm
–1
. MS (ESI) calcd for C16H21N2O5INaS2 [M+Na]
+
 486.9967, found 486.9963. 
 
3. General Procedure for Preparation of 
N-((3-iodo-1H-indol-2-yl)methyl)methanesulfonamide (6e) from 
N-((3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methylsulfonyl)methanesulfonami
de (3e) (Scheme 4) 
To a solution of  
N-((3-iodo-1-pivaloyl-1H-indol-2-yl)-methyl)-N-(methanesulfonyl)methanesulfonamide 
3e (51.24 mg, 0.10 mmol) in THF (1mL), MeOH (0.5 ml), and H2O (0.5 ml) was added 
K2CO3 (41.5 mg, 3.0 mmol). The mixture was stirred at room temperature for 24 h. 
Then, saturated NH4Cl aqueous solution (10 mL) was added to the reaction mixture, and 
the product was extracted with AcOEt (15 mL × 3). The combined extracts were washed 
by brine (10 mL) and dried over Na2SO4. The organic phase was concentrated under 
reduced pressure and the crude product was purified by column chromatography on 
silica-gel (eluent: hexane/AcOEt = 5/1), to give the desired product 6e (26.7 mg, 76 % 
yield). 
 
N-((3-iodo-1H-indol-2-yl)methyl)methanesulfonamide (6e): 
1
H NMR (400 MHz, 
CDCl3) δ 3.42 (s, 3H), 4.67 (s, 2H), 7.13-7,27 (m, 2H), 7.30 (d, J=8.0 Hz, 1H), 7.42 (d, 
J=8.0 Hz, 1H), 8.79 (br, 1H). 
13
C NMR (100 MHz, CDCl3) δ 58.2, 59.0, 67.7, 111.2, 
120.7, 120.9, 123.3, 130.2, 135.6, 136.1. IR (neat) 3291, 1450, 1220, 1078, 908, 741 
cm
–1
.  
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Chapter 5 
 
Abstract 
Ligand Coupling Reaction of (Indolyl)(aryl)iodonium Imides to Form C-N Bond at 
3-Position in Indole Group; Effect of Substitutents of Hypervalent Iodine for 
Reaction Selectivity 
N-(1’-pivaloyl-1’H-indol-3’-yl)-4-methyl-N-tosylbenzenesulfonamides were generated 
by ligand coupling reaction of (indolyl)(aryl)iodonium imides using catalytic amount of 
cupper iodide (I) or under heat conditions. Substitutent on hypervalent iodines 
controlled the reaction with high regioselectivity. 
 
Introduction 
Diaryliodonium salt is very useful aryl source for ligand of metal catalysts and arylation 
of carbon or heteroatoms by nucleophilic or radical reaction
1
. In particular, copper 
catalysts have been used for ligand coupling reaction between various compounds with 
diaryliodonium salts
2
. However, coupling reaction with unsymmetric diaryliodonium 
salts usually gives three products with low selectivity. To solve the problem, 
mesitylene(aryl)iodonium salt has been used to control regioselectivity by steric barrier 
of mesitylene group
3
.  
The author developed (indolyl)(aryl)iodonium imide, which is not only imide-combined 
hypervalent iodine but also heteroaryl(aryl)iodonium compounds
4
. To expand the 
synthetic utility of the imide-combined hypervalent iodines, study of intramolecular 
C-N ligand coupling reaction of (indolyl)(aryl)iodonium imide is very important. 
However, (indolyl)(mesityl)iodonium imide could not be isolated by the previous 
method in chapter 2
5
. Ever if it works, the yield is not so good. Then, the author studied 
designing hypervalent iodine to control selectivity of ligand coupling reaction. Here, the 
author reported regioselective C-N ligamd coupling reaction of (indolyl)(aryl)iodonium 
imides bearing ortho-alkoxyaryl group.    
 
Results and discussion 
First, the author examined C-N ligamd coupling reaction of (indolyl)(phenyl)iodonium 
imide with CuCl (10 mol %) at room temperature in dichloromethane (Scheme 1). 
However, the yield of coupling product indole (2a) was only 11 %, and that of coupling 
with a phenyl group (4a) and 3-iodoindole group (3a) were 41 % and 66 % yield, 
respectively. Then, the author studied screening reaction conditions for ligand coupling 
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reaction (Table 1). The addition of BF3•OEt2 or 1,10-phenanthroline was not much 
effective for the reaction (entries 2, 3). Heating conditions improved the selectivity 
(entries 4, 5), however, other cupper catalyst did not give good effect for yield of 2a 
(entries 6, 7). 
 
 
 
 
 
Next, the author searched C-N ligand coupling reaction of (indolyl)(aryl)iodonium 
imide bearing various substituent (Table 2). Use of 1 bearing 
3,5-bis(trifluoromethyl)phenyl (1ab) or 4-methoxyphenyl (1ac) group gave 2a in low 
yield using CuCl (20 mol%) at 100 ˚C in toluene. These results suggested that electronic 
106 
 
effect does not affect the reaction selectivity of C-N ligand coupling reaction. On the 
other hand, 1 bearing 2-n-butoxyphenyl group (1ad) extremely improved the yield of 2a. 
Zhdankin group reported that 2-alkoxyphenyl group improved solubility of ArNTs
6
. 
However, it is the first application of 2-alkoxyphenyl-combined hypervalent iodine to 
control selectivity of C-N ligand couplig reaction. 
 
 
 
To study the effect of 2-alkoxyphenyl group in 1 for regioselective C-N ligand coupling 
reaction, the author examined amination at 3-position of indole with 
(indolyl)(aryl)iodonium imide bearing various 2-alkoxy groups (Table 3). The reaction 
was carried out in the presence of a catalytic amount of CuI and Ts2NH at 150 ˚C, as 
shown in Table 3. 2-MeO (1ae) and 2-EtO (1af) phenyl groups gave 2a in good yields, 
respectively, and sterically hindered groups, such as 2-i-PrO (1ag) and 2-PhO (1ah) 
phenyl groups, also provided the desired products in high yields. Moreover, 2a was 
obtained with 1ai bearing electron-withdrawing group, 2-CF3Ophenyl group (1ai).  
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The author examined the coupling reaction of various substituted 
(indolyl)(2-butoxyphenyl)iodonium imides (1) with under optimized reaction conditions 
(Table 4).  
Electron-donating groups, such as 5-Me (1bd) and 5-MeO (1cd), on indole group 
promoted the reaction to give 3-aminoindole derivatives (2a,b) in high yields, and the 
products (2) bearing 5-Cl (2d) and 5-COOMe (2e) groups were obtained from 
hypervalent iodoine (1) in high yields, respectively. In addition, use of unsymmetrical 
imide-combined hypervalent iodine (1fd) gave desired product 2f in high yield.  
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The author also succeeded in C-N ligand coupling of (indolyl)(aryl)iodonium imide 
(1ad) without any catalysts (Scheme 2). This reaction was carried out at 150 ˚C for 4h 
under metal-free conditions and the yield of 2a was almost the same as that in C-N 
ligand coupling reaction with Cu catalyst.  
 
 
 
In conclusion, the author developed cupper-catalyzed C-N ligand coupling reaction of 
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(indolyl)(aryl)iodonium imide and regioselective coupling reaction was carried out by 
design of hypervalent iodine ligand. The reaction provided 3-imide substututed indole 
derivatives, and proceeds without metal catalysts. The author believed that the present 
regioselective coupling reaction of hypervalent iodine bearing 2-alkoxyphenyl group 
can be used for functionalization of indoles and hypervalent iodine chemistry. 
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Experimental 
1. General Methods. 
1
H NMR spectra were measured on a JEOL ECA-500 (500 MHz) 
spectrometer at ambient temperature. Data were recorded as follows: chemical shift in 
ppm f      te   l tet   ethyls l  e    the δ scale, multiplicity (s = singlet; d = doublet; 
t = triplet; q = quartet; sep = septet; m = multiplet; br = broad), coupling constant (Hz), 
integration, and assignment. 
13
C NMR spectra were measured on a JEOL ECA-500 
(125 MHz) spectrometer. Chemical shifts were recorded in ppm from the solvent 
resonance employed as the internal standard (deuterochloroform at 77.0 ppm). 
High-resolution mass spectra were recorded by Thermo Fisher Scientific Exactive 
Orbitrap mass spectrometers. Infrared (IR) spectra were recorded on a JASCO FT/IR 
4100 spectrometer. Single crystal X-ray diffraction data were collected at 173 K on a 
   ke  SMART APEX    CCD d ff  ct  ete  w th M  Kα (λ = 0.71073) radiation and 
graphite monochrometer. For thin-layer chromatography (TLC) analysis throughout this 
work, Merck precoated TLC plates (silica gel 60GF254 0.25 mm) were used. The 
products were purified by column chromatography on neutral silica-gel (Kanto 
Chemical Co., Inc. silica gel 60N, Prod. No. 37560-84; Merck silica gel 60, Prod. No. 
1.09385.9929). Visualization was accomplished by UV light (254 nm), anisaldehyde, 
KMnO4, and phosphomolybdic acid. 
 
2. 1 General Procedure Using Method A for Preparation of Indolyl(aryl)iodonium 
Imides (1)  
To prepare PhI(OAc)NTs2 were used DIB (386.5 mg, 1.2 mmol) and Ts2NH (390.5 mg, 
1.2 mmol) in MeCN (10 ml). The mixture was stirred at room temperature for 30 min. 
under argon atmosphere. Then, N-pivaloylindole (201.3 mg, 1.0 mmol) was added, and 
the solution was stirred at 40 ˚C for 7 h. The solvent was removed under reduced 
pressure. Then AcOEt (10 ml) and ether (5 ml) were added. The mixture was sonicated 
until precipitation occurred as the white solid, and ether (5 ml) was added to the mixture. 
The solid was filtrated and washed with AcOEt/ether (2:1) (15 ml), to give desired 
product 2a (597.5 mg, 82 % yield). 
 
2. 2 General Procedure Using Method B for Preparation of 
4-Methyl-N-((2”-phenoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylb
enzenesulfonamide (1ah)  
To prepare PhI(OAc)NTs2 were used 1-(diacetoxyiodo)-2-phenoxybenzene (497.0 mg, 
1.2 mmol) and Ts2NH (390.5 mg, 1.2 mmol) in MeCN (10 ml). The mixture was stirred 
at room temperature for 30 min. under argon atmosphere. Then, N-pivaloylindole (201.3 
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mg, 1.0 mmol) was added, and the solution was stirred at room temperature for 5 h. The 
solvent was removed under reduced pressure. Then, AcOEt (6 ml) was added. The 
mixture was added dropwise to ether /hexane (1:1) until the solvent changed clear 
solution to pale white, followed by sonication and addition of ether (2 ml). The solid 
was filtrated and washed with AcOEt/hexane (2:1) (15 ml), to give desired product 1ah 
(566.3 mg, 69 % yield). 
 
2. 3 General Procedure Using Method C for Preparation of 
N-((2”-isopropoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methyl-N-tosy
lbenzenesulfonamide (1ag)  
To prepare ArI(OAc)NTs2 were used 1-(diacetoxyiodo)-2-isopropoxybenzene (456.2 mg, 
1.2 mmol) and Ts2NH (390.5 mg, 1.2 mmol) in MeCN (10 ml). The mixture was stirred 
at room temperature for 30 min. under argon atmosphere. Then, N-pivaloylindole (201.3 
mg, 1.0 mmol) was added, and the solution was stirred at 40 ˚C for 5 h. The solvent was 
removed under reduced pressure. Then, AcOEt (6 ml) was added. The mixture was 
added dropwise to ether /hexane (1:1) until the solvent changed clear solution to pale 
white. The solution was stored overnight at -10 ˚C. The solid was filtrated and washed 
with AcOEt/hexane (2:1) (15 ml), to give desired product 1ag (566.5 mg, 72 % yield). 
 
The experimental data of compound 1aa-1ae : see chapter 2 
 
N-((2”-etoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methyl-N-tosylbenz
enesulfonamide (1af) (Isolated Method : A, 71 % yield) : mp. 161 °C (decomp.) 
1
H 
NMR (500 MHz, CDCl3) δ 1.45 (s, 9H), 1.54 (t, J=7.2 Hz, 3H), 2.27 (s, 6H), 4.25 (q, 
J=7.2 Hz, 2H), 6.87-6.95 (m, 5H), 6.99 (dd, J=8.3, 0.85 Hz, 1H), 7.39 (td, J=8.3, 0.85 
Hz, 1H), 7.42-7.55 (m, 8H), 8.54 (d, J=8.6 Hz, 1H), 8.88 (s, 1H). 
13
C NMR (125 MHz, 
CDCl3) δ 14.6, 21.3 (2C), 28.4 (3C), 41.8, 66.1, 82.5, 104.0, 113.0, 117.8, 119.5, 124.0, 
125.2, 126.6 (4C), 127.1, 127.6, 128.4 (4C), 133.6, 133.7, 136.3, 136.4, 140.8 (2C), 
141.3 (2C), 155.6, 177.0. IR (neat) 1712, 1467, 1278, 1127, 1079, 1046, 750, 671 cm
–1
. 
MS (ESI) calcd for C35H37N2O6INaS2 [M+Na]
+
 795.1030, found 795.1021. 
 
N-((2”-isopropoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methyl-N-tosy
lbenzenesulfonamide (1ag) (Isolated Method : C, 72 % yield) : mp. 172 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.43 (s, 9H), 1.46 (d, J=6.0 Hz, 6H), 2.26 (s, 6H), 4.74 
(sep, J=6.0 Hz, 1H), 6.83-6.93 (m, 5H), 6.99 (d, J=8.0 Hz, 1H), 7.35-7.47 (m, 8H), 7.50 
(d, J=8.0 Hz, 1H), 8.55 (d, J=8.3 Hz, 1H), 8.89 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 
112 
 
21.2 (2C), 21.8 (2C), 28.4 (3C), 41.7, 73.6, 82.1, 104.7, 114.0, 117.8, 119.5, 123.9, 
125.2, 126.5 (4C), 127.0, 127.5, 128.4 (4C), 133.1, 133.4, 136.3, 136.5, 140.7 (2C), 
141.5 (2C), 154.6, 177.1. IR (neat) 1719, 1442, 1290, 1124, 1082, 1053, 751, 670 cm
–1
. 
MS (ESI) calcd for C36H39N2O6INaS2 [M+Na]
+
 809.1186, found 809.1174. 
 
4-Methyl-N-((2”-phenoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylb
enzenesulfonamide (1ah) (Isolated Method : B, 69 % yield) : mp. 196 °C (decomp.) 
1
H 
NMR (500 MHz, CDCl3) δ 1.35 (s, 9H), 2.23 (s, 6H), 6.74 (dd, J=8.3, 1.2 Hz, 1H), 
6.83-6.92 (m, 6H), 6.99 (td, J=8.3, 1.2 Hz, 1H), 7.21 (t, J=7.5 Hz, 1H), 7.28-7.37 (m, 
4H), 7.42-7.48 (m, 5H), 7.51 (d, J=8.0 Hz, 1H), 8.10 (dd, J=8.3, 1.2 Hz, 1H), 8.48 (d, 
J=8.0 Hz, 1H), 8.75 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.3 (2C), 28.3 (3C), 41.7, 
84.8, 105.8, 117.3, 117.6, 119.8, 120.3 (2C), 125.1, 125.4, 125.6, 126.7 (4C), 126.8, 
127.7, 128.4 (4C), 130.2 (2C), 133.9, 136.1, 136.2, 136.5, 140.8 (2C), 141.2 (2C), 154.6, 
156.1, 177.0. IR (neat) 1706, 1444, 1294, 1135, 1076, 1031, 747, 670 cm
–1
. MS (ESI) 
calcd for C39H37N2O6INaS2 [M+Na]
+
 843.1030, found 843.1013. 
 
4-Methyl-N-((2”-(trifluoromethoxy)phenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl
)-N-tosylbenzenesulfonamide (1ai) (Isolated Method : B, 60 % yield) : mp. 155 °C 
(decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.40 (s, 9H), 2.23 (s, 6H), 6.86 (q, J=8.0 Hz, 
4H), 7.20 (t, J=8.0 Hz, 1H), 7.30 (d, J=8.6 Hz, 1H), 7.32-7.47 (m, 7H), 7.49 (d, J=8.0 
Hz, 1H), 8.30 (d, J=8.0 Hz, 1H), 8.46 (d, J=8.6 Hz, 1H), 8.79 (s, 1H). 
13
C NMR (125 
MHz, CDCl3) δ 21.2 (2C), 28.2 (3C), 41.6, 86.3, 107.6, 117.1, 117.5, 119.4, 124.2 (q, 
JC-F=261.1 Hz), 125.0, 126.59 (4C), 126.64, 127.6, 128.4 (4C), 128.9, 134.0, 135.9, 
136.0, 138.7, 140.76 (2C), 140.82 (2C), 147.6, 177.0. 
19
F NMR (471 MHz, CDCl3) δ 
-56.6. IR (neat) 1715, 1446, 1247, 1134, 1079, 1011, 762, 672 cm
–1
. MS (ESI) calcd for 
C34H32N2O6F3INaS2 [M+Na]
+
 835.0591, found 835.0591. 
 
N-((2”-butoxyphenyl)(5’-methyl-1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methyl-
N-tosylbenzenesulfonamide (1bd) (Isolated Method : C, 70 % yield) : mp.102-104 °C 
1
H NMR (500 MHz, CDCl3) δ 1.03 (t, J=7.2 Hz, 3H), 1.43 (s, 9H), 1.56 (sext, J=7.2 Hz, 
2H), 1.92 (quin, J=7.2 Hz, 2H), 2.27 (s, 6H), 2.45 (s, 3H), 4.19 (t, J=7.2 Hz, 2H), 
6.87-6.94 (m, 5H), 7.02 (dd, J=8.3, 0.90 Hz, 1H), 7.20 (s, 1H), 7.33 (d, J=8.6 Hz, 1H), 
7.37 (dd, J=8.3, 1.2 Hz, 1H), 7.40-7.50 (m, 5H), 8.42 (d, J=8.6 Hz, 1H), 8.84 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 13.8, 19.2, 21.3 (2C), 21.4, 28.4 (3C), 30.8, 41.7, 70.1, 
81.7, 103.8, 113.0, 117.5, 119.1, 124.1, 126.6 (4C), 127.7, 128.4 (4C), 128.6, 132.7, 
133.5, 134.5, 135.3, 136.5, 140.6 (2C), 141.6 (2C), 155.6, 177.0. IR (neat) 1712, 1465, 
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1279, 1133, 1079, 805, 763, 672 cm
–1
. MS (ESI) calcd for C38H43N2O6INaS2 [M+Na]
+
 
837.1499, found 837.1488. 
 
N-((2”-butoxyphenyl)(5’-methoxy-1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methy
l-N-tosylbenzenesulfonamide (1cd) (Isolated Method : B, 69 % yield) : mp. 156 °C 
(decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.01 (t, J=7.5 Hz, 3H), 1.43 (s, 9H), 1.54 (sext, 
J=7.5 Hz, 2H), 1.90 (quin, J=7.5 Hz, 2H), 2.27 (s, 6H), 3.81 (s, 3H), 4.18 (t, J=7.5 Hz, 
2H), 6.84 (d, J=7.5 Hz, 1H), 6.88-6.96 (m, 5H), 7.02 (dd, J=8.0, 1.2 Hz, 1H), 7.09 (dd, 
J=8.0, 1.2 Hz, 1H), 7.09 (dd, J=9.2, 2.3 Hz, 1H), 7.40 (dd, J=8.3, 1.5 Hz, 1H), 
7.42-7.51 (m, 5H), 8.45 (d, J=9.2 Hz, 1H), 8.81 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 
13.8, 19.1, 21.3 (2C), 28.5 (3C), 30.8, 41.6, 55.8, 70.2, 81.8, 101.8, 103.7, 113.1, 115.9, 
118.8, 124.0, 126.5 (4C), 128.3 (4C), 128.6, 130.8, 132.8, 133.5, 136.6, 140.6 (2C), 
141.6 (2C), 155.7, 157.6, 176.8. IR (neat) 1701, 1469, 1280, 1127, 1077, 803, 749, 664 
cm
–1
. MS (ESI) calcd for C38H44N2O7INaS2 [M+Na]
+
 853.1449, found 853.1434. 
 
N-((2”-butoxyphenyl)(5’-chloro-1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methyl-
N-tosylbenzenesulfonamide (1dd) (Isolated Method : B, 54 % yield) : mp. 182 °C 
(decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.02 (t, J=7.2 Hz, 3H), 1.45 (s, 9H), 1.55 (sext, 
J=7.2 Hz, 2H), 1.91 (quin, J=7.2 Hz, 2H), 2.27 (s, 6H), 4.16 (t, J=7.2 Hz, 2H), 
6.87-6.95 (m, 5H), 7.00 (d, J=8.0 Hz, 1H), 7.38-7.50 (m, 7H), 7.63 (d, J=8.0 Hz, 1H), 
8.44 (d, J=9.5 Hz, 1H), 8.95 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 13.8, 19.2, 21.3 
(2C), 28.3 (3C), 30.8, 41.8, 70.1, 82.2, 104.2, 113.0, 118.9, 119.2, 124.0, 126.6 (4C), 
127.1, 128.4 (4C), 129.0, 130.9, 134.0, 134.6, 137.5, 140.8 (2C), 141.4 (2C), 155.9, 
177.0. IR (neat) 1712, 1443, 1280, 1129, 1078, 805, 756, 665 cm
–1
. MS (ESI) calcd for 
C37H40N2O6ClINaS2 [M+Na]
+
 857.0953, found 857.0943. 
 
Methyl 
3-(((4”-methyl-N-tosylbenzene)sulfonamido)(2’-n-butoxyphenyl)-3-iodanyl)-1-piv
aloyl-1H-indole-5-carboxylate (1ed) (Isolated Method : C, 49 % yield) : mp. 182 °C 
(decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.00 (t, J=7.2 Hz, 3H), 1.46 (s, 9H), 1.54 (sext, 
J=7.2 Hz, 2H), 1.91 (quin, J=7.2 Hz, 2H), 2.26 (s, 6H), 3.94 (s, 3H), 4.19 (t, J=7.2 Hz, 
2H), 6.86-6.94 (m, 5H), 7.00 (dd, J=8.3, 1.2 Hz, 1H), 7.42-7.50 (m, 5H), 7.60 (dd, 
J=8.3, 1.2 Hz, 1H), 8.12 (d, J=1.7 Hz, 1H), 8.15 (dd, J=8.9, 1.7 Hz, 1H), 8.56 (d, J=8.9 
Hz, 1H), 9.02 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 13.8, 19.1, 21.2 (2C), 28.3 (3C), 
30.7, 41.8, 52.3, 70.1, 83.4, 104.2, 113.0, 117.6, 121.4, 124.0, 126.6 (4C), 127.0, 127.6, 
127.9, 128.4 (4C), 134.0, 134.3, 137.7, 138.8, 140.7 (2C), 141.6 (2C), 155.9, 166.3, 
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177.1. IR (neat) 1717, 1469, 1279, 1127, 1076, 817, 748, 664 cm
–1
. MS (ESI) calcd for 
C39H43N2O8INaS2 [M+Na]
+
 881.1398, found 881.1403. 
 
N-((2”-butoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-4-methyl-N-(methan
esulfonyl)benzenesulfonamide (1fd) (Isolated Method : C, 51 % yield) : mp.72-75 °C 
1
H NMR (500 MHz, CDCl3) δ 1.03 (t, J=7.2 Hz, 3H), 1.48 (s, 9H), 1.56 (sext, J=7.2 Hz, 
2H), 1.90 (quin, J=7.2 Hz, 2H), 2.26 (s, 3H), 2.86 (s, 3H), 4.17 (t, J=7.2 Hz, 2H), 6.90 
(d, J=8.1 Hz, 1H), 6.95 (d, J=8.0 Hz, 2H), 7.01 (d, J=8.1 Hz, 1H), 7.38 (t, J=8.3 Hz, 
1H), 7.41-7.53 (m, 7H), 8.53 (d, J=8.3 Hz, 2H), 8.79 (s, 1H). 
13
C NMR (125 MHz, 
CDCl3) δ 13.8, 19.1, 21.3, 28.4 (3C), 30.8, 41.8, 42.8, 70.1, 82.7, 104.0, 113.1, 117.7, 
119.4, 123.9, 125.2, 126.5 (2C), 127.0, 127.5, 128.5 (2C), 133.5, 133.7, 136.1, 136.2, 
140.8, 141.7, 155.8, 177.0. IR (neat) 1708, 1443, 1276, 1120, 1083, 808, 758, 658 cm
–1
. 
MS (ESI) calcd for C31H37N2O6INaS2 [M+Na]
+
 747.1030, found 747.1017. 
 
3. General Procedure for C-N Ligand Coupling Reaction of 
4-Methyl-N-((2”-n-butoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylb
enzenesulfonamide (1ad) with Cupper Catalyst (Table 3, entry 1) 
To a solution of 
4-methyl-N-((2-n-butoxyphenyl)(1-pivaloyl-1H-indol-3-yl)-3-iodanyl)-N-tosylbenzene
sulfonamide 1ad (80.1 mg, 0.10 mmol) in o-xylene (1mL) were added CuI (3.81 mg, 
0.020 mmol) and Ts2NH (6.51 mg, 0.020 mmol). The mixture was stirred at 150 ºC for 
1 h under argon atmosphere. Then, saturated NH4Cl aqueous solution (10 mL) was 
added to the reaction mixture, and the product was extracted with AcOEt (15 mL × 3). 
The combined extracts were washed by brine (10 mL) and dried over Na2SO4. The 
organic phase was concentrated under reduced pressure and the crude product was 
purified by column chromatography on silica-gel (eluent: hexane/AcOEt = 5/1), to give 
the desired product 3a (46.2 mg, 88 % yield). 
 
4-Methyl-N-(1’-pivaloyl-1’H-indol-3’-yl)-N-tosylbenzenesulfonamide (2a) : mp. 
207 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.40 (s, 9H), 2.46 (s, 6H), 7.07 (d, 
J=7.9 Hz, 1H), 7.17 (t, J=7.9 Hz, 1H), 7.30-7.36 (m, 5H), 7.46 (s, 1H), 7.87 (d, J=8.3 
Hz, 4H), 8.46 (d, J=7.9 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.7 (2C), 28.5 (3C), 
41.3, 115.8, 117.3, 118.6, 124.1, 126.0, 126.8, 127.7, 128.6 (4C), 129.6 (4C), 135.7, 
136.2 (2C), 145.2 (2C), 176.7. IR (neat) 1702, 1374, 1316, 1165 cm
–1
. MS (ESI) calcd 
for C27H28N2O5S2Na [M+Na
+
]
+
 547.1332, found 547.1316. 
 
115 
 
 
4-Methyl-N-(5’-methyl-1’-pivaloyl-1’H-indol-3’-yl)-N-tosylbenzenesulfonamide 
(2a) : mp. 214 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.39 (s, 9H), 2.28 (s, 3H), 
2.47 (s, 6H), 6.71 (s, 1H), 7.14 (d, J=8.6 Hz, 1H), 7.32 (d, J=8.3 Hz, 4H), 7.42 (s, 1H), 
7.87 (d, J=8.3 Hz, 4H), 8.31 (d, J=8.6 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.2, 
21.7 (2C), 28.5 (3C), 41.2, 115.6, 116.9, 118.4, 126.9, 127.4, 127.6, 128.7 (4C), 129.5 
(4C), 133.8, 133.9, 136.3 (2C), 145.2 (2C), 176.6. IR (neat) 1701, 1379, 1308, 1156, 
901, 811, 658 cm
–1
. MS (ESI) calcd for C28H30N2O5S2Na [M+Na
+
]
+
 561.1448, found 
561.1488. 
 
N-(5’-methoxy-1’-pivaloyl-1’H-indol-3’-yl)-4-methyl-N-tosylbenzenesulfonamide 
(2b) : mp. 224 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.39 (s, 9H), 2.46 (s, 6H), 
3.62 (s, 3H), 6.37 (d, J=2.6 Hz, 1H), 6.92 (dd, J=9.2, 2.6 Hz, 1H), 7.32 (d, J=8.3 Hz, 
4H), 7.43 (s, 1H), 7.88 (d, J=8.3 Hz, 4H), 8.34 (d, J=9.2 Hz, 1H). 
13
C NMR (125 MHz, 
CDCl3) δ 21.7 (2C), 28.6 (3C), 41.2, 55.2, 115.4, 115.6, 118.3, 127.8, 128.0, 128.6 (4C), 
129.6 (4C), 130.2, 136.4 (2C), 145.2 (2C), 156.7, 176.4. IR (neat) 1701, 1380, 1312, 
1162, 904, 814, 658 cm
–1
. MS (ESI) calcd for C28H30N2O6S2Na [M+Na
+
]
+
 577.1437, 
found 577.1437. 
 
N-(5’-chloro-1’-pivaloyl-1’H-indol-3’-yl)-4-methyl-N-tosylbenzenesulfonamide 
(2c) : mp. 201-204 °C 
1
H NMR (500 MHz, CDCl3) δ 1.41 (s, 9H), 2.48 (s, 6H), 6.81 (d, 
J=2.0 Hz, 1H), 7.27 (dd, J=8.9, 2.0 Hz, 1H), 7.33 (d, J=8.3 Hz, 4H), 7.52 (s, 1H), 7.85 
(d, J=8.3 Hz, 4H), 8.38 (d, J=8.9 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ 21.7 (2C), 
28.4 (3C), 41.3, 115.2, 118.2, 126.2, 128.0, 128.6 (4C), 128.7, 129.7 (4C), 130.0, 133.9, 
136.0 (2C), 145.6 (2C), 176.6. IR (neat) 1708, 1379, 1307, 1163, 903, 815, 660 cm
–1
. 
MS (ESI) calcd for C27H27N2ClO5S2Na [M+Na
+
]
+
 581.0492, found 581.0944. 
 
Methyl 
3-((4’-methyl-N-tosylbenzene)sulfonamido)-1-pivaloyl-1H-indole-5-carboxylate 
(2d) : mp. 224 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.41 (s, 9H), 2.46 (s, 6H), 
3.89 (s, 3H), 7.33 (d, J=8.3 Hz, 4H), 7.54 (s, 1H), 7.63 (d, J=1.5 Hz, 1H), 7.86 (d, J=8.3 
Hz, 4H), 8.02 (dd, J=8.9, 1.5 Hz, 1H), 8.50 (d, J=8.9 Hz, 1H). 
13
C NMR (125 MHz, 
CDCl3) δ 21.7 (2C), 28.4 (3C), 41.4, 52.0, 116.2, 117.1, 126.1, 126.6, 127.2, 128.6 (4C), 
128.8, 129.7 (4C), 136.0 (2C), 138.1, 145.5 (2C), 166.7, 176.7. IR (neat) 1717, 1389, 
1313, 1165, 817, 658 cm
–1
. MS (ESI) calcd for C29H30N2O7S2Na [M+Na
+
]
+
 605.1387, 
found 605.1388. 
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4-Methyl-N-(5’-methyl-1’-pivaloyl-1’H-indol-3’-yl)-N-(methanesulfonyl)benzenesu
lfonamide (2e) : mp. 217 °C (decomp.) 
1
H NMR (500 MHz, CDCl3) δ 1.44 (s, 9H), 
2.43 (s, 3H), 3.56 (s, 3H), 7.25-7.30 (m, 3H), 7.32 (d, J=8.0 Hz, 1H), 7.37 (d, J=8.0 Hz, 
1H), 7.62 (s, 1H), 7.79 (d, J=8.3 Hz, 2H), 8.48 (d, J=8.0 Hz, 1H). 
13
C NMR (125 MHz, 
CDCl3) δ 21.7, 28.5 (3C), 41.4, 44.0, 115.2, 117.4, 118.2, 124.4, 126.2, 126.7, 127.2, 
128.8 (2C), 129.6 (2C), 135.1, 136.7, 145.6, 176.7. IR (neat) 1704, 1366, 1157, 900, 
749, 660 cm
–1
. MS (ESI) calcd for C21H25N2O5S2Na [M+Na
+
]
+
 471.1019, found 
471.1020. 
 
4. General Procedure for C-N Ligand Coupling Reaction of 
4-Methyl-N-((2”-n-butoxyphenyl)(1’-pivaloyl-1’H-indol-3’-yl)-3-iodanyl)-N-tosylb
enzenesulfonamide (1ad) without Any Catalists (Scheme 2) 
To a solution of 
4-methyl-N-((2-n-butoxyphenyl)(1-pivaloyl-1H-indol-3-yl)-3-iodanyl)-N-tosylbenzene
sulfonamide 1ad (80.1 mg, 0.10 mmol) in o-xylene (1mL) was stirred at 150 ºC for 4 h 
under argon atmosphere. Then, the organic solvent was concentrated under reduced 
pressure and the crude product was purified by column chromatography on silica-gel 
(eluent: hexane/AcOEt = 5/1), to give the desired product 3a (41.5 mg, 79 % yield). 
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